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Regulation of cell division is essential for normal embryo development. The Cyclins and
their Cyclin-dependent kinases are key regulators controlling this process. In this thesis, I
examine the role of cyclin B1 and cyclin B2 in zebrafish development. It is thought that both
Cyclins are necessary for a cell to progress past the G2/M checkpoint into mitosis. First, I show
that zygotic Cyclin B1 is essential for normal cell cycle progression, but not for cells to enter
mitosis. Lack of zygotic Cyclin B1 in the early arrest mutant specter, which carries a nonsense
mutation in the cyclin B1 gene, did not stop cells from entering mitosis. However, for some cells,
M phase was abnormal and elongated, sometimes resulting in chromosomal abnormalities, while
for other cells M phase occurred normally.
Then, using CRISPR/Cas9 gene editing, I created a new mutation in cyclin B1 that failed
to complement the specter null allele, confirming that the specter mutant phenotype is the result
of disrupted Cyclin B1 function. The new mutation is a recessive gain-of-function mutation that
has a more severe phenotype. This mutation produces an alternative splice variant of cyclin B1
mRNA, that does not undergo non-sense mediated decay and could produce an altered Cyclin B1
protein lacking several key components. Analysis of this CRISPR mutant, reveals that it has a
different effect on cell cycle progression once zygotic control takes over, as all cells pause at the

G2/M checkpoint and cease to divide, eventually undergoing apoptosis. I hypothesize that lack
of Cyclin B1 in the null allele, allows another protein complex to form and sustain cell cycle
progression, whereas the product of the gain-of-function allele somehow prevents this alternative
mechanism from occurring.
To test this hypothesis, we used CRISPR/Cas9 mediated gene editing to target cyclin B2.
Using the Dual FUCCI transgene expression and antibody staining, I show that one of two
putative cyclin B2 mutations, has a very severe morphological phenotype where many cells are
in G2/M phase, but do not die. The other putative cyclin B2 mutant produced in the specter
background, has a less severe morphological phenotype. Cells progress through G2/M phase, but
mitotic cells have severe chromosomal abnormalities, much like the specter CRISPR mutant, but
form double nucleated cells, suggesting incomplete mitosis. My molecular and cellular analysis
suggest that I have created two independent recessive mutants that completely remove cyclin B
function.
In summary, using the specter and CRISPR specter mutants, I show that there might be
an alternative mechanism of cell cycle progression in zebrafish when Cyclin B1 is absent. By
attempting to knockout cyclin B2 and analyzing the new mutations in a wild-type and specter
mutant backgrounds, I show that Cyclin B proteins might have redundant functions in
progression through the G2/M checkpoint during early zebrafish development.
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CHAPTER 1

INTRODUCTION
Cell cycle is a conserved mechanism utilized by the cells to proliferate and drive genetic
variation. During embryonic development, the cell cycle guides the cellular differentiation and
overall morphogenesis. By studying the mechanism of action of the genes that control cell cycle
progression, we can understand how to regulate an uncontrolled cell proliferation, as well as
metastasis of cancer. In particular, disrupted regulation of Cyclin B leads to chromosome
instability often observed in various tumors, such as colorectal cancer and lung cancer; and
because of this, Cyclin B1 levels also serve as a prognostic marker in some types of breast cancer
(Reviewed by Casimiro et al., 2012). Zebrafish is a very valuable model to study the cell cycle
genes, because of the maternally transcribed genes that regulate an early development until
gastrulation, a stage when we can study the cellular phenotypes. This is an important advantage
over other vertebrate systems where death occurs in utero and Cyclin Bs have mostly been
studied in cell culture.
This work has its roots in my Master’s Thesis, where I described the morphological and
cellular effects of the specter null mutation in cyclin B1 gene (Petrachkova, 2015). After detailed
analysis of the specter mutant, I showed that it was a cell cycle mutation, which was confirmed
by the CRISPR-mediated mutagenesis. In my dissertation, I have examined several cell cycle
mutations in the cyclin B1 and cyclin B2 genes, which is a first work that proposes a link
between the cell cycle genes involved in the G2 to M transition and their role in growth and
development in zebrafish embryo.
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The cell cycle and its regulation
The cell cycle is a process by which a cell replicates and produces two daughter cells.
The cell cycle of somatic cells begins with interphase and ends with cell division followed by
cytokinesis. Interphase, which consists of gap 1 (G1), DNA synthesis (S), gap 2 (G2) phases.
The G1 phase is a pre-replication stage when a cell is growing and deciding whether to enter the
next cell cycle or to divert to the quiescent, non-proliferative, phase (G0). The S phase is a DNA
synthesis stage when all chromosomes are duplicated. The G2 phase is a period when the cell is
preparing to enter cell division. The actual cell division is called M phase, and it consists of four
stages: prophase, metaphase, anaphase, and telophase. In brief, prophase is a period of nuclear
envelope breakdown, chromosomes condensation, centrosomes maturation, and spindle
formation. Metaphase is a period when the condensed chromosomes align at the cell’s equator,
forming a metaphase plate. Anaphase is a period when the microtubules attached to the
chromosomes’ kinetochores begin pulling the sister chromatids to the opposite poles. Finally,
telophase, is a period when the chromosomes decondense and the nuclear envelope is restored;
followed by cytokinesis – a separation of the two daughter cells (reviewed by Schafer, 1998).
Biochemically, the cell cycle is regulated by the cyclin proteins and specific cyclindependent kinases (Cdks), which form active complexes during cell cycle checkpoints. Cyclin
D/Cdk4/6 drives cells through the G1 phase, Cyclin E/Cdk2 drives the cells through early S
phase, Cyclin A/Cdk1/2 drives the cells though mid-S-early G2 phase, and Cyclin B/Cdk1 drives
the cells through the G2/M phase.
Checkpoints control and separate the phases of the cycle. They ensure that the previous
phase of the cell cycle was completed without errors, allowing the cell to proceed into the next
phase or enter cell cycle arrest There are three cell cycle checkpoints: the G1/S or restriction
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checkpoint, G2/M or DNA synthesis checkpoint, and the M or spindle assembly checkpoint; and
one checkpoint during cytokinesis. The G1/S checkpoint is regulated by the growth factors and
Cyclin E/Cdk4/6 to ensure that there are enough proteins for DNA replication and no DNA
damage before the S phase. If the G1/S checkpoint is not satisfied, the cell goes into the G0
phase or apoptosis. The G2/M checkpoint ensures error-free DNA replication followed by the G2
to M transition which is mediated by the Cyclin B/Cdk1 (mitosis promoting factor, MPF). If this
checkpoint is not satisfied, the cell arrests in G2/M phase. The M checkpoint ensures the proper
spindle formation and microtubule attachment to the chromosomes before anaphase, which is
also mediated by the MPF inactivation (reviewed by Elledge, 1996; Kastan & Bartek, 2004).
Finally, the newly characterized cytokinesis checkpoint, or NoCut pathway, ensures timely
daughter cells abscission (Norden et al., 2006).

The cell cycle in zebrafish early development
In many organisms, after egg is fertilized, a zygote undergoes series of synchronous
divisions. These divisions occur during the first 10 cell cycles (1-8th cell cycle is the cleavage
stage; the 9th and 10th cell cycles are the blastula stage). The cell cycle during this period consists
only of the S phase and M phase and does not have the two gap phases. In zebrafish, these
divisions continue until the cell cycle 10 (2.5 h, 512-cell stage), when the midblastula transition
(MBT) begins. The MBT is a period when the cell cycle slows and zygotic transcription begins
(Kane & Kimmel, 1993; Tadros & Lipshitz, 2009). During this period, the cells fall out of
synchrony, cell motility begins and cell cycle lengthens. With the MBT, the duration of
interphase increases because of the length of the S phase. After cell cycle 10, the G1 phase is
first added to the interphase in some cells, and zygotic transcripts of the cell cycle inhibitors
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initiate the G1/S cell cycle checkpoint. The rest of the cells will add G1 in the next 4 cell cycles.
At the cell cycles 11-13 (3.5-4h, , blastula stage) the G2 phase is added to the interphase. During
this period, the blastoderm is separating into the enveloping layer, yolk syncytial layer and the
deep cells of the blastoderm (Kimmel et al., 1995). Notably, the yolk cells have a short cell
cycle, the deep cells have an intermediate cell cycle, and the enveloping layer cells have the
longest cell cycle length (Kane, Warga, & Kimmel, 1992). By the end of blastula, cell cycle 15
(30% epiboly), many cells exit cell cycle and commit to differentiation, giving rise to notochord
cells and somatic muscle cells, followed by the rise of large primary motoneurons in the next
division (Lewis and Eisen, 2003). Most of the zebrafish cell cycle and cytokinesis mutants that
arrest in early development (speed bump, zombie and ogre) show their mutant phenotype around
this period, suggesting that maternal supplies ensure a normal embryo development until the
onset of gastrulation (Haffter et al., 1996; Riley et al., 2010; Warga et al., 2016). This is one of
the most powerful advantages of zebrafish as a model organism, as opposed to the mouse.
Among other advantages, is that adult zebrafish are small, easy to handle and to maintain
their population in the laboratory setting. External fertilization and large clutches allow us to
collect hundreds of newly fertilized eggs a few times a week, which is very useful when working
with Mendelian recessive mutants. Optical clarity and fast development allow us to study
embryo development from the one-cell stage until the classic vertebrate morphological features
in just the first 48 hours post fertilization. Finally, large-scale extensive genetic screens and
sequenced zebrafish genome sequencing project allows us to utilize it as a model to study
conserved mechanisms of growth and development (Kane et al., 1996).
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A regulation of G2 to M cell cycle progression and beyond in eukaryotes mediated by
Cyclin Bs
In eukaryotes, cell cycle is regulated by cyclin-dependent kinases (Cdks) (Hartwell et al.,
1973; Nigg, 2001) and the cyclin proteins (Lohka et al., 1988; Pines, 1995). Cdks phosphorylate
specific cyclins to drive cell cycle progression (Lindqvist et al., 2009). All eukaryotes have
several classes of cyclins which form active complexes each with distinctive Cdks (Knoblich and
Lehner, 1993; Kreutzer et al., 1995). This classification is based on temporal activation of the
Cyclin/Cdk complex during cell cycle progression (Draviam et al., 2001). The Cyclin/Cdk
complexes have been discovered in all eukaryotes, suggesting that these complexes have an
evolutionary conserved and essential function (Courtot et al., 1992; Fitch et al., 1992; Knoblich
and Lehner, 1993; Kreutzer et al., 1995). Moreover, several research groups have suggested
some functional redundancy of the cyclins (reviewed by Zhang, 1999).
Before a cell is ready to enter mitosis, there is a set of changes happening in the
interphase. First, the chromosomes condense, the nuclear envelope breaks down, followed by the
formation of mitotic spindle. These changes are accompanied by, and may be controlled by, the
activation of the Cyclin/Cdk complexes. Cyclin A (A1 and A2) and Cyclin B (B1 and B2) were
the first discovered mitotic cyclins (Evans et al., 1983; Fitch et al., 1992), in the proliferating
mammalian cells (Furuno et al., 1999). The Cyclin A2/ Cdk2 complex is nuclear, and is
necessary to drive cells from G2 to prophase (reviewed by Gong, Ferrell, & Lew, 2010).
The activation of the Cyclin B/Cdk1 complex happens after a certain threshold is reached
in late S/G2 phase, however the Cdk1 remains inactive until the late G2 (reviewed by
Hörmanseder, Tischer, & Mayer, 2013). Gallant & Nigg (1992) showed that the chicken Cyclin
B expressed in HeLa cells was cytoplasmic during interphase, and translocated to the nucleus
before NEB. This observation led them to hypothesize that Cyclin B2 was the major regulator of
5

the NEB. Ablation of both, cyclin B1 and cyclin B2 mRNAs with the antisense oligonucleotides,
blocked Xenopus oocytes from NEB and entering mitosis, which supports earlier observation
(Minshull et al., 1989a). However, the knockout of only one of the two cyclin Bs, did not prevent
cell cycle progression and NEB (Minshull et al., 1989a). Later, Gong et al. (2007) argued this by
demonstrating that the nuclear Cyclin A2 was essential for the NEB in HeLa cells. Moreover,
they showed that cyclin A2 knockout cells could be rescued only if Cyclin B was expressed in
the nucleus constitutively (Gong et al., 2007). These studies show that some variation in function
of the homologous cyclins is present between different species.
After CyclinB1/Cdk1 is translocated into the nucleus, it associates with histones,
condensins, centromeres, kinetochores and the mitotic spindle, for the Cdk1 to phosphorylate the
substrates and promote the onset of metaphase (Chen et al., 2008; Jackman et al., 2003; Kimura
et al., 1998; Moore et al., 2002). Cyclin B2, on the contrary, has been reported to remain
associated with Golgi apparatus in cytoplasm of the human tissue culture cells until prophase
(Jackman et al., 1995), when it is targeted for disassembly mediated by Cyclin B2/Cdk1 (Misteli
and Warren, 1994). The Golgi apparatus modifies proteins, builds lipids, and sorts them into
cellular compartments. This trafficking is necessary to establishing cell polarity and directed
secretion (Yadav and Linstedt, 2011; Rodriguez-Boulan and Macara, 2014; Sanders and
Kaverina, 2015). This suggests, that Cyclin B2 plays a distinct role in membrane trafficking.
Golgi apparatus promotes microtubule nucleation independently of the microtubule organizing
center and centrioles. The loss of Golgi-nucleated microtubules has been reported to prevent
polarized protein trafficking and directed migration (Efimov et al., 2007). Loss of Cyclin
B2/Cdk1-mediated Golgi disassembly might be affected in the cyclin B2 mutants. Besides
localizing at Golgi, Cyclin B2 is associated with spindle and chromosomes in meiosis II in the
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oocytes of the Rana japonica frog(Kotani et al., 2001a). A recent study has shown that Cyclin
B2 proteins are also translocated into the nucleus in mouse oocytes during meiosis (Daldello et
al., 2019), which suggests that Cyclin B2 is also important for the G2 to M progression.
After the spindle assembly checkpoint is satisfied, and Cyclin Bs are targeted for
degradation by the anaphase-promoting complex/cyclosome (APC/C) (Clijsters et al., 2013;
Gérard et al., 2015). This, in turn, deactivates Cdk1, and promotes cells to exit mitosis (Lindqvist
et al., 2007). When Cyclin B1 is not degraded, the Cdk1 remains active, resulting in the
metaphase arrest (Vázquez-Novelle et al., 2014). However, Cdk1 inactivation is not crucial for
the mitotic exit, since even in the absence of active Cdk1, its substrates remain phosphorylated
(Skoufias et al., 2007). This suggests that degradation of Cyclin B1 is not enough to deactivate
Cdk1 and exit mitosis.
The Cyclin B/Cdk1 complex has several distinct roles besides promoting cells to exit
interphase and enter mitosis. First, it coordinates mitotic rounding, through Cdk1
phosphorylating its downstream substrates (Draviam et al., 2001). Indeed, Cyclin B/Cdk1 has
been shown to be sufficient to induce rounding upon injection into interphase cells (Lamb et al.,
1990), but it is not clear whether Cyclin B/Cdk1 activity regulates directly the actin filament
organization and rearrangements during cell rounding. Second, it regulates the nucleating ability
of centrosomes and the dynamics of microtubule polymerization in the prophase. (Verde et al.,
1992; Draviam et al., 2001). Third, whether Cyclin B/Cdk1 defines the length of anaphase, and
finally if Cyclin B/Cdk1 activity indirectly regulates cytokinesis(Mathieu et al., 2013). Cdk1,
Polo kinase and Aurora B move centromeres to spindle midzone to participate in cytokinesis, or
ingression furrow, to prevent chromosome lagging and breakage (Afonso et al., 2019;
Kettenbach et al., 2011). When the spindle checkpoint is satisfied, Cyclin B/Cdk1 complex is
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degraded, but its low levels argue for Cdk1 being released for cytokinesis regulation. Lack of
Cdk1 has been shown to cause late abscission, suggesting that Aurora B is a Cdk1 substrate
(Afonso et al., 2019).
Work done recently clearly shows that the function of the Cyclin Bs might have slightly
different roles in somatic cells (Table 1.1) and in the germ cells (Table 1.2) and these differences
seem species specific. There is evidence of Cyclin B/Cdk1 being not only important for the G2
to M transition, but also to regulate the progression of the M phase and mitotic exit. Research on
the role of Cyclin B/Cdk1 in mitosis indicates that Cyclin B1 is the primary Cyclin B in mouse,
causing cell cycle arrest at the G2/M checkpoint and cell death (Table 1.1, Table 1.2). However,
in C. elegans and zebrafish, cells enter mitosis, but lack of functional Cyclin B1 causes
prolonged and unregulated mitosis and, in C. elegans and human cell culture, multinucleated
cells (Table 1.1). Interestingly, that lack of Cyclin B2 in in mouse oocytes causes incomplete
nuclear maturation, aneuploidy followed by delayed entry into the M phase (Daldello et al.,
2019). These changes are not lethal, but affect mouse fertility and the size of the litter, which has
been shown before (Brandeis et al., 1998; Daldello et al., 2019).
The current research on this topic has motivated me to identify the role of Cyclin Bs in
zebrafish cell cycle and mitosis progression, and also early embryo development. Cyclin B1 is
considered the main Cyclin B1 promoting cells into mitosis. Showing that its absence does not
prevent cells from entering new rounds of division in vivo in the vertebrate is novel finding.
First, I show that in cyclin B1 mutants, many cells remain in the G2/M phase of the cell cycle,
which indicated cell cycle arrest. Second, I show that cells die, because of cell cycle progression
abnormalities, like chromosomal instability. This finding helped me to identify the role of Cyclin
B1 not only as a mitosis promoting factor, but as the mitosis regulating factor.
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Table 1.1 A summary of work done on the role of Cyclin B1 and Cyclin B2 in mitotic cells
Model
Organism

Research

Mitosis
Cyclin B1

HeLa cells

Xenopus

Mouse

HeLa cells

Human
colorectal
cancer cells
C. elegans

Mouse

Zebrafish

Expression of nondestructible avian Cyclin
B2 in HeLa cells (Gallant
and Nigg, 1992)

N/A

Overexpression of
Cytoplasmic retention
signal of Cyclin B1 and
B2 on the spindle
formation (Yoshitome et
al., 1998)
Cyclin B1 and Cyclin B2
knockout lines (Brandeis
et al., 1998)
Cdk1 substrate
specificity in response to
Cyclin B localization
(Draviam et al., 2001)

No change in bipolar spindle
formation

RNAi double knockout
of human cyclin B1 and
cyclin B2 (Bellanger and
Gramont, 2007)
Analysis of endogenous
cyclin b1 (cyb-1) and
cyclin b3 (cyb-3) in cell
cycle progression using
RNAi knockouts (van der
Voet et al., 2009)
Analysis of the lethal
cyclin B1 null mutation
in mouse embryo in vivo
(Strauss et al., 2018)
Analysis of the cyclin B1
null mutation in zebrafish
embryo in vivo
(Petrachkova et al., 2019)

Cyclin B1 mutants die in utero

Cyclin B2
Overexpression of Cyclin B2
causes mitotic arrest, multiple
mitotic spindles
Inhibition of the bipolar spindle
formation

Cyclin B2 mutants develop
normally, fertile, but are smaller
and have fewer progeny
Cyclin B1/Cdk1 facilitates
Cyclin B2/Cdk1 primary function:
Golgi apparatus disassembly
Golgi apparatus disassembly;
cannot compensate cell rounding
defects and cytoskeleton
rearrangement.
cyclin B1/B2 double mutant cells have abnormal mitosis; cells
undergo premature mitotic exit followed by endoreplication (4N
cells). Endogenous Cyclin B2 expression rescues the double mutant
phenotype.
Lack of cyb-1 does not
N/A
interfere with normal mitotic
spindles formation, but causes
misalignment of chromosomes
at metaphase plate, and
abnormal anaphase, which
results in multinucleated cells.
Lack of Cyclin B1 causes cell Cyclin B2 expression does not
cycle arrest in the G2 phase
rescue mutant phenotype.
after second division in
cleavage.
Maternal Cyclin B1 regulates
N/A
G2 to M transition until early
segmentation. Cells are
predominantly in the G2/M
phase, abnormal mitosis. Lack
of zygotic Cyclin B1 does not
prevent cells from undergoing
mitosis. A compensatory
mechanism proposed.
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Table 1.2. A summary of work done on the role of Cyclin B1 and Cyclin B2 in meiotic cells.
Model
Organism

Rana japonica
(Japanese frog)

C. elegans

Mouse

Mouse

Research

Analysis of Cyclin B1
and Cyclin B2 in spindle
formation in oocytes
(Kotani, Yoshida, Mita,
& Yamashita, 2001)
Analysis of endogenous
cyclinb1 (cyb-1) and
cyclinb3 (cyb-3) in cell
cycle progression using
RNAi knockouts in C.
elegans oocytes (van der
Voet et al., 2009)
Meiosis in Cyclin B1 and
Cyclin B2 knockout lines
in mouse (Li et al., 2018)

Meiosis in Cyclin B1 and
Cyclin B2 knockout lines
in mouse (Daldello et al.,
2019)

Meiosis
Cyclin B1
Cyclin B1 causes monopolar
spindle formation in
metaphase.
Is sufficient to promote
germinal vesicle formation.
Cyclin B1 is required for
chromosome condensation.

Cyclin B2
Cyclin B2 expression is
required for bipolar spindle
formation in metaphase. Is
sufficient to promote germinal
vesicle formation.
N/A

Cyclin B1 null mutants enter
Cyclin B2 activates Cdk1.
interphase after meiosis I.
Exogenous Cyclin B2/cdk1
Females are infertile at the
rescues Cyclin B1 mutant
germinal vesicle stage.
phenotype.
Cyclin B1/Cyclin B2 double knockout cells arrest at the germinal
vesicle stage (prophase of meiosis I).
In cyclin B1/cyclin B2
In cyclin B2 knockout,
knockout, expression of Cyclin expression of Cyclin B2/Cdk1
B1/Cdk1 forms monopolar
forms bipolar spindle. Cyclin
spindle in metaphase I.
B2 mutant oocytes have delayed
meiosis I to anaphase transition.
Most of the cells arrest in
meiosis I or telophase.

10

CHAPTER 2

LACK OF CYCLIN B1 IN ZEBRAFISH CAUSES LENGTHENING OF G2 AND M PHASES
This chapter has been published in Developmental Biology: Petrachkova T, Wortinger LA,
Bard AJ, Singh J, Warga RM, Kane DA. Lack of Cyclin B1 in zebrafish causes lengthening of G2
and M phases. Dev Biol. 2019;451(2):167-179 doi:10.1016/j.ydbio.2019.03.0.14
INTRODUCTION
Cell cycle progression is regulated by conserved Cyclin-dependent kinases (Cdk’s) and
cell cycle proteins (Cyclins). While Cdk’s are constitutively expressed throughout the cell cycle,
Cyclins are expressed more dynamically where they control individual phases of the cell cycle.
Mammals and zebrafish have two types of Cyclin B (B1 and B2) (Minshull et al., 1989; Pines
and Hunter, 1989). Chicken, frogs, flies, and worms also have a third type, Cyclin B3, essential
for germline development (Gallant and Nigg, 1994; Kreutzer et al., 1995). Both Cyclin B1 and
B2 are detectable in G1, rise through S phase and peak in late G2 or early M phase, after which
they degrade in anaphase (Brandeis and Hunt, 1996). Cyclin B1 is primarily cytoplasmic but
constantly shuttles between the nucleus and the cytoplasm in interphase, whereas Cyclin B2 is
primarily in the cytoplasm during both interphase and mitosis (Jackman et al., 2003).
The G2 to M transition of the cell cycle relies predominantly on Cyclin B1 and Cdk1
activity (reviewed by J. Pines, 1995; Santamaría et al., 2007). To this end, Cyclin B1 has four
major domains: a chromatin localization domain (CLD) essential for localization of Cyclin B1 to
chromatin and the centrosomes (Pfaff and King, 2013); a destruction box (D-box) recognized by
the anaphase promoting complex/cyclosome (APC/C) for Cyclin B1 ubiquitination during
anaphase; a cytoplasmic retention domain (CRD) preventing Cyclin B1 from binding to the
chromosomes prior to prophase; and a Cdk1-binding domain, essential for Cdk1 binding
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(Bentley et al., 2007; Draviam et al., 2001; Pfaff and King, 2013). Together with Cdk1, Cyclin
B1 forms a protein kinase holoenzyme complex, also known as the Mitosis Promoting Factor
(MPF) (Draetta et al., 1989). The MPF remains inactive until a Cyclin B1 threshold is surpassed
in late G2 of the cell cycle (Allan and Clarke, 2007). Once DNA replication is over, the MPF is
activated through Cdc25 phosphorylation of inhibitory Wee1 and Myt1 kinases, to ensure that
the MPF is fully activated (reviewed by Lindqvist et al., 2009). A high activity of the MPF
allows cells to enter mitosis as the MPF translocates to the nucleus. Once in the nucleus, the
MPF phosphorylates nuclear substrates, such as caspases, to protect mitotic cells against
apoptosis (Ikegami et al., 1999; reviewed by Porter and Donoghue, 2003). The MPF also
controls cell rounding in prophase (Gavet and Pines, 2010), and disassembly of the nuclear
lamina in early prometaphase to promote nuclear envelope breakdown (reviewed by Nigg, 2001).
Exit from mitosis is initiated by degradation of Cyclin B1 by the APC/C during mitosis (Clijsters
et al., 2013; reviewed by Zachariae and Nasmyth, 1999). Cdk1 itself remains constitutively
present to interact with other Cyclins (reviewed by Hochegger et al., 2008).
Cyclin B2 has been shown to be associated with the Golgi apparatus until prophase when
the Golgi apparatus is targeted for disassembly mediated by Cyclin B2/Cdk1 (Draviam et al.,
2001). Although not commonly believed to be important for the G2 to M transition, much like
the “Maturation” Promoting Factor is for mitosis, Cyclin B2 is essential for oocyte “maturation”.
Together with the Hec1 kinetochore component, Cyclin B2 regulates microtubule nucleation
during prophase and early prometaphase, as well as helps the centrosomes to organize the mitotic
spindle in both mouse (Daldello et al., 2018; Gui and Homer, 2013; Li et al., 2018) and frog
(Kotani et al., 2001a).
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In vivo studies show that mice lacking Cyclin B1 die in utero, whereas mice lacking
Cyclin B2 are viable, only smaller than normal, and have reduced litter sizes (Brandeis et al.,
1998). Flies lacking Cyclin B1 fail to form a spindle and cannot go through mitosis after the
mid0blastula transition (Gong et al., 2010; Knoblich and Lehner, 1993; Nieduszynski et al.,
2002). To date, however, there have been few studies that have examined the absence of
functional Cyclin B1 during early development, except a recent study in mouse that showed that
once the embryo runs out of maternal Cyclin B1, blastula cells arrest in G2 after the second
division (Strauss et al., 2018). Despite this research on mouse Cyclin B1, other studies in human
culture cells indicate that once Cyclin B1 is absent, Cyclin B2 enters the nucleus to form an
activate MPF with Cdk1 overcoming the G2/M arrest (Bellanger et al., 2007; Gallant and Nigg,
1992). Therefore, there may be some redundancy in Cyclin B roles and differences between
species.
Here we show that the zebrafish early arrest mutant specter (spr tu21) is a recessive loss of
function mutation in cyclin B1. We confirmed that spr tu21 is a mutation in cyclin B1 using
CRISPR/Cas9 mediated germline mutagenesis to create a new allele (spr ro1), which fails to
complement the original spr tu21 mutant allele. Like in other zebrafish cell cycle mutants (Kane et
al., 1996; Riley et al., 2010; Song et al., 2004; Warga et al., 2016), once maternal cyclin B1
mRNA is depleted, the zygotic phenotype is manifested. However, lack of zygotic cyclin B1
mRNA does not appear to affect the embryo until quite late in development and rather than
arresting the cell cycle, results in cells progressing through the cell cycle slower, delaying the G2
and M phases. Eventually, abnormal cell cycle progression causes numerous cellular changes,
such as fewer and bigger cells, lagging chromosomes and cells that undergo apoptosis. spr ro1
mutant embryos exhibit a similar phenotype, only more severe and with an earlier onset. Further
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analysis indicated that in the ro1 allele a Cyclin B1 product is made, but that it perhaps interferes
with the function of the MPF. We conclude that while Cyclin B1 is critical for “normal” cell
cycle progression, when it is absent there must be a compensatory mechanism that pushes cells
through the G2/M checkpoint.
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MATERIAL AND METHODS
Mapping and genetic characterization
The specter (spr tu21) mutation was isolated in the Tübingen screen (Haffter et al., 1996)
and outcrossed to the polymorphic WIK (L5) strain of wild-type fish for mapping by half tetrad
analysis (Johnson et al., 1995). Single stranded linked polymorphisms (Knapik et al., 1998),
were used as in McFarland et al. (2005) to establish linkage. This mapped specter to one arm of
Chromosome 5. Finer resolution on the Sanger map was further obtained using a haploid panel
and the following microsatellite (z) markers:
z44961 (F 5' GAG CAA TGT TTT CCC AGC AT 3', R 5' ATG GGC GGG ATT TAA
CC 3'); z7428 (F 5' ATT GGG TGG TTG TGC ATT CT 3', R 5' CTG TCC AAT CTC GCT
GTC AC 3'); z58519 (F 5' CTT GCG GTT AAA CAT GCT TG 3', R 5' TTG TCT CCC TAG
CGT GCT GT 3'); z65883 (F 5' CCT TTG GGC TTT CTG ACA AG 3', R 5' GTG TTT GGT
GAA TCA GCC CT 3'); z36189 (F 5' TAA AAT CCT ACC GCG TAC CGG 3’, R 5’ GCA
GGT GAA GGT GGA TGA AT 3'); z5538 (F 5' TCA GCC ACA TTA GGG GAA AG 3', R
5' TTC AGA AGC CAT CCA TGT TG 3' ); z3804 (F 5' GCA TCT GGT GTT GTA GG 3', R
5' CAG GAT CAA AAG CTG TGC AA 3'). This identified five potential candidate genes in a
4 Mb interval, one of which was cyclin B1 (Supplementary Table 2.1). To determine whether
spr tu21 was a mutation in cyclin B1 we used RT-PCR and verified this by SANGER sequencing
using genomic DNA from individual embryos.

Generating the specter ro1 mutant allele and identification of alternative splice variants
As described in Hwang et al. (2013) we constructed sgRNA targeted to the sequences
GGCCAGGCGAGTGTTCTACT, a region complementary to a region in the intron 1 – exon 2
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of the cyclin B1 gene. Appropriate sense and antisense oligonucleotides were annealed together
and subcloned into DR274 (Addgene) as per Hwang et al. (2013). To produce sgRNA, the vector
was linearized by digestion with DraI, and RNA was produced using the MAXIscript T7 kit
(Life Technologies). cas9 mRNA was generated using a Cas9 vector (Addgene) as per Hwang
et al. (2013) using the mMESSAGE mMACHINE T7 ULTRA kit (Life Technologies).
To mutagenize fish, we injected wild-type embryos at concentrations from 9 to 13 pg of
sgRNA together with 200pg of cas9 mRNA. The total number of embryos injected with
CRISPR/Cas9 mRNA was approximately 1300 (Fig. 2.3B). After three months of growing
mutagenized fish, only five survived. One was identified as a founder by complementation
testing.
To identify alternative splice variants, total mRNA was extracted from phenotypic wildtype embryos from a transheterozygote cross and spr ro1 mutant embryos from a spr +/ro1 cross.
Reverse transcriptase PCR was performed using the following primer pairs:
5’ CCAGTTTGTTCATCGAGTCAC 3’ and 5’ GCAATCTCTGGTGGGTACATC 3’. Purified
PCR products were then subcloned into pGEM-T Easy vectors (Promega) to generate enough
DNA for SANGER sequencing.

Live cell cycle reporting and time-lapse microscopy
For analysis of the cell cycle in spr tu21 mutants, we bred the Dual FUCCI transgene
(Bouldin and Kimelman, 2014) into the spr tu21 allele. Live anesthetized embryos were identified
as mutant or wild type by their morphological phenotype, mounted at 24 hours in 0.2% agarose
and recorded in multi-plane every 6 minutes for 4 hours as previously described in Warga and
Kane (2003), except we used a Nikon C2 confocal microscope, at 20x or 60x magnification,
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running NIS Elements Confocal software, in an imaging facility maintained at 30°C during the
recording.
For the analysis of the cell cycle in spr ro1 mutants, embryos derived from ro1
heterozygotes were injected at the 1-cell stage with 25 pg H2B-RFP mRNA (Liu et al., 2017).
Live embryos were mounted at 2-somites and recorded, as described above, every 5 minutes for
4 hours. At the end of the time-lapse, embryos were identified as mutant or wild type by their
morphological phenotype.
Image processing and analysis was done using EOS Utility 2, Adobe Photoshop CS2,
Adobe Photoshop 11.0, and NIS Elements Viewer (v. 4.20). During image processing, H2B-RFP
labeled cells were pseudocolored from red to green.

Lineage tracing
Lineage tracing was adapted from those previously described (Warga and NüssleinVolhard, 1999; Warga et al., 2009). Briefly an individual blastomere was labeled between the
1K- to 2K–cell stages with a 5% solution of neutral rhodamine-dextran (10000 MW). To count
the number of enveloping layer cells, embryos were oriented in 3% methyl cellulose in
Daniaeu’s media and examined on a Zeiss Axioskop at: 40% epiboly, 60% epiboly, tailbud, 3-,
15-, and 18-somites and at 24 hours. All embryos were re-examined at 24 hours except in the
case of 18-somites (18 hours) and 24 hours where embryos were also re-examined at 36 hours.

In situ hybridization, BrdU labeling, antibody, and DAPI staining
Whole-mount RNA in situ hybridization was carried out using digoxigenin-labeled
riboprobes following the protocol in Thisse and Thisse (2008). For cyclin B1 in situ
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hybridization, embryos collected at 15-, 20-, and 24-hours (Table 1), were first sorted by their
morphological phenotype prior fixation before further characterization. BrdU pulse labeling was
performed as described by Phillips et al. (2006) and stained with an anti-BrdU antibody (Abcam
ab1894, 1:1000). Whole-mount antibody staining was carried out using an anti-active Caspase 3
antibody (BD Biosciences, 1:200), an anti-αTubulin antibody (Developmental Studies
Hybridoma Bank, 1:25), an anti-GFP antibody (Santa Cruz, 1:500) or an anti-Phospho-Histone
H3 antibody (Santa Cruz, 1:1000) and detected with an AP-conjugated or peroxidase-conjugated
secondary antibody (Santa Cruz, 1:1000) or Alexa Fluor 488-, 594-, 647-conjugated secondary
antibodies (ThermoFisher Scientific, 1:200). DAPI staining was used at a concentration 1 ng/mL.
Embryos were cleared in 70% glycerol and photographed using a Sony F-707 digital
camera or Canon T5 digital camera on a Zeiss Axioskop II, or a Nikon SMZU binocular
stereomicroscope. In the case of fluorescent detection, we used a Nikon C2 Confocal microscope
running NIS Elements Confocal software. Image processing was as described above.
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RESULTS
The spr mutant exhibits delayed development with ongoing apoptosis
The original specter (spr) allele was isolated in the Tübingen screen (Haffter et al., 1996)
and identified in the early arrest group for phenotypes that displayed gross cellular abnormalities
in the first 24 hours of development (Kane et al., 1996). Represented by 2 Mendelian recessive
lethal alleles (tu21 and ta214), both were first distinguishable at 7-somites (12.5 hours, Fig.
2.1A, A') by a smaller head and tail compared to wild-type siblings. By 10-somites (14 hours),
mutant embryos were noticeably shorter, lacked clear somite boundaries, had smaller eye
placodes, and the head and nervous system looked opaque. These defects increased over time so
that by 20-somites (19 hours), somite borders in the mutants were no longer distinguishable (Fig.
2.1B, B') and by 30-somites (24 hours), motor activity was abnormal.
Common characteristics for mutants that affect the cell cycle are loss of optical
transparency, due to generalized cell death (Song et al., 2004; Warga et al., 2016), and for cells
to be larger and fewer in number (Riley et al., 2010; Warga et al., 2016). We found that spr
mutants had extensive apoptosis (Fig. 2.1C, C'), as revealed by antibody staining for the active
form of Caspase-3 (Negron and Lockshin, 2004). Labeling of the blood cells by various markers
showed that they were bigger and less numerous in the mutant (Fig. 2.1D-F'). Thus, spr mutants
superficially resemble other cell cycle mutants.

spr is a mutation in cyclin B1
Initial mapping, using gynogenetic diploid embryos (Streisinger et al., 1986), linked
spr tu21 to linkage group 5. Fine mapping of spr tu21, using haploid embryos and seven
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Figure 2.1
The spr mutant phenotype.
(A, B) Morphology of the live embryo, side view of: (A, B) wild-type and (A', B') spr tu21
embryos. Arrows indicate darkening in the head and trunk. Note the undefined somite borders in
the mutant by 20-somites (19 hours). (C, C') Apoptosis, visualized by antibody staining for an
active form of Caspase 3, is evident in the head of the spr mutant by 25-somites (21.5 hours).
Embryos are shown is side view using pax2a mRNA expression to define the area between the
hindbrain and optic stalk. (D-F') Blood cells are larger and less frequent in the spr mutant.
(D, D') Labeling of the blood by the erythrocyte marker, hbbe2 (Brownlie et al., 1998), 8/8
mutants and 20/20 wild-type embryos displayed this phenotype; (E, E') the macrophage marker,
lcp1 (Herbomel et al., 1999), 10/10 mutants and 17/17 wild-type embryos displayed this
phenotype; (F, F'); and the neutrophil marker, mpx (Bennett et al., 2001; Lieschke et al., 2001),
10/10 mutants and 21/21 wild-type embryos displayed this phenotype. Boxes indicate the areas
enlarged at higher magnification, scale bar is 20 µm.

microsatellite (z) markers narrowed it to a region between the markers z58519 and z65883 where
no recombination was observed (Fig. 2.2A). These markers delineate approximately 85 genes
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including cyclin B1 (Table 2.1).
Based on the cell cycle phenotype, cyclin B1 was the most promising candidate gene.

Figure 2.2
Identification of spr tu21 as a mutation in cyclin B1 gene.
(A) A partial genetic map of Linkage Group 5 showing microsatellite (z) markers used in mapping
on the left; and the number of recombinants in relation to the total number of individuals on the
right. Combined haploid and diploid data show the least number of recombinants between the
specter allele and z58519 and z65883, an interval that includes 85 genes (Supplementary Table 1).
(B) Chromatograph sequence data showing the C139T transition that results in a premature stop
codon (red asterisk). (C) Exon structure of the cyclin B1 gene product showing 9 exons (E1-E9)
and putative protein coding regions: chromatin localization domain (CLD), destruction box (Dbox), cytoplasmic retention domain (CRD), and Cdk1-binding domain. The spr tu21 allele has a
premature stop codon in exon 2 (red asterisk). (D-G') cyclin B1 mRNA is (D, E) maternally, and
(F, G) zygotically expressed. (F'-G') Note that expression of cyclin B1 mRNA in the mutant
embryo is significantly diminished at 10-somites (14 hours) and absent by 15-somites (16.5
hours).
Therefore, we sequenced mutant cDNA revealing a transition that caused a nonsense mutation
(C139T; Fig. 2.2B) in exon 2 of the gene. This product, if transcribed, would result in a product
lacking the Cdk1 binding domain, the destruction box, and the cytoplasmic retention domain –
all critical for Cyclin B1 activity (Fig. 2.2C). In situ hybridization for the cyclin B1 mRNA (Fig.
2.2D-G') showed it was present in the two-cell embryo and maternal transcripts were maintained
through early gastrulation (Fig. 2.2D, E). However, where in wild-type embryos cyclin B1 is
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expressed throughout somitogenesis (Fig. 2.2F, G), in mutant embryos it is not (Fig. 2.2F', G').
We interpret this to mean that this mutation likely produces a nonfunctional gene product that
undergoes nonsense-mediated RNA decay. Thus by 10-somites (14 hours), the embryo appears
to have exhausted all maternal stores of cyclin B1 transcripts.

Gene editing confirms that spr is a mutation in cyclin B1
To demonstrate that spr tu21 was a mutation in cyclin B1, we first attempted mRNA
rescue using wild-type cyclin B1. Injecting cyclin B1 mRNA into embryos derived from tu21
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Figure 2.3
CRISPR/Cas9-mediated mutagenesis confirms spr tu21 is a mutation in the
cyclin B1 gene.
(A) Schematic representation of the CRISPR/Cas9 system, recognizing the target site within
exon 2 of the cyclin B1 gene. Blue, guide RNA (sgRNA); green, target site where ag is the
acceptor site of intron 1; red, PAM site. (B) Diagram of CRISPR/Cas9-mediated mutagenesis.
Embryos from a wild-type cross (G0) were injected at the 2-cell stage with the cas9 mRNA and
sgRNA. After 3 months, founders were complementation tested to spr tu21 heterozygotes. In the
G1, 10% of the eggs were spr tu21/spr ro1 transheterozygotes suggesting that the germline clone
was approximately 40% of the germline. After outcrossing the G1 spr ro1 founder to wild-type
fish, identification of the spr ro1 carriers (G2) was done by incrossing. (C-F) In vivo morphology
and expression of cyclin B1 mRNA in: (C') wild-type, (D') spr tu21, (E') spr tu21/spr ro1, and (F')
spr ro1 mutant embryos at 25 hours. All embryos are shown in side view. Note that the spr tu21/
spr ro1 (E'), and spr ro1 (F') mutant embryos have zygotic cyclin B1 mRNA transcripts at 20 hours,
but spr tu21 mutant embryos do not. (G) Chromatograph sequence showing a splice-site mutation
occurs in the spr ro1. The spr ro1 mutant has a 2-base deletion (AG acceptor site) and 4 base
insertion (GGAT), underlined. Green, sgRNA target site; red, PAM site.
heterozygotes at the 1-cell stage, did not alter the morphological phenotype of the mutant or its
siblings. Further detection with antibody staining also did not reveal changes in mitosis or
apoptosis. Undeterred, we changed strategy and edited the cyclin B1 gene using CRISPR/Cas9.
Our synthesized sgRNA had a recognition sequence in the second exon, 102 bp upstream of the
mutation found in the spr tu21 allele (Fig. 2.3A). We identified cyclin B1-edited founders by
complementation testing with spr tu21 heterozygotes (Fig. 2.3B). 10% of the progeny failed to
complement, and the transheterozygote spr tu21/ ro1 embryos resembled the spr tu21 mutant
phenotype (Fig. 2.3C-E), albeit more severe. Sequencing of spr ro1 mutant embryos showed that
the edited sequence had a splice site mutation with a deletion of the ag acceptor splicing site and
an insertion of four nucleotides (Fig. 2.3G). We conclude from these experiments that spr is
caused by a mutation in cyclin B1.

The spr ro1 mutation possibly alters the Cyclin B1 protein
outcrossing and recovering the spr ro1 allele, we found that like spr tu21, it behaved as a
Mendelian recessive lethal with no apparent dominant heterozygous phenotype (Table 2.1).
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However, when homozygous it had an even more severe morphological phenotype than the null
allele (Fig. 2.3C-F) suggesting it was a gain-of-function. We first asked if cyclin B1 mRNA was
expressed and found that spr ro1 mutants exhibited robust cyclin B1 expression (Fig. 2.3F')
similar to that of wild-type embryos and very different from that seen in spr tu21 mutants (Fig.
2.3D'). By comparison, the spr tu21/ro1 transheterozygote had an intermediate level of cyclin B1
transcripts (Fig. 2.3E'). Therefore, spr ro1 mutants produce cyclin B1 transcripts that do not
undergo degradation.
To understand our in situ data, we first sorted embryos by wild type or mutant phenotype
prior to fixation, followed by in situ hybridization, after which we sorted each category by the
intensity of their cyclin B1 expression (Table 1). We found that in a spr ro1 cross (Table 1), all
embryos, both wild type (74% of the cross) and mutant (26% of the cross), had strong cyclin B1
expression. However, in a spr tu21 cross (Table 1), not all wild-type embryos had strong cyclin B1
expression (26% of the cross), as some had weaker expression (46% of the cross).
Table 2.1 Intensity of cyclin B1 mRNA expression between 16 and 24 hours.
specter cross

Phenotype
a

Strong (%)

Intermediate (%)

None (%)

Total embryos (%)

26 (26%)
0

46 (46%)
0

0
28 (28%)

100 (100%)b

+/tu21 x +/tu21

wild type
mutanta

+/tu21 x +/ro1

wild typea
mutanta

43 (53%)
0

20 (24%)
19 (23%)

0
0

82 (100%)c

+/ro1 x +/ro1

wild typea
mutanta

118 (74%)
42 (26%)e

0
0

0
0

160 (100%)d

a

Statistically consistent with the Mendelian homozygous recessive segregation, using the chi
square test.
b
Embryos collected from four clutches in a +/tu21 x +/tu21 cross.
c
Embryos collected from two clutches in a +/tu21 x +/ro1 cross.
d
Embryos collected from four clutches in a +/ro1 x +/ro1 cross.
e
spr ro1 mutants exhibited stronger cyclin B1 expression compared to the transheterozygote but
weaker than phenotypic wild type.
In the quarter of the embryos that were mutant there was no expression (28% of the cross). This
distribution correlates to the expected number of genotypic wild type, heterozygotes, and mutant.
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Thus, it would seem that if embryos inherit one copy of the tu21 allele, whose transcript
undergoes nonsense mediated decay, cyclin B1 expression is less robust that normal. When we
examined a transheterozygote cross (Table 1) we also found that not all wild-type embryos had
strong cyclin B1 expression (53% of the cross), as a portion of wild-type embryos exhibited
weaker expression (24% of the cross), much like that of the transheterozygote mutant (23% of
the cross). This distribution supports the idea that strong expression only happens when embryos
do not inherit the tu21 allele (all the wild type and half the heterozygotes). Altogether these
results argue that intermediate expression is solely the result of the wild-type or ro1 allele as the
tu21 allele has no detectable mRNA activity.
Further analysis revealed that spr ro1 mutants had many alternatively spliced mRNA
products compared to the expected 741 bp product. This was demonstrated by extracting total
mRNA from homozygous mutants and amplifying a fragment of the cyclin B1 cDNA using a
forward primer in the exon 1 and a reverse primer near the beginning of exon 6 (Fig. 2.4A).
spr ro1 mutants had additional products of 900 bp and 1200 bp (Fig. 2.4A). Because embryos
were sorted by their morphological phenotype, the wild-type pool also displayed these additional
ro1 products, although much fainter, as two thirds of these individuals were heterozygous. After
subcloning these fragments into vectors, we also identified a further product of 250 bp (Fig.
2.4B) that we did not see before probably because of its small size.
We cloned and sequenced a subset of these cDNAs and found that most of them lead to
out of frame transcripts with premature stop codons (Fig. 2.4C). Transcript 1 found a new (ag)
acceptor site 4 nucleotides earlier than the original acceptor site, while transcript 2 found an (ag)
acceptor site 48 nucleotides earlier than the original acceptor site. Both transcripts resulted in a
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Figure 2.4
The spr ro1 mutant has alternative splice variants.
(A) Selection of cyclin B1 transcripts in wild-type and spr ro1 mutant embryos at 30 hours. spr ro1
mutants have additional transcription products. The expected product size is 741 bp (PCR
product produced by a forward primer in the 5’UTR and a reverse primer in exon 6), but spr ro1
mutants also have a 900 bp and 1200 bp product. Extra products seen in a pool of in wild-type
siblings are much weaker and result from heterozygous individuals that are phenotypically wildtype. (B) Additional cyclin B1 transcript found after cloning into the pGEMT Easy vector. The
255 bp product amplified using the T7 and SP6 primers is an alternatively spliced cyclin B1
mRNA (cDNA) product. (C) Splice site map of the cyclin B1 gene in wild-type, spr tu21, and spr
ro1
(1-4). Primers used are marked on the wild-type schematic with black arrows, the expected
cDNA product is 741 bp. Grey box is the part of the transcript that was not amplified in the PCR
reaction. A red asterisk indicates introduced stop codons. The dashed line indicates the beginning
of E2 (yellow) to help visualize additional nucleotides. spr ro1 mutants have at least four
alternative splice site variants: (1) acceptor site in intron 1 is 4 nucleotides upstream of the
original acceptor site (-4) followed by a stop codon in the E2; (2) acceptor site in intron 1 is 48
nucleotides upstream of the original acceptor site (-48) followed by a stop codon in E2; (3) intron
retention splice variant, with premature stop codon +132 bp of the intron; and (4) In-frame splice
site, where the first acceptor site is in intron 5, skipping E2-E5.
frameshift mutation and a premature stop codon in exon 2. Transcript 3 retained intron 1,
resulting in a premature stop codon in the retained intron.
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Transcript 4 however, had an alternative splicing variant where exon 2 through exon 5
were skipped, but remained in frame (Fig. 2.4C). This transcript possibly explains expression of
cyclin B1 in the spr ro1 mutant (Fig. 2.3F') as it would not be degraded by nonsense-mediated
degradation. If translated, transcript 4 would produce a protein with an expected size of 203 aa
and would lack the destruction box, necessary for the protein targeted degradation in anaphase
(Clute and Pines, 1999), but still retain a large portion of the Cdk1-binding domain. Thus, this
product might interfere with other Cdk1-binding proteins and explain the more severe, gain-offunction phenotype.

The cell cycle is altered in specter mutants
Cyclin B has a well-characterized function in the G2/M transition as well as multiple
roles during mitosis itself (reviewed by Pines, 1995; reviewed by Santamaría et al., 2007). To
determine whether cells in both alleles maintain a wild type mitotic index, we first examined
phospho-histone H3 staining which labels the chromosomes from prophase to early anaphase
(Hendzel et al., 1997) (Fig. 2.5A-A''). Counting the number of mitotic cells in rhombomere 4,
outlined by expression of egrb2 (krox20) in rhombomeres 3 and 5 (Oxtoby and Jowett, 1993),
we found that the number of mitotic cells did not change between 7- and 20-somites (12 hours
and 19 hours) in spr tu21 mutants, whereas in wild type it was increasing (Fig. 2.5B). However, at
25-somites (21.5 hours), the number of mitotic cells was significantly lower, compared to wildtype (Fig. 2.5B). In contrast, the number of mitotic cells in spr ro1 mutants was already
significantly diminished by 7-somites and continued to decline between 7- to 25-somites (12 to
21.5 hours) (Fig. 2.5B). Taking into account the more severe phenotype (Fig. 2.3F') and a
possible dominant effect of the gain-of-function ro1 allele, we more carefully examined the

27

number of mitotic cells in their phenotypically wild-type siblings (60 embryos from 3 different
clutches). There was no significant difference among the wild-type group, supporting that ro1
behaves as a recessive allele. Likewise, anti-pH3 staining reveals that neural cells normally
undergo division at the midline in phenotypically wild-type siblings (Fig. 2.5A, arrow), however
neither of the mutant alleles exhibited this behavior. Instead, cells in the spr tu21 mutant seem to
divide after they leave the midline and cells in spr ro1 do not divide at all.

Figure 2.5
Cyclin B1 mutants have an abnormal cell cycle progression.
(A-A'') anti-pH3 staining shows spr mutants have fewer cells in mitosis between the egr2b
stripes in rhombomeres 3 and 5, dorsal view. Mitotic cells align at the dorsal midline (white
arrow) in the wild-type embryo (A), but do not in the spr tu21 mutant (A') whose mitotic cells
are irregularly shaped. In the spr ro1 mutant (A''), pH3 staining is weak and reveals few mitotic
cells. (B) Quantification of the number of mitotic cells between the egr2b stripes in the wildtype embryos (grey), spr tu21mutant (yellow), and spr ro1 mutant (green) between 7- and 25somites (12 and 21.5 hours). Starting at 15-somites (16.5 hours), the number of mitotic cells in
the spr tu21 allele is significantly fewer (p<0.05) compared to wild-type embryos. The counts
for the spr ro1 allele are statistically significant compared to both, wild-type and spr tu21 at all
stages (p<0.05). (C-E'') The Dual FUCCI transgene shows that cells in the spr mutant reside in
the wrong phase of the cell cycle at 20-somites. Shown are populations of cells in the tail
where the cell cycle reporter mCherry-Cdt1 (red) defines cells in G1(G0) stage (C-E) and the
Cerulean-Geminin (blue) defines cells in S/G2/early M stages (C'-D''). Whereas the majority of
cells in wild-type embryos are in the G1(G0) stage of cell cycle (C-C''), the majority of cells in
spr tu21(D-D'') and spr ro1(E-E'') mutants are in the S/G2/early M phase of the cell cycle. Scale
bar is 100 µm. Inserts show that G1(G0) cells have abnormal shapes in mutant embryos, scale
bar is 10 µm.
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We initially hypothesized that pH3-positive cells at the earlier stages in spr tu21 mutants
were the same cells at later stages of development, arrested in the G2/M transition. To determine
if this were so, we used the Dual Fluorescent Ubiquitination Cell-Cycle Indicator (FUCCI) (Abe
et al., 2013; Sugimoto et al., 2004; Sugiyama et al., 2009). This construct takes advantage of the
oscillating levels of Cdt1, which accumulates during G1 phase, and Geminin, which accumulates
during S, G2, and early M phase, to report the stage of the cell cycle. In zebrafish, a single
transgene expresses mCherry under the control of a Cdt1-degron, and Cerulean under the control
of a Geminin-degron (Bouldin and Kimelman, 2014). We hypothesized that if cells stopped
dividing in mutant embryos, they would be arrested in the G2 and early M (blue) phases of the
cell cycle in mutant embryos. In wild-type embryos, cells were predominantly in the G1 (red)
phase of the cell cycle (Fig. 2.5C-C''). In contrast, in both spr tu21 (Fig. 2.5D-D'') and spr tu21/ro1
(Fig. 2.5E-E'') mutant embryos cells were predominantly in the S, G2, or early M (blue) phase of
the cell cycle. This suggests a possible cell cycle arrest. When cells were in G1, their
morphology was altered compared to wild-type (Fig. 2.5C, D, E): not only were nuclei bigger,
indicative of endoreplication, but many were pyknotic suggesting that these cells were
undergoing apoptosis.

Cells in spr tu21 mutants continue to slowly divide
To determine if cells really stop dividing, we labeled single cells in the mid-blastula with
lineage tracer dye and followed divisions in the enveloping layer (EVL) (Fig. 2.6A). Unlike the
deep cells, EVL cells tend to survive in both mutant alleles, perhaps because they divide less
frequently. Cell cycle mutants typically do not exhibit their phenotypes until maternal transcripts
are depleted (Kane et al., 1996; Unhavaithaya et al., 2013; Warga et al., 2016), therefore we
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waited to examine embryos until 30% epiboly (4.66 hours), a few hours after zygotic
transcription begins.

We found that constant UV light caused high amounts of cell death in spr mutants,
compared to wild-type siblings, thus, we only examined clones intermittently no more than three
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Figure 2.6
Cell division does not completely stop in spr mutants; however, each allele has a
unique phenotype.
(A) Illustration of lineage tracing analysis for EVL cells in wild-type and mutant embryos. (B)
Average number of cell divisions in a clone between the time marked and 24 or 36 hours. Each
point is based on 3 or more clones. After tailbud, EVL cells cease to divide in the spr ro1 mutant.
(C) Frames from a time-lapse recording, showing cell divisions still occur at 24 hours in the
EVL of wild-type embryos (top panel) and spr tu21 mutants (bottom panel).The Dual FUCCI
transgene reports cells in the S/G2/early M phase of the cell cycle (blue) or in the G1(G0) phase
of cell cycle (red). Wild-type cells take approximately 20 minutes to go from metaphase to the
next S-phase, whereas mutants take about 1 hour. Scale bar is 10 µm. (D) Frames from a timelapse recording, showing that deep cells continue to divide at 5-somites (11.5 hours) in wild-type
embryos (top panel) and spr ro1 mutants (bottom panel) using H2B-RFP mRNA (pseudo colored
in green) shows that wild-type cells take approximately 15 minutes to get through mitosis,
whereas mutants take about 35 minutes. Scale bar is 5 µm.
times selecting an early time-point (between 30% epiboly to mid-somites) and a later time-point
(24 and/or 36 hours of development) (Fig. 2.6B). Surprisingly, we found that the cells in the
spr tu21 mutant did not stop dividing during the observed period. However, in the spr ro1 allele,
there were no cell divisions after tailbud.
To determine if the reason EVL cells in the spr tu21 mutant have fewer divisions is that
their cell cycle is longer than cells in wild-type, we recorded embryos, using the Dual FUCCI
transgene (Fig. 2.6C, Supplementary Movie 1, Movie 2) beginning at 24 hours of development,
when all maternal products are presumably exhausted (Fig. 2.2D'). Because the cell cycle at this
stage takes approximately 8 hours (Siefert et al., 2015), we recorded embryos for 10 hours and
limited UV damage by not using the mCherry-Cdt1 signal. We found that EVL cells in the wild
type spent an average of 21.7±4.11 minutes in mid-M to S phase (from the loss of the CeruleanGeminin signal to regaining it in the daughter cells), whereas EVL cells in the spr tu21 mutant
spent an average of 55.25±11.05 minutes in the same stage of the cell cycle (p<0.05). Hence,
spr tu21 mutant cells spent more time in mitosis.
Although EVL cells no longer divide after tailbud in the spr ro1 mutant (Fig. 2.6B), we did
not know whether deep cells, which give rise to the embryos proper (Kimmel et al., 1990), cease
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to divide. To this end, we injected H2B-RFP mRNA at the 1-cell stage and then recorded
embryos beginning at 2-somites (10.5 hours). As the cell cycle at this earlier stage is
approximately from 4 to 5 hours (Kimmel et al., 1994; Siefert et al., 2015), (Fig. 2.6D,
Supplementary Movie 3, Movie 4), we only recorded embryos for 4.5 hours. We observed 25
divisions in a wild-type sibling embryo during this period, but only 8 in the mutant. Most mutant
cell divisions occurred during the first hour of recording, the last division being recorded at 5somites (11.7 hours) (Fig. 2.6D). Notably, this final cell spent far longer time in metaphase than
normal, much like spr tu21 EVL cells do later (Fig. 2.6C, Supplementary Movie 1, Movie 2).
Hence, this demonstrates that spr ro1 mutants also exhibit an increased period spent in M phase.

spr tu21 mutant cells have a longer G2 phase
To establish if the G2 phase of the cell cycle was also lengthened, we labeled wild-type
and spr tu21 embryos at 24 hours with BrdU for 1 hour. Afterwards, we stained with an anti-BrdU
antibody to label cells in the S phase of cell cycle, an anti-GFP antibody to label cells in S
through early M (the Cerulean-Geminin signal), and an anti-pH3 antibody to label cells in
mitosis (Fig. 2.7A-B'''). To analyze these results, we counted cells positive for these markers in
different combinations to distinguish between cell cycle phases (Fig. 2.7C). Our data showed
that: first, there were significantly more wild-type cells positive for only BrdU (S phase), and
BrdU with other markers (S→M; S→G2→M; S→M) than those in the mutants. Second, there
were significantly fewer wild-type cells positive for only Geminin (G2 phase) and Geminin with
anti-pH3 (G2→M) than those in the mutants. Third, there was no significant difference between
the number of cells positive for only anti-pH3 (M phase).
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In summary, we found a population of cells in spr tu21 mutants that can go through a new
cell cycle like wild-type cells, even at 24 hours. However, there were fewer cells that phased
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Figure 2.7
Cell division does not completely stop in spr mutants; however, each allele has a
unique phenotype.
(A) Illustration of lineage tracing analysis for EVL cells in wild-type and mutant embryos. (B)
Average number of cell divisions in a clone between the time marked and 24 or 36 hours. Each
point is based on 3 or more clones. After tailbud, EVL cells cease to divide in the spr ro1 mutant.
(C) Frames from a time-lapse recording, showing cell divisions still occur at 24 hours in the
EVL of wild-type embryos (top panel) and spr tu21 mutants (bottom panel).The Dual FUCCI
transgene reports cells in the S/G2/early M phase of the cell cycle (blue) or in the G1(G0) phase
of cell cycle (red). Wild-type cells take approximately 20 minutes to go from metaphase to the
next S-phase; whereas mutants take about 1 hour. Scale bar is 10 µm. (D) Frames from a timelapse recording, showing that deep cells continue to divide at 5-somites (11.5 hours) in wild-type
embryos (top panel) and spr ro1 mutants (bottom panel) using H2B-RFP mRNA (pseudo colored
in green) shows that wild-type cells take approximately 15 minutes to get through mitosis,
whereas mutants take about 35 minutes. Scale bar is 5 µm.
from S to G2 or to M, as the majority of the mutant cells were in the G2 phase and G2/M
transition compared to their wild-type siblings.
Although cells in the spr tu21 loss-of-function allele remain mostly in the G2/M phase of
the cell cycle, altogether, these results show that cells are not arrested, rather they just spend far
longer in G2 and M phases. Therefore, lack of zygotic Cyclin B1 does not prevent cells from
dividing, it simply slows them down.

spr mutant cells exhibit signs of chromosomal instability
One of the functions of an active MPF is to control chromosome condensation (Kimura et
al., 1998) and microtubule dynamics during mitosis. To further investigate why mutant cells do
not go through mitosis as fast as wild-type cells, we examined their chromosomes and
microtubules more closely using DAPI nuclear staining and an anti-alpha-Tubulin antibody at
24-hours concentrating on deep cells derivatives (Fig. 2.8), which we know still divide, at least
in the tail of the spr tu21 mutant (Fig. 2.6D, Supplementary Movie 2). Ordinarily, microtubules
ensure a correct and equal segregation of chromosomal content in the two daughter cells (Fig.
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2.8A-A''). In spr tu21 mutants, there was no difference in chromatin condensation at mitotic entry.
However, we saw abnormalities in many mutant cells during anaphase and telophase (Fig. 2.8BD''). While some cells separated their genetic material normally, others had an abnormal
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Figure 2.8
spr mutants show signs of chromosome instability.
DAPI staining and anti-α-Tubulin staining in the wild-type embryo (A-A''), the spr tu21 mutant
(B-E''), spr tu21/ro1 transheterozygote (F-H''), and the spr ro1 mutant (I-J'') at 24 hours. Symbols
are: red arrows, chromosome separation defects; red arrowheads, pyknotic nuclei suggestive of
cell death; white arrowheads, polar microtubules; open white arrowheads, astral microtubules;
open white arrows, apoptotic microtubules; white arrows, abnormal spindle microtubule
organization; dashed line, expected spindle orientation; solid line, observed spindle orientation.
Scale bar is 10 µm.
microtubule organization where astral microtubules were absent and the central spindle
microtubules were hyper aggregated (Fig. 2.8B', B''). In addition, some cells had microtubules
attachment errors, resulting in lagging chromosomes (Fig. 2.8C-C'') or chromatin bridges (Fig.
2.8D-D''). We also observed pyknotic nuclei (Fig. 2.8E-E'') having the typical apoptotic
microtubule network described by Moss et al., 2006 that are thought the result of genomic
instability and aneuploidy.
Surprisingly, even in the spr tu21/ro1 and spr ro1 mutants, divisions at 24 hours still
occurred (Fig. 2.8F-J''), although these were few and predominantly in ventral epidermal cells,
and not the tail. As above, some cells in telophase, appeared normal (Fig. 2.8F-F''), suggesting a
successful division. Yet, like the null mutant, there were cells in telophase with over bundled
astral and central microtubules (Fig. 2.8G', H', I', J'), microtubule attachment errors with lagging
chromosomes (Fig. 2.8G, H, J), as well as pyknotic nuclei (Fig. 2.8F, red arrowhead). Overall,
however, microtubule organization was more disrupted in the spr ro1 mutant cells, including
highly concentrated and unfocused microtubules at the onset of anaphase with abnormal spindle
orientations (Fig. 2.8I-I''). Notably this latter phenotype was also observed in the spr tu21/ro1
mutant, only not as severe, but never in the spr tu21 mutant (data not shown). These data suggest
that in the absence of a wild-type Cyclin B1 product, the gene product from even one ro1 allele
is enough to prevent a compensatory mechanism for sustaining normal cell division.
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DISCUSSION
As a gateway to mitosis, Cyclin B1 and Cdk1 play an essential role in cell cycle
progression. However, their role is not fully understood in early development or in vivo. Here we
show that the zebrafish mutant specter is a mutation in cyclin B1. Lack of zygotic Cyclin B1
does not prevent cells from entering new rounds of cell division. Rather, many mutant cells cycle
more slowly and spend longer in G2 and M phases of the cell cycle and, of those, many enter
apoptosis. We propose that although critical for a healthy timely division, other cell cycle
proteins in part fulfil the function of Cyclin B1 to promote a cell through this portion of the cell
cycle, suggesting fail safe mechanisms for this ancient conserved process.

The specter mutant is caused by a mutation in cyclin B1
We mapped the spr mutant to cyclin B1, sequenced the mutant gene and found a
premature stop in exon 2 (Fig. 2.2). Rescue by the wild-type mRNA was not successful, possibly
because there was not enough wild-type cyclin B1 mRNA left by the time its translation is
required, combined with the fact that Cyclin B1 protein is degraded every cell cycle (Brandeis et
al., 1996). Our result is not unprecedented because similar attempts to rescue other cell cycle
mutants in the laboratory, such as zombie (Kane et al., 1996), have proved unsuccessful
(unpublished). Where cell cycle mutants have been rescued, rescue may be transient as rescue of
early mitotic inhibitor 1 mutants manifests during gastrulation and declines by tailbud suggesting
that these synthetic transcripts are short lived (Zhang et al., 2008). In our case, the specter mutant
phenotype is not visible, some two hours after gastrulation (Fig. 2.1). An alternative explanation
for lack of rescue may be that the injected wild-type cyclin B1 mRNA does not go through the
necessary post-transcriptional modifications. Harvey et al., (2013) showed that polyadenylation
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of the cyclin B1 3' UTR during early cleavage stages is highest during mitosis. Perhaps without a
full 3' UTR sequence the injected mRNA is not translated.
Making a CRISPR mutant that failed to complement spr tu21, we confirmed specter is a
mutation in сyclin B1. The CRISPR mutant is the result of a splice site mutation which causes a
gain-of-function phenotype (Fig. 2.3 and Fig. 2.5). Unlike the nonsense mutation, the CRISPR
mutant displays zygotic expression of cyclin B1, suggesting that in the spr tu21 allele nonsensemediated decay occurs, supporting that it is a null mutation. However, even if its mRNAs were
translated, the protein would only have a truncated chromatin localization domain (Pfaff and
King, 2013), and no other essential domains (Bentley et al., 2007; Draviam et al., 2001; Pfaff and
King, 2013). Together these data support the idea that spr tu21 is very likely a loss of function
mutation in cyclin B1.

The ro1 allele causes a more severe phenotype than the null tu21 allele
We confirmed that spr tu21 is indeed a mutation in cyclin B1 by creating a CRISPR
mutant. Surprisingly, this new mutant has a more severe phenotype than the nonsense mutant.
One hypothesis is that the tu21 allele is a hypomorph, which seems unlikely because like many
nonsense mutants its mRNA is degraded, and that the ro1 allele is the null. Another hypothesis,
however, is that the ro1 allele is acting in a recessive gain-of-function fashion, blocking a
compensatory mechanism when homozygous to overcome the G2/M arrest. We favor this
explanation because although the spr ro1 mutant phenotype is more severe than the nonsense
mutant, suggesting that it is a gain-of-function, it does not seem to have a dominant interfering
effect when heterozygous like other similar cell cycle mutants in zebrafish such as cellular island
(Yabe et al., 2009). Recessive gain-of-function mutations are not common, but in C. elegans and
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humans a number have been described. These include mutations in degenerin causing neuronal
degeneration in C. elegans (García-Añoveros et al., 1995; reviewed by Lester and Karschin,
2000), and mutations in BRDT, a testis-specific gene, required for fertility in humans (Li et al.,
2017). The products of these genes contribute to multimeric proteins, perhaps similar to Cyclin
B1 which forms a complex with Cdk1 to create Mitosis Promoting Factor.
Notably, the spr ro1 mutant has an alternative splice site resulting in several different
transcripts, one of which skips exons 2 through 5, remaining in frame (Fig. 2.4), and thus
escaping nonsense-mediated degradation. Conceptual translation of this spr ro1 product would
produce a Cyclin B1 protein missing a part of the chromatin localization domain, all of the
destruction box, all of the cytoplasmic retention domain, and a part of the Cdk1-binding domain.
This would cause Cyclin B1 to remain in the nucleus, while bound to Cdk1, and never getting
ubiquitinated. Failure of degradation should prevent exit from the G2/M checkpoint, which
would lead to apoptosis (Strauss et al., 2018). On the other hand, an abnormal Cdk1-binding
domain might also prevent successful phosphorylation of nuclear caspases that prevent apoptosis
(Allan and Clarke, 2007; Plaster et al., 2006). It is possible this interfering product outcompetes
the wild-type maternal product once zygotic transcription begins, explaining perhaps its earlier
phenotype. Regardless, in the ro1 allele, by the end of gastrulation EVL cells no longer divide,
and at early somite stages deep cells show signs of mitotic delay (Fig. 2.6). These observations
suggest that maternal supplies are likely too depleted to sustain normal cell division some 12
hours later at 24 hours (Fig. 2.8). spr tu21/ro1 transheterozygote display similar phenotypes at 24
hours (Fig. 2.8), where here as well abnormal Cyclin B1 would be produced. This, unlike the
spr tu21 mutant, where lack of zygotic product can not interfere with any “potential” remaining
maternal supplies.
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Loss of zygotic Cyclin B1 slows the cell cycle but does not stop it
Maternal cyclin B1 transcripts are present at least until the mid-blastula transition (Fig.
2.2D), providing the embryo with enough product to develop before zygotic transcription is
activated (Kane and Kimmel, 1993). Many cell cycle mutants however, do not manifest a
phenotype until the onset of gastrulation (6 hours) (Kane et al., 1996; Riley et al., 2010; Song et
al., 2004; Warga et al., 2016) some three or more cell cycles past the mid-blastula transition,
suggesting that the expression of maternal transcripts sustain normal development up to this
point. specter mutants, on the other hand, develop normally for longer until approximately 7somites (12 hours), although this time varies and can be much later. However, even after 24
hours, cells still cycle, although the majority of cells are predominantly in the G2 or M phase of
the cell cycle, indicating that cells are delayed in these phases (Fig. 2.7). Therefore, it seems
possible that maternal input of cyclin B1 at a very low level sustains normal development well
into somitogenesis, but once this threshold falls, the cell cycle is compromised.
This is consistent with observations in the crash-and-burn mutant, carrying a mutation in
the Mybl2b transcription factor (formerly known as b-Myb), where cells also show signs of
delayed mitosis by 15-somites (Shepard et al., 2005). Mybl2b regulates progression through the
G1 to S phases of the cell cycle, and indirectly, progression through the G2 to M phase of the
cell cycle by upregulating cyclin B1. Knockdown of mybl2b results in reduction of Cyclin B1
and Cdk1 expression (Okada et al., 2002; Shepard et al., 2005). Like in the spr mutant, cells in
the crash-and-burn mutant exhibit abnormal mitotic spindles and unseparated chromosomes
(Shepard et al., 2005; Stern et al., 2005), however, unlike cells in the spr mutant, none of these
cells escape mitotic arrest and cell death likely because absence of Mybl2b has far more severe
effects on the cell cycle.
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Figure 2.9
Model of cell cycle progression in wild-type, spr tu21 and spr ro1 mutants.
Cyclin B1 (CcnB1) forms an active mitosis promoting factor (MPF) with Cdk1 at the end of the
G2 phase as the Cyclin B1 threshold is reached. This complex is then translocated to the nucleus
to overcome the G2/M checkpoint and allow entry into mitosis in wild type (WT). In the absence
of functional zygotic Cyclin B1 (spr tu21), the transition though the G2/M checkpoint still occurs.
Perhaps because another cell cycle protein forms a partly functional MPF with Cdk1, allowing
cells to divide. However, mitosis takes longer occasional with chromosomal instability and
subsequent apoptosis. In contrast, in the presence of an altered Cyclin B1 protein (spr ro1), MPF
forms, preventing other proteins from binding to Cdk1, but this MPF is not functional and cells
arrest at the G2/M checkpoint or undergo apoptosis once maternal supplies of wild-type
Cyclin B1 are depleted.
Why does lack of Cyclin B1 stop cell division in the mouse but not in zebrafish? Perhaps
in zebrafish, low levels of maternal cyclin B1 transcripts generate enough protein to sustain cell
divisions well up to 24 hours, occluding the true loss-of-function phenotype. However, because
Cyclin B1 is degraded after each cell cycle (Brandeis and Hunt, 1996; Clute and Pines, 1999),
over time there would eventually be no more Cyclin B1 once maternal transcripts are degraded.
Whether this happens by early somite stages, like most cell cycle genes (Riley et al., 2010; Song
et al., 2004; Warga et al., 2016), is unclear, but unlike cyclin A and cyclin B2, degradation of
maternal cyclin B1 is not zygotically regulated (Audic et al., 2001). Thus, even in the absence of
a zygotic product like in the tu21 allele or the expression of an altered zygotic product like in the
ro1 allele, maternal Cyclin B1 should clear normally, and most likely before 24 hours.
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Hence, we hypothesize that in zebrafish, another cell cycle protein partially compensates
for the absence of zygotic Cyclin B1. We know that cyclin B2 mRNA is expressed maternally,
and is ubiquitously distributed throughout both, wild type and spr tu21 mutants at 24 hours (T.P.
unpublished). Although current research in mouse shows little support for the Cyclin B2
regulating the G2 to M transition (Strauss et al., 2018), in human culture cells, Cyclin B2
partially compensates for absence of Cyclin B1 by forming an active MPF with Cdk1 (Bellanger
et al., 2007). Therefore, it is possible in zebrafish that Cyclin B2 compensates for Cyclin B1 to
promote cell divisions in response to G2/M arrest. Further possibility is that Cyclin A
compensates for lack of Cyclin B1 as is observed in human culture cell studies (Gong et al.,
2010) (Fig. 2.9). However, it should be noted that some mutant cells undergo successful rounds
of cell division, not all cells overcome lack of endogenous Cyclin B1. This suggests a
compensatory mechanism that is only partly effective, and not sufficient for a completely normal
cell cycle. This is in agreement with previous studies on Cyclin B1 deficient cells in human
culture cell studies where cells show persistent lagging chromosomes and delayed mitosis
(Knoblich and Lehner, 1993; Nam and Van Deursen, 2014). We also hypothesize that only when
Cdk1 is prevented from binding to any factor is the cell cycle really stopped (Fig. 2.9) as is seen,
for the most part, in the spr ro1 allele. 5
In summary, we show that Cyclin B1 is essential for normal cell cycle progression. Yet
lack of zygotic Cyclin B1 does not prevent cells from dividing as expected, stopping them at the
G2/M checkpoint. Instead, cells slow down and continue to divide. Hence, our data argues there
may be more players than Cyclin B1 to coordinate mitotic entry in keeping with the redundancy
often seen in ancient conserved processes. In our future work, we will examine the possibility
that Cyclin B2 is one of those players.
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CHAPTER 3

MAKING THE CYCLIN B2 MUTANTS USING CRISPR/CAS9-MEDIATED KNOCK-IN
BACKGROUND
Due to the discovery of embryonic stem (ES) cells over 35 years ago, the mouse
community has had the tools to generate true reverse genetic models where a gene is targeted for
disruption to determine what is its phenotype. Coupled with the mouse’s close evolutionary
distance to humans, and its rapid generation times, conditional knockout of a gene by ES cell
technology allowed the mouse to become the premier genetic biomedical model organism.
However, what with the discovery of targeted nuclease technologies, such as zinc finger
nucleases, TALENs and CRISPR/Cas9, other model organisms can now create mutations in their
favorite gene. This is because targeted nuclease technologies allow for the generation of mosaic
knockout animals in the F0, with the potential for germline transmission and recovery of a full
knockout phenotype in the F1 and F2 generation. Of these reverse genetics methodologies,
CRISPR/Cas9 has perhaps become the most popular technology due to its ease of use, efficiency
and reduced costs and is now perhaps the most widely used method to knock-out genes and edit
parts of the genome in different model organisms, including zebrafish.

CRISPR/Cas9 in bacteria: an acquired immunity
The CRISPR/Cas9 system was first discovered in bacteria. It took 15 years after the first
description of these unusual repeat sequences in prokaryotes (Ishino et al., 1987) to the eventual
discovery of the unique structural composition of these repetitive DNA sequences in bacteria that
we now know as CRISPR (clustered regulatory interspaced short palindromic repeats) (Jansen et
44

al., 2002). Bacteria integrate short fragments of the invading viral DNA into the CRISPR locus
of the host chromosome as spacers. This way, bacteria has a protective mechanism, similar to
genetic memory. When the virus attacks again, the bacteria can synthesize short crRNA
sequences from the CRSIPR loci to recognize the viral DNA and induce a break by attracting the
Cas9 endonuclease to the matching site, and destroy it by introducing the double-stranded breaks
(Barrangou et al., 2007; Mojica J.M. et al., 2005).
To date, there are a total of six types of CRISPR mechanisms in prokaryotes. All are
associated with some type of Cas endonuclease(s). The type II CRISPR system derived from
Streptococcus pyogenes has perhaps the simplest organization. Its genomic sequence transcribes
three different elements: 1) a trans-activating CRISPR RNA (tracrRNA) , necessary for
activating Cas9 (Chylinski et al., 2014; Chylinski et al., 2013); 2) a Cas9 mRNA; and 3) a
precursor crRNA, which identifies the target sequence(s) – the invading foreign DNA (reviewed
by Lino et al., 2018). Together the tracrRNA and the crRNA, create a single-guide RNA
(sgRNA) complex that binds to Cas9. Upon binding with the sgRNA, Cas9 undergoes a
structural rearrangement and creates two lobes on both sides of the RNA-DNA heteroduplex: a
recognition (REC) lobe a nuclease (NUC) lobe (Jinek et al., 2014). ). If there is enough
homology between the target DNA and the sgRNA, the sgRNA will anneal to the target DNA
sequence in a 3’ to 5’ direction (Chylinski et al., 2013). The REC lobe of Cas9 will find and
cleave the non-target DNA sequence in a cell by searching for the protospacer adjacent motif
(PAM) (5’-NGG-3’) which is located downstream from the target (Nishimasu et al., 2015). The
NUC lobe, cleaves the target strand (Anders et al., 2014; Jinek et al., 2014; Nishimasu
et al., 2015), thus introducing a double stranded break (DSB) around the target site. Upon

45

recognition of these breaks, the cell activates DNA repair mechanisms, but these usually fail to
reconstruct the missing pieces due to the lack of a local homologous DNA template.
Thus, in the repair of the DSB we see insertions and deletions, commonly referred to as
indel mutations. Both are particularly effective in knocking out the gene of interest when
introduced into the coding regions of the DNA, because either usually result in a frameshift
mutation resulting in a premature stop codon. Because mRNA transcripts with a premature stop
codon will be recognized and targeted for degradation by the nonsense mediated decay
machinery, a functional product of the edited gene will not be produced (Jinek et al., 2014).
Therefore, the simplicity of this system makes it very valuable and has a potential of being
utilized for genome editing.

CRISPR/Cas9 editing in eukaryotes
The type II CRISPR system is now the most used system for editing genomes in model
eukaryotic organisms. In 2013, Cong et al. (2013) were the first group to successfully use the
Type II CRISPR/Cas9 system in animals to show its efficiency in the targeted cleavage of two
endogenous loci in human and mouse cell culture. Later that year, Hwang et al. (2013) showed
that this method of genome editing could be used in vivo in the zebrafish to target fumaratehydratase, which codes for an enzyme that is a part of Krebs cycle and that this method was as
efficient as Zinc Finger Nucleases (ZFNs) or Transcription activator-like nucleases (TALENs).
Another group (Chang et al., 2013), used the Type II CRISPR/Cas9 system in zebrafish somatic
cells to replicate the etsrp (Sumanas and Lin, 2005)and fau/gata5 (Reiter et al., 1999) mutant
phenotypes characterized by abnormalities in heart (the cardio-vascular system) development.
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Researchers continued to test this new editing tool in other model organisms. Wang et al.
(2013) co-injected two sgRNAs into cell culture to target two alleles of the Ten-eleven
translocation (Tet) family, Tet1 and Tet2. With 80% efficiency, they created biallelic mutations
in the two genes. This work showed that CRISPR/Cas9 can be successfully used for targeting
multiple genes at once in vivo. Bassett et al. (2013) injected sgRNA into Drosophila embryos to
knock-out yellow and white genes for pigment in the eye. With 88% efficiency, they introduced
insertions and deletions in the region of interest for both genes in both somatic cells and in the
germline. Friedland et al. (2013) injected sgRNA into C. elegans to knock out the unc-119 and
dpy-13 genes in the germline. They created a novel Cas9-SV40 nuclear localization signal (NLS)
fusion construct under the control of the eft-3 gene, to direct its transport into the nucleus, and to
drive its expression in the germline. In summary, CRISPR/Cas9 has shown to be as an efficient
method of knocking out eukaryotic genes in different model organisms.

Repair mechanisms of DNA cleaved by CRISPR/Cas9
As described above, after the sgRNA locates the target sequence, Cas9 makes a DSB near
the target site. However, this does not guarantee an immediate knock out of the gene. Some
endogenous DNA repair systems find the DSB and create irreversible changes in the targeted
region, often resulting in an indel mutation, but some DNA repair systems are more precise and
less error prone. To predict high efficiency of gene editing when using CRISPR/Cas9, it is
important to understand how these DNA repair systems work.
In eukaryotes, there are two major mechanisms of DSB repair: non-homologous end
joining (NHEJ) and homology-directed repair (HDR). In the absence of the template DNA,
NHEJ modifies both ends and ligates a DSB, but often introduces mistakes. This mechanism is
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not cell cycle dependent and can be activated at any phase of the cell cycle. It is also the least
time consuming. HDR is a more precise mechanism that activates during S/G2/M, and is
considered error-free, because it uses the homologous DNA template to seal the gaps in the
sequence (reviewed by Mcvey and Lee, 2008). It is activated during the post-replication phase,
preventing recombination between non-homologous DNA (Choi et al., 2017).
The key steps of the NHEJ are: 1) The Ku70/Ku80 heterodimer recognizes the broken
ends and binds to them creating a noncovalent complex. 2) The Ku70/Ku80 heterodimer recruits
the key enzymes to form a pair-end complex. And 3) The pair-end complex stabilizes and
modifies the broken ends. Overall, Ku70/Ku80 serves several functions: first, it stabilizes the
broken ends, serves as a scaffold in creating the pair-end complex, and second it prevents the
DSB ends from non-specific processing by exonucleases (Shao et al., 2012).
Usually, the DSB ends are not blunt and the excessive single-stranded segments might be
trimmed by nucleases or, in other cases, DNA polymerases might fill in short segments to create
complementary single-stranded DNA (Ma et al., 2002; Povirk et al., 2007). To synthesize a
complementary strand, the NHEJ machinery uses the family of X polymerases (Pol μ and Pol λ),
but they have a proof-reading activity, thus are prone to errors (Loc’h et al., 2019).
Indels generated by NHEJ tend to be short, up to 10 base pairs, and there is a two thirds
chance they result in a frameshift mutation and make a null allele. When the DSB is mediated by
CRISPR/Cas9 targeting, it is important to analyze the region around the target site. If it is
flanked by microhomology regions, there is a chance that the broken ends could be repaired by
microhomology end joining. Once the DSB ends gets unwound, the pair-end complex starts
scanning for short, up to 25 base pair, complementary sequences. In the end, a short duplex is
formed, single stranded regions that lack homology get trimmed, and the ligase seals the gap.
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Therefore, microhomology end joining often results in deletions (reviewed byMcVey and Lee,
2008).
HDR is a more precise method of repairing DSB because it uses homologous sequences
as a template to restore broken ends. Depending on the origin of the DNA template, HDR can
use either a homologous strand of a sister chromatid or use single-strand annealing. The latter
uses homologous regions within the same chromosome. The key steps of HDR are: 1) Endo- and
exonucleases process the broken ends to create the 3’-and 5’-single stranded ends of DNA
(Czornak et al., 2008; Fiorentini et al., 1997). 2) The D-loop intermediate forms: the 3’end of the
invading strand primes DNA synthesis off the template duplex DNA, and the repair proceeds by
engaging the opposite end of the DSB (Rossi et al., 2011). 3) When the two homologous DNA
duplexes are joined together, they form a Double Holliday junction. The Holliday junctions can
continue to relocate, e.g. strand migration, resulting in extension of the heteroduplex – a double
strand between two almost complementary strands of two homologous DNA molecules. 4) A
Double Holliday junction can be resolved by DNA helicase and topoisomerase dissolution into
obligatory non-crossover products, or by a structure specific endonuclease into crossover and
non-crossover products (reviewed by Brandsma and van Gent, 2012).
When the CRISPR/Cas9 introduces the DSB, it will be repaired by mostly utilizing the
NHEJ, because the HDR repair has shown to have low efficiency. Nonetheless, the Cas9
efficiency is very high, and it should continue to nick the DNA until there is no recognizable
target sequence. When using more than one sgRNA, there is a chance of a deletion of the region
flacked by the two targets, and the two distal ends to get ligated together, which can introduce a
large deletion, therefore increase the chance of knocking out the wild-type allele.
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CRISPR/Cas9 has one major flaw – off-targets. A good sgRNA is supposed to scan the
DNA sequence, locate the PAM site, and recognize the target, however Cas9 might not always
cut only in the vicinity of the PAM site. Much research has been done on identifying appropriate
sgRNAs that contribute to the editing efficacy (Fu et al., 2014; Gaudelli et al., 2017; Hwang et
al., 2013). CHOPCHOP is one of the online platforms used to create efficient gRNAs. Its
algorithm analyzes different genomes for DNA targeting. As well as data on epigenetic
regulation, transcriptional regulation and sequence composition to predict possible DNA repair
mechanisms and outcomes after the DSB (Labun et al., 2019).

In vivo homologous recombination and CRISPR/Cas9 gene editing
To ensure a more precise and efficient gene editing using CRISPR/Cas9, we can now
utilize the Cas9-mediated in vivo homologous recombination. When the Cas9 makes a doublestranded break, and we introduce a homologous DNA template into the cell, the DSB can then be
repaired via HDR using this template. One advantage of this system is that we can modify the
homologous DNA template and introduce knock-ins, e.g. in-frame GFP constructs and directed
mutations.
This method has begun with the first molecular “rapid cloning” technique that was
successfully developed and tested by the Berg group (Jackson et al., 1972). Their tool became a
staple of a classic technique for modern gene cloning. The first recombinant molecule was the
SV40 virus and bacteriophage λ. They used the R1 restriction digest enzymes to linearize the two
DNA fragments. However, R1 leaves blunt ends, making it difficult to ligate the two fragments.
To overcome this, they added relatively short poly(dA) or poly(dT) extensions to create sticky
ends at the 3’-ends of the two DNA fragments. The DNA fragments with the poly(dA) tails were
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annealed to the DNA fragments with the poly(dT) ends, and when mixed together, the
complementary ends were ligated, creating the first recombinant DNA molecule (Jackson et al.,
1972).
Gene cloning methods have greatly advanced, and today there are many approaches on
how to clone your gene of interest, such as restriction-digest cloning, plasmid cloning by PCR,
Gibson assembly cloning, and annealed-oligo cloning (reviewed by Cohen, 2013; Stevenson et
al., 2013). Today, one of the simplest and fastest methods for ligation independent cloning, or in
vivo homologous recombination. The gene of interest is first subcloned into a plasmid vector that
is produced and multiplied by E. coli. Next two DNA fragments: the vector and the insert are
linearized using PCR. The PCR products that are flanked on both sides by long sequences (up to
60 base pairs) that are complementary to the ends of the linear plasmids (Stevenson et al., 2013).
Post-amplification, both the plasmid and the insert must be treated with the DpnI restriction
enzyme. DpnI recognized methylated recognition sites (GATC) in order to cleave the template
DNA. The plasmid template and the PCR product template have methylated adenines in their
GATC sequences put there by the bacteria. The DpnI is used to remove these non-mutated
strands, only leaving the new mutated sequences, and to remove circular products. In the final
step, skipping ligation, the plasmid anneals with the PCR product during transformation in
E. coli. (Stevenson et al., 2013). This method of cloning has been reported to give a 95% success
rate (Jacobus and Gross, 2015), and can be used for targeted CRISPR/Cas9 knock-in gene
editing. By using in vivo homologous recombination, we can create a construct that will have
homologous regions to the endogenous gene with the in-frame GFP. When the sgRNA and Cas9
target the endogenous gene, the introduced construct can then be recognized by the HDR
machinery and used a template.
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METHODS
Cloning of genomic cyclin B2
To clone genomic cyclin B2, I first amplified the wild-type cyclin B2 using 50 ng of
B2F1 and B2R1 primers (Appendix A) via PCR (expected product size 990 base pairs). The
wild-type genomic DNA extracted from the fin clip of wild-type fish (biber background) was
used as a template (5 µl of a 1:20 dilution of the DNA extract from the 50 µl lysis buffer. PCR
was carried out using standard conditions: denaturation, 5 minutes at 95°C; 35 cycles of
denaturation for 30 seconds at 94°C, annealing for 30 seconds at 57°C, and extension for 1
minute; followed by the final extension, 7 minutes at 72°C using the PTC-100 thermocycler (MJ
Research). 10 µl of the PCR product was loaded on the 1% agarose gel to verify the product
amplification using gel electrophoresis. 187.5 µl of the amplified PCR product was purified
using a QIAquick Purification Kit (QIAGEN). To verify the final concentration of the purified
PCR product, 5 µl of the eluted DNA and 5 µl of the Hyper Ladder was loaded on 1% agarose
gel. 25 ng of the purified PCR product was used for the 5 µl ligation reaction into the pGEM-T
Easy vector (Promega) (2.5 µl 2x rapid ligation buffer, 0.5 ul vector,1.5 µl insert, 0.5 µl T4 DNA
ligase). After incubation of the ligation reaction at 4°C overnight, 2 µl were transformed into
JM109 E.coli competent cells (40L, Promega) as per pGEM-T Easy (Promega) transformation
protocol. To increase colony concentration, the transformation cultures were spun down at 1000
rpm, 900 µl of supernatant (SOC media) was replaced with LB broth (200 µl). 100 µl of the
resuspended cultures were plated on the LB (Miller’s) agar plates (40 g/L) containing
Carbenicillin (1:100, Sigma-Aldrich), and incubated overnight at 37°C.
6 isolated colonies were used to extract bacterial DNA using bacterial lysis (10 mM TrisHCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl2, 0.3% Tween 20, 0.3% Triton X100). A small fraction
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of a colony picked by a pipette tip was dunked into 25 µl of lysis buffer and incubated for 18
minutes at 98°C. Colony PCR reactions were done using the T7/SP6, B2F1/B2R1, and
B2F1/SP6 primers (Appendix A). Amplified PCR products were loaded on the 3% agarose gel to
verify the product size. Two colonies were chosen to isolate plasmid DNA using midi kit (Zymo
Research). The final concentration of the plasmid DNA was assessed using Nanodrop 1000
spectrophotometer. Isolated plasmid DNA was sent to be Sanger sequenced to the University of
Michigan sequencing core using in-house T7/SP6 primers.

PCR amplification using Q5 high fidelity Taq polymerase and in vivo homologous
recombination of vector and insert
The gfp-SV40PolyA region was amplified from the T2KXIG^in vector by PCR
amplification (F1 pT2 GFP/R2 pT2 GFP, Appendix A). The pGEM-T Easy plasmid with the
cyclin B2 was linearized and amplified by PCR amplification (ccnb2 F1-pGEM-T Easy/ ccnb2R2-pGEM-T Easy, Appendix A). Both reactions were done using a high fidelity Q5 Taq
polymerase (New England Biolabs). The PCR was carried out using the New England Biolab
protocol. Annealing temperature was adjusted depending on the minimal melting temperature of
one of the primers. Extension time was adjusted as 30 seconds/kb. PCR products were treated
with 1µl of DpnI for 1 hours at 37°C, followed by PCR product purification using QIAquick
Purification Kit (QIAGEN). The final concentration of the purified eluted PCR products was 40
ng/µl (gfp-SV40PolyA) and 15 ng/µl (ccnb2 pGEM-T Easy). Both PCR products (100 ng of
cyclin B2 pGEM-T Easy, 50 ng of gfp-SV40PolyA) were added to DH5-α E.coli competent cells
(40L, Promega) as per pGEM-T Easy (Promega) transformation protocol. 100 µl of cell culture
was plated on two LB agar plates at described previously and incubated at 37°C overnight. Four
colony PCR reaction were performed on 8 isolated colonies using B2F1/R-CFP, B2F2/R-CFP,
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T7/B2R1, T7/R-CFP primers (Appendix A). The colony PCR products were confirmed on the
1% agarose gel using gel electrophoresis. Plasmid DNA was isolated using midi QIAGEN
Plasmid Midi kit per manufacturer’s instructions. Plasmid DNA was eluted in 30 µl of TE buffer,
concentrations were obtained using Nanodrop 1000 spectrophotometer. Isolated plasmid DNA
was sent to be Sanger sequenced to the University of Michigan sequencing core using ccnb2 F1pGEM-T Easy/ ccnb2-R2-pGEM-T Easy primers.

Phenol-chloroform extraction
Isolated plasmid DNA was brought up to 200 µl with TE buffer. One volume (200 µl) of
the phenol-chloroform mixture was added and the solution was vortexed. To separate the
aqueous layer, the solution was centrifuged (HERMLE Z200 Microcentrifuge) for 5 minutes.
The aqueous layer was placed into a new 1.5 µl microcentrifuge tube. One volume (200 µl) of
chloroform was added, vortexed, and centrifuged for 5 minutes. The separated aqueous layer was
placed into a new 1.5 µl microcentrifuge tube. 1/10 of the volume (0.2 µl) of Sodium Acetate
(2.5M, pH 5.0) and 500 µl of ice cold 96% Ethanol was added, vortexed, and incubated at -20°C
for 1.5 hours. The solution was then centrifuged at for 15 minutes (14000 rpm, Beckman
Microfuge). The supernatant was removed, the precipitate was washed with 75% Ethanol, and
centrifuged for 5 minutes. The supernatant was carefully removed without disturbing the pellet.
The pellet was air dried for 2 minutes and dissolved in 20 µl of TE buffer (4 µl TE buffer per 1
µg of insert DNA).
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In vitro Cas9 nuclease cleavage assay
Cas9 protein from Streptococcus pyogenes with NLS (PNA Bio) was used in in vitro
cleavage assay as described in the PNA Bio protocol. Reaction assembly: 200 ng of Cas9 protein
(0.2 µl), 1µl of 10x NED Buffer 3 (New England Biolabs), 1 µl of 10x BSA, 100 ng of Target
DNA (1 µl), 100 ng of sgRNA, 5.8 µl of water ( to bring the final volume to 10 µl). The
assembled reaction was mixed, spun down, and incubated in water bath at 37°C for 1 hour. To
heat inactivate Cas9 nuclease, the reaction was heated up to 70°C for 10 minutes. The reaction
was tested on 1% agarose gel.

Embryo injections
Fish of the wild-type background were set up in mating boxes in the morning. In the
afternoon, embryos were collected and washed with E3 media and transferred to a glass petri
dish with Danieus media (58mM NaCl, 0.7mM KCl, 0.4mM MgSO4 7H2O, 0.6mM Ca(NO3)2,
5mM HEPES). Embryos were dechorinated at 1-cell stage and transferred to a fresh dish with
Danieus media containing penicillin and streptomycin (50mM, Sigma-Aldrich, St. Louis, MO).
Injection mixture was prepared: 0.86 µl of Cas9 protein ( at 1000 ng/µl), 0.9 µl sgRNA (Target
2) (at 50 ng/µl) (Synthego), 1.76 µl of pGEM-T Easy: cyclinB2-gfp-Poly A plasmid (at 100 ng/
µl), 2 µl of 5x Morpholino Buffer. Embryos were injected using a Narishage micromanipulator
and an ASI pressure injector. For each injection experiment, 300 pg of Cas9 protein and 50 pg of
sgRNA were injected into 4-16-cell embryo. The injected embryos were left in the incubator at
33°C. Media was replaced with the fresh Danieus media containing antibiotic every 3 hours.
Embryos were checked for the GFP-expression the next day.
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Genomic DNA extraction
For genomic DNA extraction whole embryos or fin clips were used. To prepare the
embryo samples, the 24-hour dechorinated embryos were placed into 50 µl lysis buffer in a 200
µl 96-well plate on ice. To prepare the fin clips, adult fish were placed on their sides on a lab
bench covered in layers of paper towels. The fish was covered by hand leaving the tail fin
uncovered. Approximately 2-3 mm of the tail fin was cut using a clean sharp razor blade. The fin
clips were then placed into 50 µl lysis buffer on ice. The plate was then sealed with the tape and
incubated at 95°C for 20 mites. 50 µg of Proteinase K (Sigma) was added and incubated at 55°C
for 2 hours. In the final step, the Proteinase K was deactivated at 95°C for 30 minutes. Extracted
embryo DNA was then diluted at 1:10 in sterile water, and fin clip DNA was diluted at 1:20 in
sterile water.
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RESULTS
Creating the construct for knock-in CRISPR-Cas9 editing of the cyclin B2 gene
In Chapter II, I showed that the lack of Cyclin B1 does not prevent cells from going into
new rounds of cell division. Some studies in cell culture have showed that Cyclin B2 can
promote cells into cell division (Gallant & Nigg, 1992; Nam & Deursen, 2014; Bellanger et al.,
2007), thus rescuing these cells. To address the role of Cyclin B2 in cell cycle progression, we
used CRISPR/Cas9 gene editing to create cyclin B2 deficient mutants.
To create a cyclinB2 mutation I engineered a construct where GFP was inserted into the
5’ portion of the cyclinB2 gene. The idea was that after a double stranded break was induced in
the endogenous cyclin B2 gene by Cas9, the homologous arms of my engineered cyclin B2-GFP
construct plasmid would serve as a template and recombine with the endogenous sequence via
homologous recombination (Fig. 3.1). Upon successful recombination, the cyclin B2 promoter
should drive the expression of GFP, which can be easily visualized using fluorescent
microscopy. I also engineered this Cyclin B2-GFP construct to have has a point mutation – a
deletion of one nucleotide in the PAM site (Fig. 3.2, red), this was to prevent the sgRNA from
recognizing the target sequence (Fig. 3.2, green) and Cas9 from introducing a new DSB after
homologous recombination. This point mutation also results in a frame shift, and a premature
stop codon in exon 3, downstream of GFP (Fig. 3.2, asterisk).
To create this fusion construct, first, using PCR, I amplified a 991 base pair fragment of
the 5’ end of the cyclin B2 gene and using TA cloning inserted this PCR product into the pGEMT Easy vector (Fig. 3.2, Fig. 3.3). The forward primer (F1 ccnb2) for this PCR product was in the
Exon 1, 100 base pairs upstream from the start codon, and the reverse primer (R1 ccnB2) was in
the 3’ end of Exon 4. Primer sequences are provided in the methods. Extracted plasmid DNA
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was sent out for Sanger sequencing to identify single nucleotide polymorphisms, which might
interfere with homologous recombination. I found 8 polymorphisms in the cloned region (Fig.
3.2). Four of them were in the coding region: one transition (A974G) in exon 3 and three
transversions (C1290T, T1410C, T1415C) in Exon 4, all result in silent mutations. These regions
were avoided when making the target and primers for the next step of recombineering, GFP
inserted into the cyclin B2 gene.

Figure 3.1
A diagram of the CRISPR/Cas9-mediated knock-in of the cyclin B2-gfp construct
into the endogenous cyclin B2.
Upon injection of the sgRNA that recognizes the target site in exon 3 (blue), the Cas9, introduces
a DSB, and the cyclin B2-gfp-polyA plasmid carrying the 614 bp and 458 bp homology arms will
recombine into the endogenous cyclin B2 via homologous recombination0
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Figure 3.2
A genomic sequence of cyclin B2 (exon 1-exon 4).
Forward primer B2F1 (turquoise) is in exon 1, reverse primer B2R1 (red) is in exon 4. The start
ATG site (blue) in exon 1. Single nucleotide polymorphisms are the highlighted nucleotides in
yellow. The sgRNA target site in exon 3 (green) and the PAM site CCG. Red asterisk marks the
perspective stop codon (TGA1421) in exon 3 after recombineering.
For recombineering the gfp-Poly A insert into the cyclin B2-pGEM-T Easy plasmid I
designed two sets of primers: one pair to amplify the pGEM-T Easy- cyclin B2 plasmid and the
other pair, to amplify the gfp-Poly A insert using the pT2KXIG plasmid as a template. Here, the
forward primer of cyclin B2 (B2F1) starts on the third nucleotide of the PAM site (Fig. 3.2) in
exon 3 and amplifies the 3’ end of the sequence. Whereas the reverse primer of cyclin B2 (B2R1)
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Figure 3.3
A schematic diagram of cloning of the cyclin B2 and gfp-poly A PCR fragments
by homologous recombination in E. coli.
The gfp-poly A region was amplified from the pT2KXIG plasmid by PCR using primers, which
contained short 5’ overhangs (blue) matching both ends of the subcloned fragment of cyclin B2.
The pGEM-T Easy plasmid carrying the cyclin B2 region was linearized by PCR using primers
which contained short 5’ overhangs (red and pink) matching both ends of the gfp fragment. After
the DpnI treatment and DNA fragment purification, vector and the insert were mixed in 2:1 ratio
and co-transformed into E. coli.
starts on the first nucleotide of the PAM site in exon 3 and amplifies the 5’ end of the sequence.
To amplify the gfp-Poly A insert, I designed a forward primer that starts at the GFP start site and
a reverse primer that starts at the Poly A termination sequence (Appendix A). The 5’ overhangs
of the forward and reverse cyclin B2 primers are homologous to the overhangs of the gfp-Poly A
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primers (Fig. 3.3) and will be recognized in the ensuing in vivo homologous recombination in
E. coli. Once the PCR was complete, DpnI was added directly to the finished reactions to destroy
the methylated template sequences (Jacobus and Gross, 2015).
Finally, these newly synthesized products were transformed into E. coli, and plated on
media with ampicillin to select for the recombined clones. Prior to the plasmid DNA extraction, I
verified that the recombinant colonies had the correct insert by using colony PCR. Here, I used
two forward primers B2F1 and B2F2 ccnb2 primers with the Reverse R-CFP located in the
middle of the GPF sequence (expected PCR product size is 1059 bp and 753 bp, respectively)
(Fig. 3. 4).

Figure 3.4
Gel electrophoresis of the amplified colony PCR products.
Lanes 1A-1H, the PCR products amplified by PCR using the B2F1/R-CFP primers, the expected
band size is 1059 bp. Lanes 2A-2H, the PCR products amplified by PCR using the B2F2/R-CFP
primers, the expected band size is 753 bp. 1 Kb plus DNA ladder.
Out of the eight tested colonies, four amplified the expected product sizes, and were
grown up to extract plasmid DNA for Sanger sequencing. All four clones had the correct
sequence with the gfp-Poly A sequence (Fig. 3.5, light green) inserted in-frame into the middle of
the cyclin B2 sequence. Resulting in a product that had the 611 bp and 458 bp homology arms
with endogenous cyclin B2 (Fig. 3.5). Prior to injecting embryos, I used an in vitro cleavage
assay (Jinek et al., 2012) to determine if the Cas9 protein, and the two sgRNAs targeting exon 3
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Figure 3.5
A plasmid DNA sequence of the pGEM-T Easy-cyclin B2-gfp-Poly A after
recombineering.
The gfp-Pol A segment is inserted in frame in between exon 3 of cyclin B2. A one nucleotide
deletion in exon 3 of cyclin B2 results in a premature stop codon in exon 3 (red asterisk).
and exon 4 of cyclin B2, would recognize and cut the pGEM-T Easy-cyclin B2-GFP-PolyA
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(Jinek et al., 2012) (Fig. 3.6). To eliminate the possibility of the Cas9 recognizing and targeting
the cyclin B2 sequence after the knock-in, I used only one target in exon 3 to create the DSB in
the endogenous cyclin B2 gene. I also used cas9 mRNA instead of the protein, which is thought
to increase the targeting efficiency (Albadri et al., 2017; Hu et al., 2018).

Figure 3.6
Cas 9 nuclease cleavage assay to test the efficiency of sgRNAs targeting exon 3
and exon 4 of the cyclin B2 gene.
Lane 1: Cas9 + sgRNA (exon 4) + pGEM-T Easy-cyclin B2. After a single cut introduced by
Cas9, the expected linear product is 4006 bp. A smear of the sgRNA is visible at the bottom of
the gel.
Lane 2: Cas9 + pGEM-T Easy-cyclin B2 (no sgRNA). Cas9 cannot make a cut because there is
no sgRNA to guide it to the target sequence, therefore no linear product is expected.
Lane 3: Cas9 + 2 sgRNAs (exon 3 and exon 4) + pGEM-T Easy-cyclin B2. The two targets are
292 bp apart, and after Cas9 makes two cuts, the expected linear products are ~290 bp and
~3800 bp. A smear of the sgRNA is visible at the bottom of the gel, thus the smaller band is not
visible.
Lane 4: Cas9 + sgRNA (exon 3) + pGEM-T Easy-cyclin B2-gfp-PolyA (no target site in exon 3).
The plasmid has a disrupted target 3 sequence, and therefore is not recognized by the Cas9.
Notice a circular plasmid (high band smear) and a smear of the sgRNA is visible at the bottom of
the gel.
Lane 5: Cas9 +sgRNA (exon 4) + pGEM-T Easy-cyclin B2-gfp-PolyA. The plasmid has a target
sequence in exon 4, and is recognized by Cas9, the expected linear product is 4972 bp. Notice
that not all plasmid is cut, and a smear of the sgRNA is visible at the bottom of the gel.
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Editing cyclin B2 with the CRISPR/Cas9-GFP construct
200 wild-type embryos carrying the Dual FUCCI reporter were injected at the 1-16-cell
stage with the pGEM-T Easy-cyclin B2-gfp-PolyA plasmid, the sgRNA targeting exon 3 of cyclin
B2 and cas9 mRNA. During gastrulation and 24 hours after injection, embryos were analyzed for
fluorescence. There was a population of cells carrying a green signal, but very small, which

Figure 3.7
Gel electrophoresis of the PCR products amplified from embryos injected with the
CRISPR/Cas9 and cyclin B2-gfp-Poly A plasmid.
To the left are uninjected control embryos (1A-1C), and to the right are embryos injected with the
cyclin B2-GFP plasmid, the sgRNA with a target in exon 3 of cyclin B2 and the cas9 mRNA (2A3H). Embryos were lysed at 24h and their DNA was amplified using the forward primer B2F2
(exon 1) and the reverse primer CFP-R (GFP) within the homology arms. The expected product
size of 753bp only appears in the injected (2A-3H) embryos. Amplification of the 753bp band in
the uninjected control 1A, might indicate contamination.
could indicate a low recombination event frequency. To verify the presence of the pGEM-T
Easy-cyclin B2-GFP-PolyA plasmid in the embryos’ genome, 16 CRISPR/Cas9 injected
embryos and 8 uninjected embryos were lysed and their DNA was amplified using several sets
primers within the pGEM-T Easy-cyclin B2-GFP plasmid (B2F1/CFP-R; B2F2/CFP-R; GFP
F7/B2R2). Using the forward primer B2F2 (cyclin B2 exon 1) and the reverse primer CFP-R
(GFP), 13 out of 16 CRISPR/Cas9 injected embryos had an expected 753 bp product, which
indicates that the pGEM-T Easy-cyclin B2-GFP plasmid was present in the genome of these
embryos (Fig. 3.7).
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As a control, The DNA of uninjected embryos not carrying the pGEM-T Easy-cyclin B2GFP plasmid was also amplified with these primers, some amplified this product as well (Fig.
3.7, 1A). These data suggested possible contamination with the pGEM-T Easy-cyclin B2-GFP
plasmid. Therefore, I tested the cyclin B2-GFP primers (GFP F7/B2R2) using a different source
of DNA, here I used wild-type adult fish (Fig. 3.8A) as a control and the cyclinB2-GFP plasmid
itself (Fig. 3.8B). The expected product size is 782 bp. Unexpectedly, I found a 500 bp product
and a 150 bp PCR product (Fig. 3.8A) in the control, which is difficult to explain.
The uninjected embryos, serving as a control, could not have carried the pGEM-T Easycyclin B2-GFP plasmid, yet some had amplified this product as well (Fig. 3.7, 1A). These data
suggested possible contamination with the pGEM-T Easy-cyclin B2-GFP plasmid. Therefore,

Figure 3.8
A gel electrophoresis showing the PCR products amplified using the pGEM-T
Easy-cyclin B2-GFP plasmid.
(A) Gel electrophoresis of the PCR products amplified using the GFP-F7 forward primer and
B2R2 reverse from DNA of wild-type adult fish shows two unexpected products of ~500 bp and
~150 bp. (B) The amplified product of the cyclinB2-GFP plasmid, the expected 782 bp product
amplified.

first, I tested the GFP primers (GFP F7 with B2R2) using wild-type fin clip DNA (Fig. 3.8A) as
a control and cyclinB2-GFP plasmid (Fig. 3.8B). Expected product size is 782 bp. Unexpectedly,
I found a 500 bp product and 150 bp PCR product (Fig. 3.8A) in the control, which is difficult to
explain.
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Testing other primer combinations within the homology arms, but not the primers that
were in the plasmid and outside in the endogenous gene, I was able to amplify the plasmid from
the injected embryos DNA, but not the plasmid within the cyclin B2 gene (Fig. 3.9). The result is
not clear, suggesting that the plasmid was there, but not in the anticipated region.

Figure 3.9
Gel electrophoresis with the PCR products amplified to verify the homologous
recombination in embryos injected with the CRISPR/Cas9 and the pGEM-T Easy plasmid.
(Lanes 1-4) cyclin B2-GFP plasmid DNA used as a control; (Lanes 5-7) finclip DNA from
embryos injected with the cyclin B2-GFP plasmid, the sgRNA and cas9 mRNA using primers
within and outside homology arms.
Lanes 1, 5 – F1/CFP-R (within homology arms), expected product size 1059 bp.
Lanes 2, 6 – F2/CFP-R (within homology arms), expected product size 753 bp.
Lane 3 – GFP F7/R1 (within homology arms), expected product size 782 bp.
Lane 4 – B2F4/CFP-R (insert outside homology arms), no amplification is expected.
Lane 7 – GFP F7/R4 intron 4 (insert outside homology arms), no amplification of the expected
product size of 885 bp. The plasmid is present in the injected embryos DNA, but not recombined
within endogenous cyclin B2.
Considering that the injected and tested embryos had some fluorescence (data not shown)
and I put the remaining 150 injected embryos in the nursery to grow to adulthood. I recovered 11
fish that grew to adulthood. Seven of these fish were genotyped using DNA extracted from their
tail fins. Using PCR, I amplified DNA within several different regions of the cyclin B2 gene
within and outside the homology arms. Using the B2F2/B2R2 primers, I amplified the expected
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product (1094nt, without GFP insert), which indicated the absence of the GFP insert in these
fish. Using the forward or reverse primer with the primer in cyclin B2, I did not amplify any
product (data not shown). These data indicated the absence of the GFP insert in these fish, which
meant that these fish did not have edited cyclin B2.

Figure 3.10 Embryos injected with the pGEM-T Easy-cyclin B2-GFP plasmid, the sgRNA and
Cas 9 protein at 24 hours.
(A-A′′) Uninjected control embryo, (B-B′′) injected embryos, head, side view. Note, the GFP
expression is seen in both control and experiment embryos.
In a second experiment, I injected 150 embryos with the sgRNA and the Cas9 protein.
After injections, the embryos were raised to 24 hours, checked for fluorescence (Fig. 3.10) and
lysed (40 injected embryos, as well as 5 Cas9 protein injected, and 8 uninjected embryos). I saw
some expression in the control uninjected embryos (Fig. 3.10A-A′′) and in the CRISPR injected
embryos (Fig. 3.10B-B′′), which meant that it might be a false positive result, because dying
cells usually exhibit fluorescence as well.
The embryo DNA was amplified using several sets primers within the pGEM-T Easycyclin B2-GFP plasmid and outside the homology arms to verify that the insertion occurred in
the region of interest. According to the amplified product size using primers within the
homology arms, the CRISPR injected embryos carried the plasmid. However, using primers
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outside of the homology arms (B2F1/B2R4), I did not confirm this result. If there was the GFP
insert, I would expect to see a 2060 bp PCR product. Instead, I only saw the 1094 bp product,
suggesting there was no GFP insert in these embryos (Fig. 3.11A). Using another set of primers,
I amplified a product within the pGEM-T Easy-cyclin B2-GFP plasmid sequence (B2F1/R-CFP),
which indicates that these embryos had the plasmid sequence in their DNA, but it did not
recombine with the endogenous sequence (Fig.3.11B). However, the wild-type uninjected
control also had the same size band, which suggests possible contamination or non-specific
binding (Fig. 3.11B, lane 2B).

Figure 3.11 Gel electrophoresis of the DNA amplified from embryos injected with the
CRISPR/Cas9 and pGEM-T Easy-cyclin B2-GFP plasmid.
(A) Primers used (B2F1/B2R4) are outsize the homology arms in the endogenous gene. And the,
expected product size is 2090 bp. However, the amplified product size is 1094 bp, which suggests
that these embryos do not have the recombined plasmid. (B) Primers used (B2F1/CFP-R) are
within the cyclin B2-GFP insert and the expected product size is 1058bp, which is what we see.
Lanes 1A-2A, 2C – injected embryos; lane 2B – an uninjected control embryo. The control DNA
from an uninjected embryo (2B) also amplifies the product with the GFP insert.
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SUMMARY
In this chapter III I show one of the approaches I used to mutagenize the cyclin B2 gene.
After successfully creating a construct with gfp flanked by cyclin B2 homology arms, I injected
this construct into zebrafish embryos using the CRISPR/Cas9 system to create a double-stranded
break. I hoped this method would introduce gfp into the cyclin B2 reading frame and that
mutagenized cells would fluoresce. This knock-in approach would have been a useful tool in
creating a cyclin B2 knock-out because we do not know what the cyclin b2 mutant phenotype in
zebrafish is. After a thorough analysis of the injected embryos and growing them to adulthood,
we concluded that these fish did not carry the anticipated construct in the cyclin B2 region.
Rather, homologous recombination seemed to occur, but was off-target and thus not useful for
disrupting cyclin B2 function.
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CHAPTER 4

CREATING A DYSFUNCTIONAL CYCLIN B2 USING MULTIPLE SINGLE GUIDE RNA’S
In Chapter III, I described my attempt of editing cyclin B2 using in vivo homologous
recombination to knock in a GPF-reporter vector to visualize mosaic mutant expression in the
edited cells. Seeing no confirmation of a successful knock-in, I then proceeded to making
multiple sgRNAs to target the 5’ end of the cyclin B2 gene, predicting with this method to make
not only indel mutations, but also big deletions of coding regions. Normally, to recover the null
embryos using CRISPR/Cas9 and a single sgRNA in zebrafish requires raising two generations
to obtain a stable line. However, it has been reported that using, two or more sgRNAs targeting a
coding sequence in multiple sites, generates a bi-allelic knockout in the G0 much more
efficiently than a single sgRNA (Wu et al., 2018). In this chapter, I describe the construction of
six sgRNAs to target cyclin B2 and the genetic analysis of the G0 and G1 generations.
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METHODS
Making single guide RNA’s for CRISPR/Cas9 editing
Oligonucleotide sequences for target 1 (5’ TAGGCACGCTCTGGTGAGTATT 3, 5’
AAACGGAGAATGCGGGCTCTCCC 3’), target 3 (5’ TAGGCTGTCCGTCCCCGTTATA 3’,
5’ AAACTATAACGGGGACGGACAG 3’), target 5 (5’ TAGGAAGTTTTCTACGGGTCAC
3’, 5’ TTCAAAAGATGCCCAGTGCAAA 3’), and target 6 (5’
TAGGTCTTACGGAGAGCTTCAA 3’, 5’ AAACGTGACCCGTAGAAAACTT 3’) (Wu et al.,
2018), and for target 2 (5’ TAGGGGGGTGCACGACAGCTGAC 3’, 5’
AAACGTCAGCTGTCGTGCACCCC 3’), and target 4 (5’
TAGGGGGAGAATGCGGGCTCTCC 3’, 5’ AAACGGAGAATGCGGGCTCTCCC 3’)
(Synthego CRISPR Design Tool) were ordered from IDT.
12.5 µl of 100 mM forward and 12.5 µl of 100 mM reverse primers were added to 5 µl
annealing buffer (10mM Tris, 50mM NaCl, 1mM EDTA), the volume was brought up to 10 µl
with RNase free water. A beaker filled with 1L of water was placed to boil. When the water
cooled down to 92°C, the microcentrifuge tubes were placed floating on top for 5 minutes (while
maintaining the temperature). After 5 minutes, the beaker was placed on lab bench and let slowly
cool off to room temperature.
The annealed oligonucleotides were used to ligate into linearized DR274 plasmid (using
BsaI, NEB) (Addgene). For each ligation reaction (2 µl 10x Thermal Scientific Buffer T4, 50 ng
linearized plasmid, 1.5 µl T4 DNA ligase) a 1:30 primer dilution was added (0.7 µl RNase free
water, 0.3 µl annealed oligonucleotides), the volume was brought up to 15 µl with RNase free
water. No primer was added to a control ligation reaction. Ligation reactions were placed at 4°C
overnight. To test ligation, 17 µl of each ligation reaction was loaded on 1% agarose gel.
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3 µl of each ligation reaction were transformed using JM109 E.coli competent cells (50
µl) and plated on a fresh Kanamycin plate to grow overnight at 37°C. Isolated colonies were
tested using colony PCR. The primers that were used in annealing reaction and the primers
within the DR274 plasmid 1958F (5’ TGCTATGGAGGTCAGGTATG 3’) and 260R (5’
GAAGGTGAGCCAGTGAGTTG 3’) (IDT) were used for colony PCR.
Plasmid DNA was isolated using mini prep (QIAGEN) as per manufacturer’s protocol,
eluted in 30 µl buffer EB. Isolated plasmid DNA was sent to be Sanger sequenced to the
University of Michigan sequencing core using the M13 forward primer (5’
GTAAAACGACGGCCAG 3’).
To make single guise RNA (sgRNA), first, the target plasmid was linearized using DraI
(New England Biolabs). 10 µg of the target plasmid was mixed with 10 µl 10x fast digest buffer,
5 µl DraI enzyme and brought to 100 µl with water. The plasmid was digested for 1 hours at
37°C, followed by the enzyme heat-inactivation at 70°C for 20 minutes. 1 µl of digest (~100 ng)
was loaded on a mini gel to determine if the plasmid DNA was digested. Linearized plasmid
precipitated using 2.5 M Sodium Acetate and 500 µl ethanol. The reaction was placed at -20°C
overnight. The next day, the reaction was centrifuged (14000 rpm) for 10 minutes at room
temperature, and the supernatant was removed. The pellet was washed with 70% ethanol and air
dried for 2 minutes. The pellet was resuspended in 20 µl low TE buffer. The sgRNA was
synthesized using the MAXIscript T7 kit (Life Technologies). Assembled reaction (10X buffer,
500 ng/µl DNA, 4 µl dNTP’s, 2 µl T7 enzyme) was spun down and put in 37°C water bath
overnight. The next day, 1 µl of DNaseI was added and the reaction was incubated at 37°C for
20 minutes. To protect the RNA, 0.8 µl of 0.5M EDTA was added, followed by heat inactivation
at 75°C for 10 minutes. 1 µl of reaction was loaded on the 1% agarose gel to determine the
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sgRNA concentration. To prevent RNA degradation, 1 ml of bleach was added to the gel prior to
pouring it into the box.

CRISPR/Cas9 injections to target cyclin B2
Embryos derived from wild-type parents carrying the Dual FUCCI transgene (Bouldin et
al., 2014) were injected (as described in chapter III) with four sgRNAs (targets 1-4) and Cas9
protein or cas9 mRNA. Embryos derived from the sprtu21/+ incross were injected (as described in
chapter III) with four sgRNAs (target 1-4) and cas9 mRNA. Injection mixture with the Cas9
protein was prepared: 1 µl sgRNA target 1 (160 ng/ µl), 1 µl sgRNA target 2 (160 ng/µl), 2 µl
sgRNA target 3 (50 ng/µl), 2 µl sgRNA target 4 (50 ng/µl), 1 µl Cas9 protein (1000 ng/µl), 1 µl
TRIS (10mM pH 7.5) and incubated on ice for 10 minutes. Injected droplet size was 70-100
micrometers. For the control, embryos were injected with the mixture of 1 µl Cas9 protein (1000
ng/µl) diluted in 7 µl of RNase free water.
Injection mixture with cas9 mRNA was prepared: 1 µl of cas9-NLS mRNA (150 ng/µl),
0.2 µl sgRNA target 1 (160 ng/ µl), 0.2 µl sgRNA target 2 (160 ng/µl), 0.2 µl sgRNA target 3
(50 ng/µl), 0.2 µl sgRNA target 4 (50 ng/µl). Injected droplet size was 70-100 micrometers.
After injections, embryos were left in the incubator (33°C) and monitored periodically
(every2 hours). Damaged embryos were removed from the dish. At 24 hours, embryos derived
from the sprtu21 heterozygote cross were sorted for the sprtu21 mutant phenotype (25% of the
clutch). The remaining clutch was left to grow. Injected embryos were kept in the incubator for
10 days and then moved to boxes and added to the fish system in the fish to grow to adulthood.
Genomic
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For the mutation analysis, genomic DNA was extracted from the injected embryos and
from adult fish fins as described in chapter III.

Total RNA extraction and cyclin B2 cDNA synthesis
100 phenotypically wild-type embryos and 12 phenotypically abnormal embryos from the
G0 CRISPR B2;WT incross, 100 phenotypically wild-type embryos from one G0 CRISPR
B2;sprtu21 incross, and 100 wild-type embryos and 100 phenotypically mutant embryos were
collected at 24 hours post fertilization. Embryos were dechorinated and placed in four 2 ml
microcentrifuge tubes. 1 ml of Trizol (Invitrogen) was added each tube, and vortexed for 5-7
minutes until the embryos fell apart. The samples were incubated for 5 minutes at room
temperature, followed by the addition of 200 µl of chloroform, vortexed and incubated for 5
minutes at room temperature. The aqueous and phenol phase were separated by centrifugation at
4000 rpm at 4°C for 15 minutes. The aqueous phase was transferred into a clean 1.5 ml
microcentrifuge tube and total RNA was precipitation by adding 500 µl of isopropanol and
centrifuged at 4000 rpm at 4°C for 15 minutes. The pellet was washed with 70% ethanol,
centrifuged at 4000 rpm at 4°C for 15 minutes. Ethanol was removed, the pellet was air dried for
2 minutes, and dissolved in 100 µl RNase free water (0.5 µg of total RNA/embryo).
Reverse transcriptase PCR was performed using B2F1
(5’GTACTGTATACGCACGGCTTG3’) and B2F5 (5’CAGATCCTTCACCAGTGAGG3’)
primers. PCR conditions as described in chapter III. Purified PCR products were subcloned into
pGEM-T Easy vector (Promega) to identify alternative splice variants.
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RESULTS
Constructing the sgRNAs via restriction digest
To efficiently knock out cyclin B2, I constructed six sgRNAs targeting coding sequences
in exon 1, exon 3, exon 4 (two targets), as well as exon 5 (2 targets) (Fig. 4.1A, B) (Hwang et al.,
2013; Wu et al., 2018). The sequences for the set of four guides (targets 1, 3, 5, and 6) were
obtained from the database created by Wu et al. (2018). The sequences for the set of the other 2
guides (targets 2 and 4) was generated using the Synthego CRISPR Design Tool. To synthesize
the sgRNAs, we constructed 6 expression vectors under the control of the T7 promoter to drive
expression of the RNA polymerase-mediated capped, polyadenylated mRNA encoding the
sgRNAs each of which was 18-19 nucleotides complementary to coding sequences in the
cyclin B2 gene (Fig. 4.1C). The appropriate sense and antisense oligonucleotides (IDT) with the
5’ overhangs (5’TAGG3’ and 3’CAAA5’) complementary to the plasmid DNA were first
annealed together (Fig. 4.1B) and then subcloned into the DB2R274 plasmid (Addgene; Fig.
4.1C) as per Hwang et al. (2013).
To subclone the target sequences, first, the DB2R274 plasmid was linearized with BsaI
(Fig. 4.1C). BsaI is a Type IIS restriction enzyme that recognizes a non-palindromic asymmetric
site (5’ GGTCTC (N)1/(N)5 3’) and cleaves DNA one and five nucleotides away from it. BsaI
makes the DB2R274 plasmid in two sites. Thus, after digestion, a short 21 bp long sequence with
the 5’ overhangs were removed, leaving a linearized plasmid with unique 4-nucleotide 5’overhangs (3’ATCC5’ and 5’GTTT3’), complementary to the annealed oligonucleotides. These
overhangs assure directional assembly of the vector and insert using DNA ligase. Following
plasmid transformation into E.coli, I performed colony PCR, and then I extracted plasmid DNA
for Sanger sequencing. Sequencing confirmed seamless ligation of all six targets with the 3’-end
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of the T7 promoter and the 5’-end of the scaffold RNA sequence in the DB2R274 plasmid (Fig.
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Figure 4.1
Constructing new sgRNAs to target cyclin B2 gene.
(A) A genomic map of the cyclin B2 gene with 8 exons (black indicates coding sequence), the
5’UTR and 3’UTR (white boxes) and location of the six sgRNAs. The PAM sites for every
sgRNA target are highlighted in red. Scale 100 base pairs. (B) A list of the forward and reverse
oligonucleotide sequences with the 5’ overhangs complementary to the T7 (blue) and the
scaffold RNA (scRNA) sequence (orange). (C) A BsaI restriction enzyme digestion of the
DB2R274 plasmid with the following ligation of Target 1 into the plasmid. (D) Sanger
sequencing chromatographs showing the 6 ligated sgRNA targets between the T7 sequence
(underlined in blue) and the scRNA (underlined in orange) into the DB2R274 plasmid.
4.1D). Next, the vector was linearized by digestion with DraI (5’ TTTAAA 3’), followed by the
Sodium Acetate precipitation and subsequent synthesis of the sgRNAs using the MAXIscript T7
kit (Life Technologies).

Figure 4.2
A Cas9 nuclease cleavage assay testing Target 1 and Target 2 sgRNAs.
Lane 1, pGEM-T Easy:cyclin B2 plasmid DNA, Target 2 sgRNA, Cas9 protein. The sgRNA is
the smear at the bottom of the lane. Lane 2, pGEM-T Easy:cyclin B2 plasmid DNA, Target 1
sgRNA, Cas9 protein. In both cases, the Cas9 protein cuts the pGEM-T Easy:cyclin B2 plasmid
when either sgRNA is provided producing the expected a 4 kb linear product. Target 2 sgRNA
also makes an additional cut so that a 1.8 kb product is produced. Note, some of the plasmid
remains circular at the top of the gel. To the left of lane 1 is the molecular weight marker, the
1Kb plus ladder.
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Before proceeding to microinjections, I performed a nuclease cleavage assay to verify
that the Cas9 protein cuts the template DNA when recognized by the sgRNA (Fig. 4.2). For this
experiment, we used the pGEM-T Easy plasmid with the subcloned genomic cyclin B2 sequence
(Fig. 3.3) and the sgRNA’s for Target 1 and Target 2 (Fig. 4.1). Albeit not all the plasmid being
cut, perhaps because Target 2 sgRNA recognized the template DNA sequence (Fig. 4.2, Lane
1)and produced the expected 4 kb product. Surprisingly, when we used the Target 1 sgRNA, we
saw two linear fragments a 4 kb product and a 1.8 kb product, suggesting Cas9 recognized the
plasmid in two sites. In summary, I successfully constructed 6 sgRNAs to target coding regions
of the cyclin B2 which was confirmed by the Sanger sequencing.

Targeting cyclin B2 gene with multiple sgRNAs
There has not been a published study of the cyclin B2 null mutant in zebrafish,
thus we could only hypothesize a potential cyclin B2 mutant phenotype. We hypothesized that
lack of Cyclin B2 would not affect the embryo morphology and would not interfere with
gastrulation and major tissue types formation in the presence of endogenous Cyclin B1. Our
alternative hypothesis was that lack of Cyclin B2 causes changes in Golgi disassembly (Jackman
et al., 1995; Draviam at el., 2001); spindle apparatus organization and spindle movement
(Gallant & Nigg, 1992; van der Voet, Lorson, Srinivasan, Bennett, & van den Heuvel, 2009;
Yoshitome, Furuno, & Sagata, 1998), leading to cell migration defects during gastrulation
(Yadav and Linstedt, 2011; Rodriguez-Boulan and Macara, 2014; Sanders and Kaverina, 2015)
(Table 1.1). Based on what we know when cyclin B1 is mutated, when in the null cyclin B1
spr tu21 mutant background where cells continue to cycle albeit more slowly, – we would expect
if cyclin B2 is also mutated a full cell cycle arrest and a more severe morphological and cellular
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phenotype, perhaps like the mutant phenotype of the gain-of-function cyclin B1 spr ro1 allele
where we believe a mutant interfering product is made that blocks semi-rescue by Cyclin B2.
To mutagenize cyclin B2 in zebrafish embryos, we chose to inject the mixture of four
sgRNAs (targets 1-4) simultaneously, along with the Cas9 protein (Petrachkova et al., 2019) or
cas9 mRNA with a nuclear localization signal (Jao et al., 2013) into embryos of the wildtype
background or spr tu21. I decided to work with the first four targets and not to inject the two
targets in exon 5, because of the length of exon 4 (2130 bp) and lack of reliable primers to
amplify a product over 2000 bp. As a control, we had two groups of embryos: in one, siblings
from the same crosses were injected with only Cas9 protein or cas9 mRNA to account for
possible toxicity from injecting the endonuclease or its mRNA. In the second group, siblings
were left uninjected to account for other factors, like the quality of the eggs and the temperature
regime in the first 24 hours of development. After injections, all embryos were placed in the
incubator (33°C) until the first week of life and afterwards put at 30°C and monitored
periodically until adulthood.
In the first experiment, a total of 721 (G0) embryos derived from the wild-type fish were
injected with four sgRNAs and the Cas9 protein (223) or with the cas9 mRNA (498) (Fig. 4.3A,
Table 4.1). When the putative founders from this cross grew up to adulthood (6 fish), I incrossed
them to test whether the wild type cyclin B2 allele was disrupted. After multiple incrosses, we
found one male and one female that gave rise to progeny (G1) with a surprisingly distinct, early,
and severe mutant phenotype in 5% of the clutch (Fig. 4.3A). This would indicate a theoretical
clone size of 20% in the germ line. These mutants had very short body axes by early
segmentation stage, which became quite dark perhaps indicating cell death.
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Table 4.1 Survival rates of embryos injected with CRISPR B2
Genotypic
background
WT
spr tu21

No. of G0 embryos injected with
4sgRNAs and:
Cas9 protein
223
cas9 mRNA
498
cas9 mRNA
410

No. of G0 embryos grown to
adulthood
4 females and 2 males
4 males
5 females and 7 males

In the second experiment, a total of 410 embryos (G0), derived from the spr tu21
heterozygous incross, were injected with the same four sgRNAs and the cas9 mRNA (Fig. 4.3B,
Table 4.1). The next day after injections, I removed the 25% which were spr tu21 mutants based
on their phenotype. The remaining 75% of the clutch was left to grow to adulthood. At 4 months,
when the G0 fish were adults (7 fish), I crossed them to the spr tu21 known carriers to identify the
spr tu21heterozygotes. We identified 7 fish to carry the mutant tu21 allele (Table 4.1), and after
incrossing them, the G1 progeny were accessed for a double mutant phenotype. If we had
disrupted the cyclin B2 allele and created a recessive mutation, then normally we would expect a
double mutant phenotype in 1/16 (6.25%) of the G1, however in these experiments not all the
germ cells are targeted by the CRISPR, and also the CRISPR could disrupt both cyclin B2
alleles, that is why we could not rely on Mendelian segregation.
Interestingly, in most incrosses, we saw the expected 25% of the clutch to have the tu21
mutant phenotype, and no other phenotypes. However, in some incrosses, I saw on the average
34% of the clutch with the tu21-like mutant phenotype, and I saw morphological heterogeneity
among these embryos. Some of the embryos in the clutch had a very dark and smaller head,
reminiscent of the ro1 mutant phenotype (Fig. 2.3F) whereas the remainder looked just like tu21
(Fig. 2.3D). We know that the spr tu21 mutation is a homozygous recessive mutation and there is
no apparent heterozygous effect (Petrachkova et al., 2019). Therefore, I hypothesize that the
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introduced mutation in the cyclin B2 gene of these fish has no visible phenotype, unless
combined with at least one tu21 mutant allele.
Next, we tested whether the cyclin B2 mutagenized allele here would use wild-type
background and spr tu21 mutant background from the first experiment fails to complement the
mutagenized allele from the second experiment, analyzing the progeny from this cross
(Fig. 4.3C). This method might reveal whether the mutant phenotype that we saw in the G1 from
the first cross: short and ugly (Fig. 4.3A) and G1 from the second cross: spr enhanced
(Fig. 4.3B) is caused by a mutation in the same gene. We found that 2% of the progeny from
such a cross produced embryos with a spr tu21-like mutant phenotype, but not as severe as is seen

Figure 4.3
A schematic description of making a cyclin B2 mutant line using CRISPR/Cas9
gene editing.
(A) The G0 embryos derived from wild-type background fish injected with the Cas9 protein and
the 4 sgRNAs. After the G0 generation was grown to adulthood, they were incrossed to produce
the G1 derived. The G1 were then assessed for their mutant phenotype and genotype. (B) The G0
embryos derived from tu21 mutant background fish injected with the cas9 mRNA and the 4
sgRNAs. 24 hours after injections, the spr tu21 mutants (25% of the clutch) were removed based
on their phenotype. The rest of the G0 clutch was grown to adulthood. Afterwards, they were
incrossed to produce G1 progeny. These G1 were then assessed for the mutant phenotype and
genotype. (C) Adult G0 fish from cross A (purple) and cross B (green) were incrossed to test for
complementation.
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normally in any other crosses. Because the one allele of tu21 present, concluded that the
mutagenized cyclin B2 alleles failed to complement and maybe the low percent of mutant
phenotype is due to mosaicism in the germline. Considering the variety and inconsistency in
mutant phenotypes observed within these crosses (Fig. 4.3A-C), I hypothesize that I created
multiple different mutations in the cyclin B2 gene.

Genotyping CRISPR cyclin B2 injected embryos using genomic DNA
When embryos are injected with CRISPR/Cas9 at the 2-16-cell stage, we expect many
cells to have a single allele disrupted. Alternatively, some cells may have both alleles disrupted.
Along with assessing the early development of these embryos and describing any morphological
abnormalities while searching for the cyclin B2 mutant phenotype, I decided to analyze the
genomic cyclin B2 of these embryos and their cyclin B2 mRNA transcripts. The first analysis
using PCR amplification and genomic DNA asked if the G0 injected embryos (one day after
CRISPR/Cas9 injection) exhibited evidence of gene editing, the second analysis asked if the
adult G0 fish (4 months after CRISPR/Cas9 injection) exhibited evidence of gene editing, and
the third analysis asked if the progeny of the G0 fish (the 1 day old G1 embryos) exhibited
evidence of gene editing. Finally, we extracted cyclin B2 mRNA and used RT-PCR to analyze
the coding sequence of the G1 embryos. We found that some of the injected G0 embryos and
their progeny have disrupted cyclin B2 genomic sequence.
After injecting the four sgRNAs and the Cas9 protein into 220 embryos derived from a
wild-type cross (Fig. 4.3A CRISPR B2), I observed that they were approximately 2 hours behind
in development, compared to the Cas9 injected (33 embryos) and uninjected sibling? (53
embryos) control groups. This lagging is common in embryos that have been injected with
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oligonucleotides or mRNA, but may also be due to the defects that I saw at the end of
gastrulation, such as the yolk cell protruding, preventing the blastoderm to cover it on time in the
sgRNA and Cas9 injected embryos. In addition, the injected embryos survival rate was
considerably lower in the Cas9 injected control group (24%), than in the CRISPR/Cas9 injected
group (32%), which might indicate high toxicity levels from the Cas9 protein alone.

Figure 4.4
Analysis of the genomic cyclin B2 in CRISPR B2/Cas9 protein injected G0
embryos.
Lanes 1A-10H, DNA extracted from 71 embryos injected with the CRISPR B2/Cas9 protein,
lanes C (control) at the end of each row, is DNA extracted from noninjected siblings. Genomic
DNA was amplified by PCR using the B2F5/B2R4 primers, whose expected product size is
1068 bp (arrow). In the middle of each row is the molecular weight marker, the 1Kb plus ladder.
To identify whether there were indel mutations in these embryos, I extracted genomic
DNA from 71 CRISPR/Cas9 injected embryos (Fig. 4.3A) at the 2-somite stage, as well as from
4 Cas9 injected control embryos, and from 4 uninjected control embryos at the 8-somite stage.
Next using gene specific primers, I amplified a portion of the cyclin B2 gene using PCR
(Fig. 4.4). When using primers outside the CRISPR target sites (B2F5 in exon 1 and B2R4 in
intron 4, Appendix A), a 1068 bp product is expected from genomic wild-type DNA. Most of the
controls exhibited the correct product size, but only 14 embryos injected with the CRISPR/Cas9
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had the wild type PCR product (1A-1D, 1F, 2A, 3A-3B, 4A, 5A-5F) (Fig. 4.4). However, lack of
additional PCR products in these embryos did not suggest the addition of potential indel
mutations, unless the indel was not large enough to be visible on the electrophoresis gel.
Because I would expect these embryos to be mosaic and I do not know the size of the
clones, it is possible that there was not enough DNA to amplify from the potential small number
of mutated cells using PCR. The rest of the embryos did not amplify any product whatsoever.
This could be explained by the lack of primers’ annealing sites to the gene edited DNA. On the
other hand, considering that some level of mosaicism is expected, it seems more likely these
PCR reactions simply did not work although it is not clear why. After testing additional sets of
primers for functionality, we repeated PCR amplification of the putative gene-edited cyclin B2
DNA using primers located within the CRISPR target sites (B2F2 in exon 2 and B2R8 in exon 3,
Appendix A). For this experiment, we used DNA from 8 CRISPR/Cas9 injected embryos (3A3H), fin-clip DNA from 4 wild-type fish and embryo DNA from 4 uninjected sibling embryos
(Fig. 4.5). In all the DNA samples we amplified the expected wild-type product (365 bp), and no
additional bands. Because I used the same DNA in both this and the previous experiment (Fig.
4.4, lanes 3A-3H), this result suggests that the absence of a PCR product in the previous

Figure 4.5
Analysis of the genomic cyclin B2 in the CRISPR B2/Cas9 injected G0 embryos
using the primers around the Target 2 site.
Lanes 3A-3H, DNA extracted from 8 embryos injected with the CRISPR B2/Cas9 protein. Wildtype fin clip DNA (4 lanes) and embryo DNA of uninjected sibling embryos (4 lanes) used as a
control. The DNA was amplified using the B2F2/B2R8 primers, which give an expected product
size 365 bp. In the middle, is a molecular weight marker, the 1Kb plus ladder.
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experiment (lanes 3C-3H ; Fig. 4.4) was not simply due to error but perhaps the result of one of
the primer sites potentially being disrupted.

Figure 4.6
Analysis of the genomic cyclin B2 in fin clip DNA of the adult G0 fish.
DNA was amplified using the primers B2 F9563/B2 R9567, with an expected product size of
1218 bp. (A) G0 fish from the wild-type background, that had been injected with the CRISPR
B2/Cas9 protein (lanes 1A-1F) or the CRISPR/cas9 mRNA (lanes 2A-2D). Note, the
unexpected product of 350 bp in lane 1A and 1F. (B) G0 fish from the spr tu21 background, that
had been injected with the CRISPR B2/cas9 mRNA (lanes 3A-4H). Note, the unexpected
product of 350 bp in lanes 4A and 4E. Lanes C are the control wild-type fin clip DNA from a
different background. In the middle of each row is the molecular weight marker, the 1Kb plus
ladder.
One possibility is that the indel mutations might be very small and hard to visualize using
gel electrophoresis, so I purified the amplified PCR product from three G0 injected embryos
(Fig. 4.3B), 1 uninjected control, and 2 CRISPR B2/cas9 mRNA injected embryos, and sent
these off for Sanger sequencing. Sanger sequencing did not confirm any heterozygosity or
mutations in the two CRISPR/Cas9 injected embryos (data not shown). However, since the B2F2
and B2R8 primers amplified the region only around target 2, this did not exclude that there might
be mutations outside this region.
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Although this analysis was inconclusive, given the slower growth of these injected
embryos, which might indicate a mutant phenotype (Brandeis et al., 1998; Daldello et al., 2019),
I decided to grow them to adulthood. Four months later, I extracted genomic DNA from fin clips
of 6 of the G0 fish injected with CRISPR B2/Cas9 protein and 4 of the G0 fish injected with
CRISPR B2/cas9 mRNA derived from the wild-type background (Fig. 4.3A, Fig. 4.6A). I also
derived embryonic (G1) DNA by incrossing the CRISPR B2/Cas9 protein injected fish (Fig.
4.6B). Again, these were analyzed using primers within the cyclin B2 gene.
Using a forward primer in the 5’UTR (B2 F9563, Appendix A) and a reverse primer in
intron 4 (B2 R9567 Appendix A), I expected to amplify a wild-type product of 1281 bp (Fig.
4.6). Out 10 DNA samples extracted from fin clips (adult G0 fish), we amplified a cyclin B2
product only in 3 samples (Fig. 4.6A, lanes 1A, 1E-1F). The sample in the lane 1A had a wildtype product of the expected size and a smaller 350 bp product. The samples in the lane 1E had
only a wild-type product, and sample in the lane 1F had only the 350 bp product (Fig. 4.6A).
This result supports the idea that there are fish with a deletion of approximately 850 bp. Out of
24 DNA samples extracted from the G1 embryos, we amplified a cyclin B2 product in only 3
samples (Fig. 4.6B, lanes 3A, 4.6A, 4E). The sample in lane 3A had only the wild-type 1218 bp
product, whereas samples in lanes 4A and 4E had a product of approximately 350 bp (Fig. 4.6B).
While not amplifying a product in the other samples is somewhat distressing, this result was
promising and further supported that there might be G1 fish homozygous for a deletion in
cyclin B2.
To verify this result, I used other sets of primers to amplify cyclin B2. As before, I used
fin clip DNA derived from adult G0 fish injected with 4 sgRNAs and the Cas9 protein (CRISPR
B2/Cas9 protein) or the cas9 mRNA (CRISPR B2/cas9 mRNA) (Fig. 4.7, lanes 1A-2E), as wells
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as embryo DNA derived from their G1 progeny: CRISPR B2/Cas9 protein (Fig. 4.7, lanes 3A5H), or CRISPR B2/cas9 mRNA (Fig. 4.7, lanes 6A-6H). Here, I amplified a region within the
sequence covered by the previous primers, using the forward primer in the 5’UTR (B2 F9563)
and a reverse primer at the exon 4/intron 4 boundary (B2 R9565) (Appendix A).
I expected to amplify a wild-type product of 963 bp (Fig. 4.7). Half of the fin clip DNA samples
(lanes 1A-1E) and 5 embryo DNA samples (lanes 3A, 4A, 4F, 6C, 6G) had this 963 bp product
(Fig. 4.7) and no other size products, suggesting that there is no big size deletion or insertion
within the amplified sequence, or that the primer annealing sites are not there any longer.

Figure 4.7
Analysis of the genomic cyclin B2 in adult G0 fish and their G1 embryos.
DNA was amplified using the primers B2 F9563/B2 R9565, with an expected product size of
963 bp. Lanes 1A-2E, fin clip DNA extracted from the G0 fish from the wild-type background,
that had been injected with the CRISPR B2/Cas9 protein (lanes 1A-1F) or the CRISPR/cas9
mRNA (lanes 2A-2E). Lanes 3A-5H, are embryonic DNA extracted from the G1 progeny
derived from the incross of the CRISPR B2/Cas9 protein injected into the wild-type background
G0 fish (1A-1F – are their parents). Lanes 6A-6H, are embryonic DNA extracted from the G1
progeny derived from the incross of the CRISPR B2/cas9 mRNA injected into the spr tu21
background G0 fish. . Lanes C are the control wild-type fin clip DNA from a different
background. In the middle of each row is the molecular weight marker, the 1Kb plus ladder.
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Altogether, these data show that genomic DNA extracted from the adult G0 fish and their
G1 progeny has an intact sequence in the 5’UTR that can be amplified by the same forward
primer in some embryos. My data also indicates that the site for the B2 R9565 primer may be
deleted in some mutated alleles, which would explain only one wild-type product and no smaller
products. A good example is the fin clip DNA in lane 1A where the B2 F9563/B2 R9567 primers
cover the genomic sequence from the 5’UTR to the intron 4, amplifying two bands (Fig. 4.6, lane
1A), while the B2 F9563/B2 R9565 primers cover the sequence from the 5’UTR to the
exon4/intron4 boundary amplifying only one band (Fig. 4.7, lane 1A) from possibly only one
cyclin B2 allele.
Looking at the genomic DNA analysis of the G0 injected fish and their progeny as a
whole, as well as at the preliminary phenotypic data of the G1 progeny (Fig. 4.3), we conclude
that we likely have disrupted the genomic sequence of cyclin B2 in a portion of these fish using
CRSPR/Cas9 gene editing. However, more analysis is needed to identify the introduced
mutation(s) in cyclin B2.

Genotyping CRISPR cyclin B2 injected embryos using mRNA
To further investigate and identify these putative mutations in cyclin B2, I extracted total
RNA from G1 embryos derived from two different backgrounds. Embryos from the first
background were derived from the wild-type fish injected with the CRISPR B2/Cas9 protein
(Fig. 4.3A). We did not use the G1 progeny derived from the wild-type fish injected with the
CRISPR B2/cas9 mRNA because we did not see mutant phenotype. Embryos from the second
background were derived from the spr +/tu21 heterozygous fish injected with the CRISPR B2/cas9
mRNA (CRISPR B2;tu21).
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To extract total RNA, we collected embryos at 24 hours of development and sorted them
by phenotype. From the first background, we collected and combined 100 embryos from one
clutch that were mostly wild-type in phenotype, including the 12 embryos with the mutant
phenotype. From the second background I collected embryos derived from two crosses. In cross
1, where 37% of the embryos had the mutant phenotype (125/340), I collected only the ones with
the wild-type phenotype. From cross 2, where 32% of the embryos had the mutant phenotype
(101/316) I collected 92 embryos that were mutant in phenotype and 100 embryos that were
wild-type in phenotype.
After performing RT-PCR, I analyzed the PCR products on an electrophoresis gel
(Fig. 4.8). As a negative control, we included a PCR reaction using genomic fin-clip DNA
(Fig. 4.8B). Unexpectedly, for the G1 embryos derived from the wild-type edited background, I
did not amplify the expected 1352 bp wild-type product. Instead, I amplified a 190 bp product

Figure 4.8
Analysis of the cDNA extracted from the G1 progeny.
The cDNA was amplified using RT-PCR and primers in the 5’- and 3’-UTR regions,
B2F1/B2R4, whose expected product size is 1352 bp. (A) cDNA extracted from the G1 wildtype and mutant embryos derived from incross of the G0 wild-type background fish injected
with the CRISPR B2/Cas9 protein. (B) cDNA extracted from the G1 wild-type and mutant
embryos derived from incross of the G0 spr tu21-mutant background fish injected with the
CRISPR B2/cas9 mRNA. Lanes 1, wild-type embryos from one clutch. Lanes 2, wild-type
embryos from a second clutch, and lane 3, their siblings with the spr-like mutant phenotype.
Lanes C, a negative control, genomic DNA from fin clip of a wild-type fish. The molecular
weight marker, the 1Kb plus ladder.
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(Fig. 4.8A). This was puzzling because most of the embryos appeared wild type, and I should
have amplified the wild type product.
For the G1 embryos derived from the spr tu21 background (CRISPR B2;tu21), I found two
new products one at 850 bp and the other at 170 bp. These data are promising, suggesting that
these embryos might have an alternative cyclin B2 variant, however this does not explain lack of
the wild type product.
To identify whether the cyclin B2 coding DNA was indeed carrying a deletion(s)
mutation, I subcloned the above amplified fragments into the pGEM-T Easy vector and
transfected into JM109 competent cells. I then used colony PCR and the T7/SP6 primers to test

Figure 4.9
Colony PCR of the gene-edited cyclin B2 DNA subclones using the T7/SP6
primers.
(A) The cDNA of the G1 embryos derived from the CRISPR/Cas9 protein injected G0 incross.
(B) The cDNA of the G1 phenotypically wild-type embryos, derived from the CRISPR/cas9
mRNA injected G0 fish of the spr tu21 background. (C) The cDNA of the G1 phenotypically spr
mutant embryos, derived from the CRISPR/cas9 mRNA injected G0 fish of the spr tu21
background. The arrowheads indicate the clones used for the plasmid DNA extraction. In the
middle of each row is the molecular weight marker, the 1Kb plus ladder.
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these transformed clones (Fig. 4.9). However, this did not confirm ligation of the 850 bp product,
and I only recovered the smaller inserts of 180 bp and 350 bp. In addition, I recovered a large
number that had a <200 bp product, which is about the expected size if the vector self-ligated,
indicating perhaps false positive results.
To analyze these subcloned products, I chose several promising clones from each
transformation grew 5 ml cultures and extracted their plasmid DNA (QIAprep, Qiagen).
Normally I would have sent these out for Sanger sequencing, but because of the COVID-19
pandemic, this was not possible, instead I followed this up with a PCR analysis to try and map
where the possible deletions occurred.
For the PCR analysis, first I lysed single E.coli colonies to release plasmid DNA
subcloned from the embryos from the wild type background (Fig. 4.10, lanes 1A-1F) and from
the sprtu21 mutant background (Fig. 4.10, lanes 2A-D wild-type phenotype, lanes 2E-H mutant
phenotype). As a control, I used the wild type DNA (Fig. 4.10, lane c1) and the genomic wild
type plasmid DNA (Fig. 4.10, lane c2). For the PCR, I used the forward primer in exon 1 (B2F6)
with 3 reverse primers: a reverse primer in exon 3 (B2R8), in exon 6 (R9571), and in exon 8
(B2R5) (Fig. 4.10) (Appendix A). Using the B2F6/B2R8 primers, I amplified the expected wild
type product (315 bp) and no other products, spanning a region around the 4 sgRNAs target sites
(Fig. 4.10A). Using the B2F6/B2R5 primers, I amplified the region from exon 1 to exon 8 in
only some colonies (expected product size 1139 bp) (Fig. 4.10B, lanes 1B-1D, 2E-2H).
Surprisingly, I amplified the second, smaller, product in two colonies (Fig. 4.10, lanes 1D, 2G).
Considering that each colony must be a single clone, it is possible that I tested more than one
colony at once. Using the B2F6/R9571 primers (Appendix A), I did not amplify any product,
except the expected wild type product in the control (Fig. 4.10 C). These data show that I
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subcloned cyclin B2 cDNA into pGEM-T Easy plasmid, and that I can amplify the expected
wild-type product (exon 1-3) in all tested clones. However, because I cannot amplify the
expected product using the reverse primer in exon 5, and no product when using the reverse
primer in exon 8, it is possible that those clones do not have the annealing sites for these reverse
primers any longer, and there could be alternative splice variants.

Figure 4.10 Colony PCR of the gene-edited cyclin B2 DNA subclones.
(A) Colony PCR using primers in exon 1 (B2F6) and exon 3 (B2R8), expected product size is
315 bp using cDNA and 555 bp using genomic DNA. (B) Colony PCR using primers in exon 1
(B2F6) and exon 8 (B2R5), expected product size is 1139 bp using cDNA. (C) Colony PCR
using primers in exon 1 (B2F6) and exon 6 (B2 R9571), expected product size is 930 bp using
cDNA. Note, genomic cDNA is a negative control, no product expected. Lanes 1A-1F, the
cDNA of the G1 embryos derived from the CRISPR/Cas9 protein injected G0 incross. Lanes
2A-2H, the cDNA of the G1 phenotypically wild-type embryos (lanes 2A-2D) and
phenotypically spr mutant embryos (lanes 2E-2H). Lane c1, control wild type cyclin B2 plasmid
cDNA. Lane c2, control wild-type cyclin B2 genomic plasmid DNA. To the right of each gel is a
diagram of the coding regions of cyclin B2, relative location of the forward and reverse primers
(black arrows), and relative location of the sgRNA target sites (red arrowheads) In the middle of
each row is the molecular weight marker, the 1Kb plus ladder.
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SUMMARY
In this chapter, I showed how I constructed multiple sgRNAs to target cyclin B2. By
microinjecting a mixture of four sgRNAs and the Cas9 protein or cas9 mRNA into the embryos
from the wild-type or the sprtu21 background, I attempted to knock-out cyclin B2. The injected G0
generation did not have an obvious mutant phenotype upon injection, however they did grow
slower to adulthood. When the G0 generation grew to adulthood, I incrossed them to identify the
founder fish. The fish from the wild-type background produced progeny (G1) with a surprisingly
severe mutant phenotype in 5% of the clutch. The fish from the sprtu21 mutant phenotype
produced progeny (G1) with a specter-like mutant phenotype in approximately 34% of the
clutch, while the expected mutant phenotype from the tu2 carriers incross is only 25%. After
crossing the G0 from both backgrounds, I determined that the alleles failed to complement, and
considering several distinct mutant-like phenotypes in the G1 generations, I hypothesized that I
created multiple different mutations in the cyclin B2 gene.
To identify which mutations I had introduced, I amplified different regions of genomic
cyclin B2 from DNA extracted from the G0 embryos, G0 adult fish, and G1 embryos. I also
extracted total mRNA and analyzed cyclin B2 cDNA to analyze the coding sequence. Genomic
DNA analysis showed that there might be smaller products, and, perhaps, lack of certain primer
annealing sites. cDNA analysis showed that there might be alternative transcripts, but more
analysis is needed to identify the mutation(s), e.g. Sanger sequencing.
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CHAPTER 5

PHENOTYPE OF THE PUTATIVE CYCLIN B2 MUTANT
In Chapter IV, I described two methods of knocking out cyclin B2 in the wild-type and
spr tu21 mutant background. An initial morphological analysis of the G0 generation showed that
there were no obvious morphological changes in the injected embryos. After raising the G0
generation and incrossing it, I identified several fish that produce a portion of progeny (G1) with
a tentative mutant phenotype (Fig. 4.3A, B) In this chapter, I focus on the analysis and detailed
description of these putative cyclin B2 mutants. First, I describe changes in the expression of
zygotic cyclin B2 and cyclin B1 transcripts in the 1 day embryo. Second, to identify the role of
cyclin B2 in the zebrafish cell cycle, I describe changes in cell cycle progression of these
mutants. Finally, I propose a model to explain the observed cell cycle alterations in the spr tu21
and spr ro1 mutants based on the analysis of the putative cyclin B2 and cyclin B1;B2 double
mutants.
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METHODS
cyclin B2 RNA probe synthesis, in situ hybridization
Rachel Warga made the cyclin B2 RNA probe by subcloning the entire cyclin B2 coding
sequence from the 5’UTR to the 3’UTR (primers: B2F1/B2R5). The isolated plasmid DNA with
the cyclin B2 sequence was linearized, phenol-chloroform extracted and used for the in vitro
transcription using SP6 (Invitrogen) RNA polymerase and a DIG RNA labeling (Roche). The
RNA probe was precipitated by adding 70% ethanol and resuspended in ribonuclease (RNase)
free water.
Whole mount in situ hybridization was performed as described in chapter II. The RNA
riboprobes used: cyclin B1 (sense and antisense), cyclin B2 (sense and antisense), notch1b,
deltaA, and islet1. Embryos were cleared and stored in 70% glycerol or 1x PBST. To prevent
contamination and embryo degradation, an anti-bacterial agent Thimerosal powder was added to
PBS for preservation (a small quantity on the tip of a spatula added to 50 ml of 1x PBS buffer).

Live cell cycle reporting and antibody staining
For cell cycle analysis, embryos carrying the Dual FUCCI transgene were mounted at 24
hours in 0.2% agarose and placed between the two coverslips for live analysis. Whole mount
antibody staining was performed using anti-Phospho-Histone H3 antibody (Santa-Cruz, 1:1000)
and detected with the anti-mouse Alexa Flour-488-conjugated antibody (ThermoFisher
Scientific, 1:200). One at a time, whole embryos were analyzed under the fluorescent microscope
after removing yolk and placed between two cover slips to flatten out the body. Fluorescent
detection was done using the Nikon C2 confocal microscope, at 20x or 60x magnification as
described in Chapter II.
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RESULTS
Analysis of cyclin B2 mRNA expression in the CRISPR/Cas9 cyclin B2 edited fish
A portion of The G1 embryos showed a distinct mutant phenotype, suggesting that we
knocked out cyclin B2 in at least some of the germline progenitors of the G0 fish. Considering
that CRISPR/Cas9 was injected at the 2-16-cell stage, it is likely that only portion of the cells in
an embryonic germline are edited. To test whether the severe mutant phenotype that I observed is
due to an altered cyclin B2 gene, I used whole mount in situ hybridization to examine its
expression (Fig. 5.1 and 5.2). Like cyclin B1 (Fig. 2.2D), cyclin B2 mRNA is maternally
expressed (Fig. 5.1A, B, D and E), and zygotic expression is ubiquitous and robust (Fig. 5.1C
and F). Before analyzing cyclin B2 expression in CRISPR B2 embryos, I determined cyclin B2
expression in the sprtu21 and sprro1 mutants. Embryos from both backgrounds were raised to 25somites, sorted by wild type or mutant phenotype prior to fixing, followed by in situ
hybridization. All had the same strong homogeneous expression of cyclin B2 (Fig. 5.2).

Figure 5.1
cyclin B2 is maternally expressed in the spr tu21 and spr ro1 embryos.
(A, D) Lack of cyclin B2 expression in the embryos labeled with the cyclin B2 sense riboprobe.
(B, C) cyclin B2 mRNA expression in the sprtu21 embryos at 128-cell stage (N= 30/30) and
shield stage (N = 25/25). (E, F) cyclin B2 mRNA expression in the sprro1 embryos at 128-cell
stage (N= 41/41) and shield stage (N = 40/40).
Next, I analyzed the CRISPR B2 crosses from both the wild-type (Fig. 4.3A; here,
CRISPR B2/Cas9 protein) and specter mutant background (Fig. 4.3B). All embryos from both
crosses had cyclin B2 expression, which suggests that any mutant phenotypes were not the result
of a null mutation. On the other hand, I saw heterogenous expression within the clutch of both
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backgrounds (Fig. 5.3), in both the phenotypically wild-type and mutant siblings, suggesting that
perhaps one of the cyclin B2 alleles might have been affected.

Figure 5.2
cyclin B2 is zygotically expressed in the spr tu21 and spr ro1 embryos at 24 hours.
Both wild-type embryos have robust cyclin B2 expression (A,B), no heterozygous effect
observed. Note, reduced expression in the mutants compared (A′, B′) to their wild-type siblings
is due to fewer cells in the embryos. Wild-type siblings, N=80 (tu21 and ro1 background); tu21
mutants, N=40; ro1 mutants, N=40.
When embryos from the CRISPR B2/Cas9 protein incross, were raised to 24 hours, I saw
that 5% of the clutch (G1) has an abnormal phenotype (Fig. 4.3A), such as dark head and short
body. The darkening in the head suggested that there might be a lot of pyknotic cells and cell
death; the short body suggested that embryos had fewer cells, therefore they might exhibit
abnormal cell cycle progression. After fixing and staining embryos for cyclin B2, I found that the
phenotypically wild-type embryos had either strong (13/38) or and weak (25/38) cyclin B2

Figure 5.3
cyclin B2 mRNA expression in the CRISPR B2 WT background and in the
CRISPR B2 sprtu21 background at 24 hours.
(A-B′) cyclin B2 expression varies within the pool of phenotypically wild-type (A-A′) and
potential mutant (B-B′) embryos derived from the CRISPR B2 WT background. (C-D′) A
similar variability in expression is also found in the pool of phenotypically wild-type (C-C′)
and mutant (D-D′) embryos derived from the CRISPR B2 sprtu21 background.
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expression (Fig. 5.3A-A′). Notably, the class of embryos (5 embryos) that I had sorted because
they looked different also had this variable cyclin B2 expression (Fig. 5.3B-B′). The variability
of cyclin B2 expression in wild-type looking embryos suggests that at least one cyclin B2 allele
could be affected, thus producing weaker expression, like the sprtu21 heterozygotes expressing
cyclin B1 (Table 2.1). Weaker and variable expression in the abnormal looking embryos suggests
that both cyclin B2 alleles could be affected.

Figure 5.4
cyclin B1 expression in the CRISPR B2;tu21 mutants.
(A-A′′) cyclin B1 expression in the sprtu21 phenotypically wild-type (A-A′) and mutant embryos
(A′′) at 24 hours.
Note, heterozygous embryos have weaker cyclin B1 expression (A′) and sprtu21 homozygous
mutants lack cyclin B1 expression (A′′). (B-B′′′) cyclin B1 expression in the CRISPR;tu21
phenotypically wild-type (B-B′) and mutant embryos (B′′-B′′) at 24 hours. Note, spr tu21
heterozygous embryos have weaker cyclin B1 expression (B′), sprtu21 homozygous mutants lack
cyclin B1 expression (B′′) and could possibly be cyclin B1;cyclin B2 mutants. (B′′′) A
phenotypically mutant embryo with cyclin B1 expression is likely a cyclin B2 mutant.
When embryos derived from the CRISPR B2;tu21 background (Fig. 4.3B) were raised to
24-hours, 34% of the clutch, more than a quarter, had the spr tu21 mutant phenotype, suggesting
that some of these embryos could be mutant for both, cyclin B1 and cyclin B2. The chi-square
analysis rejected the hypothesis of a single-gene mutation (p < 0.001). Phenotypically wild-type
embryos had either strong (194/269) or weak (75/269) cyclin B2 expression (Fig. 5.3C-C′).
Whereas spr tu21 mutant embryos with a more severe phenotype had markedly weaker expression
(30/92), suggesting that these embryos might be a double mutant (Fig. 5.3D-D′).
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Figure 5.5
cyclin B1 expression in the embryos derived from derived from the CRISPR
B2;WT and CRISPR B2;tu21 cross at 24-hours.
(A, B) Phenotypically wild-type embryos have variable cyclin B1 mRNA expression. (C)
Potentially transheterozygous cyclin B2 mutant embryo.
Considering that sprtu21 mutants lack cyclin B1 expression at 24-hours, I decided to use
this as a method to identify potential cyclin B2 mutants (Fig. 5.4). I hypothesized, that if a
specter-like mutant looking embryo has cyclin B1 expression, then this mutant phenotype is not a
result of the mutation in cyclin B1, but perhaps in cyclin B2. For the control, I used embryos
from a spr+/tu21 incross, which, as expected, and we have previously shown (Table 2.1), had a
robust cyclin B1 expression in 1/4 of the clutch, an intermediate expression in 1/2 of the clutch,
and no expression in the remaining 1/4 of the clutch (Fig. 4 A-A′′). Embryos from the
CRISPR B2/WT;sprtu21/WT (CRISPR B2;tu21) incross were sorted by their phenotype before
fixing. I used 35 phenotypically wild-type embryos and 31 phenotypically mutant embryos (Fig.
5.B-B′′′). The phenotypically wild-type embryos from the CRISPR B2;tu21 incross had either a
robust or intermediate expression, as expected (Fig. 5. 4B-B′). Out of 31 embryos bearing the
homozygous sprtu21 mutant phenotype, I found one that had cyclin B1 expression (Fig. 5.4 B′′′).
In addition, this mutant had a more severe mutant phenotype and did not look like a sprtu21
mutant, suggesting that this embryo’ abnormal phenotype is not a result of the specter mutation
in cyclin B1.
Because of the disparity between phenotypes for the potential cyclin B2 mutant derived
from the CRISPR B2 wild-type background (CRISPR B2;WT) (Fig. 4.3A) and the CRISPR B2
sprtu21 (CRISPR B;tu21) mutant background (Fig. 4.3B), it is possible that these two lines have
two different mutations. To verify that these mutations are in the cyclin B2 gene, I used a
complementation test. I crossed the G0 CRISPR B2;WT fish with the G0 CRISPR B2;tu21 fish
and analyzed the transheterozygous progeny at 24 hours. On average, I would see 2% of the
embryos that showed a mutant phenotype, which did not look as severe as the phenotype derived
from either of the parental incrosses. This suggests, that both alleles failed to complement, and
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both mutant lines have a mutation in the same gene. Also, because I see a variable mutant
phenotype from these tree crosses in the G1 generation (Fig. 4.3), it is likely that there are at
least two different mutations in the cyclin B2 gene. From here on I will refer to the potential
cyclin B2 mutant derived from the CRISPR B2;WT and CRISPR B2;tu21 cross as the
transheterozygous cyclin B2 mutant.
To analyze the transheterozygous mutants, I first used cyclin B1 staining. Considering the
morphological resemblance between the homozygous sprtu21 mutant and the transheterozygous
cyclin B2 mutant, and that one of the parents is a carrier for the tu21 mutant allele, I wanted to
verify that these transheterozygous cyclin B2 mutant embryos are not the result of a mistake and
were not homozygous for sprtu21. I used cyclin B1 expression as a reliable marker of the sprtu21
mutant embryos (Fig. 5.5A-C). Out of 69 wild-type embryos, 36 had a stronger expression (Fig.
5.5A) and 33 had a weaker expression (Fig. 5.5B), as expected when a heterozygous sprtu21/+
crossed to a homozygous (spr+/+) fish. Notably, out of 6 mutant embryos, 4 had strong cyclin B1
expression (Fig. 5.5C), when compared to the mutant siblings. Since not a single embryo lacked
cyclin B1 expression, it was clear that the observed mutant phenotype was not the result of being
homozygous for the sprtu21 mutation.

Figure 5.6
Heterogenous expression of cyclin B2 mRNA in the phenotypically wild-type
embryos at 24-hours from the CRISPR B2;WT crossed to the CRISPR B2;tu21.
Next, I checked whether embryos from this transheterozygous cross lacked cyclin B2
expression. For this experiment, I used the remaining wild type looking embryos from the same
clutch. Out of 41 wild-type embryos, 21 had stronger cyclin B2 expression (Fig. 5.6A), compared
to the siblings (Fig. 5.6A′). If both parents had 50% of the germline carrying the cyclin B2
mutant allele, I would expect 2/3 of the phenotypically wild-type embryos to have weaker cyclin
B2 expression, like heterozygous embryos from the sprtu21 incross. However, this is not what I
saw, considering the low frequency of the mutant embryos, it is likely that the clone size in the
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germline is small, and that the embryos with a weaker cyclin B2 expression (N = 20/41) are
heterozygous for the cyclin B2 mutant allele.
In summary, in the G1 embryos derived from the CRISPR B2;WT incross and the
CRISPR B2;tu21 result in a mutant phenotype that may be the result of mutating the cyclin B2
allele. Analysis of both cyclin B1 and cyclin B2 expression in these clutches suggests that a
portion of the embryos have weaker cyclin B2 expression. This is reminiscent of the CRISPR
mutation in cyclin B1 (ro1) where weaker cyclin B1 expression is observed (Fig. 2.3F′).
Furthermore, analysis of the putative CRISPR B2 transheterozygote strongly supports that I
created two independent mutations and therefore each background might be missing a functional
copy of cyclin B2 allele.

Analysis of cell cycle progression in the CRISPR/Cas9 cyclin B2 edited fish
Since I saw a distinct mutant phenotype in the G1 progeny of the CRISPR injected
embryos in the wild-type and spr mutant background, I wanted to check whether there are any
changes in cell cycle progression in these embryos. It has been shown that cyclin B2
overexpression leads to abnormal spindle polarity and chromosome segregation in mouse
embryonic fibroblasts (Nam and Van Deursen, 2014). Also, Mathieu et al. (2013) showed that
Cyclin B2 promotes timely abscission in Drosophila oocytes. Considering that I do not know
what type of mutation I have introduced using CRISPR/Cas9, and that there has not been a study
reported on the role of Cyclin B2 in the zebrafish cell cycle, I hypothesized that such a severe
mutant phenotype might be explained by abnormal cell cycle.
To analyze the cell cycle, I looked at Cdt1 and Geminin expression using the Dual
FUCCI transgene (Bouldin and Kimelman, 2014; Petrachkova et al., 2019). The Cdt1-mCherry
reporter is expressed when the cell is in the G1 phase of the cell cycle (red) to promote the next
DNA synthesis phase (DNA licensing). To prevent DNA re-replication, Cdt1 is degraded in the
S phase, and Geminin is accumulated (blue) to maintain the inhibition of DNA licensing until
Geminin is degraded in anaphase by the APC/C (Ballabeni et al., 2013). For this reason, cells in
the mid-M phase do not exhibit any Gemini expression.
Wild-type and mutant embryos from the three G0 crosses (i.e. the two incrosses (Fig.
4.3A, B) or the transheterozygote cross (Fig. 4.3C)) were sorted by the morphological phenotype
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at the 24 hours and then visualized by confocal microscopy. As a control I used the 24-hour
embryos from the sprtu21 heterozygote incross (Fig. 5.7). As described before, the wild-type
siblings (spr+/+ and spr+/tu21) had mostly “red” cells in the G1 phase, unlike mutant embryos at
24 hours. sprtu21 mutants had mostly “blue” cells in the S/G2 phase of the cell cycle, and the
majority of cells in the G1 phase were pyknotic. As I have shown previously, lack of Cyclin B1
causes a lot of cells to arrest in the G2/M phase, yet some cells do continue to enter cell division
(Petrachkova et al., 2019).
Next, I looked at the embryos from the CRISPR B2;WT incross. As expected, most cells
in the wild-type siblings from the CRISPR B2;WT incross were in G1 (Fig. 5.8A, B), however
on the yolk some G1 cells were pyknotic (Fig. 5.8A). Pyknotic cells are not common in the wildtype embryos unless embryo was damaged. I also saw a few cells in the S/G2/early M phase both
on the yolk (Fig. 5.8A′) and in the tail (Fig. 5.8B′). Mutant embryos seemed to have fewer cells
visualized with the Dual FUCCI transgene, which suggests that there are many unlabeled cells,
likely either in the M phase or perhaps the transgene has turned off as occurs in some cell types
once they differentiate and exit cell cycle (Fig. 5.8C-D′′). However, overall, there were many

Figure 5.7
Cells in the sprtu21 mutants are predominantly in the S and G2 phase of cell cycle
at 24-hours.
Shown are populations of cells in the yolk where the Dual FUCCI cell cycle reporter mCherryCdt1 (red) defines cells in G1(G0) stage (A-B) and the Cerulean-Geminin (blue) defines cells in
S/G2/early M stages (A'-B'). Scale bar is 100 µm.
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more cells in the S/G2/early M phase both on the yolk (Fig. 5.8C′) or in the tail (Fig. 5.8D′).
Interestingly, unlike the sprtu21 mutant, these mutant embryos had no pyknotic cells, a sign of
apoptosis in tu21 mutants. This observation suggested the darkening of the body in the CRISPR
B2 mutants was not caused by cells dying.

Figure 5.8
Cells in the CRISPR B2;WT mutants are predominantly in the S/G2/early M
phase of cell cycle at 24-hours.
(A-B'') Shown are populations of cells in the yolk (A-A'') and in the tail (B-B'') of the wild-type
sibling at 24 hours (A′ white arrow, pyknotic cells). (C-D'') Shown are populations of cells in
the yolk (C-C'') and in the tail (D-D'') of the mutant embryo at 24 hours. Note, most of the cells
are blue (S/G2/early M) and no pyknotic cells. Dual FUCCI cell cycle reporter mCherry-Cdt1
(red) defines cells in G1(G0) stage and the Cerulean-Geminin (blue) defines cells in S/G2/early
M stages. Scale bar is 100 µm.
Next, I looked at the embryos from the CRISPR B2;tu21 incross. Likewise, Most cells in
the wild-type siblings from the CRISPR B2;tu21 incross were in G1 and not S/G2/early M (Fig.
5.9A, B) As we noted above, the mutant embryo had far more blue cells than wild type, however
in this background many of these cells were binuclear (Fig. 5.9C, C′ white arrows). There were
also a lot of pyknotic cells in the S phase (pinks cells) (Fig. 5.9C′-C′′). Cell death is common in
the sprtu21 mutant, but not binuclear cells. These observations suggest that these mutants may be
lacking both cyclin B1 and cyclin B2.
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Figure 5.9
Cells in the CRISPR B2;tu21 mutants are predominantly in the S/G2/early M
phase of cell cycle and have double nuclei at 24-hours.
. (A-B'') Shown are populations of cells in the yolk (A-A'') and in the tail (B-B'') of the wildtype sibling at 24 hours. (C-D'') Shown are populations of cells in the yolk (C-C'') and in the tail
(D-D'') of the mutant embryo at 24 hours. Note, most of the cells are blue (S/G2/early M), some
of the blue cells have double nuclei (white arrows, D'), pyknotic cells in the yolk (C-C') indicate
cell death. Dual FUCCI cell cycle reporter mCherry-Cdt1 (red) defines cells in G1(G0) stage
and the Cerulean-Geminin (blue) defines cells in S/G2/early M stages. Scale bar is 100 µm.
Next, I wanted to ask if the CRISPR B2 transheterozygote (Fig. 4.3C) also had changes
in cell cycle progression. I hypothesized that since CRISPR B2;WT and CRISPR B2;tu21 fail to
complement, but do not have as severe a mutant phenotype as that derived from the individual
incrosses (Fig. 4.3A,B), I might see a less severe cellular phenotype in wild-type siblings and
mutant embryos were comparatively alike with equivalent number of blue cells in S/G2/early M
(Fig. 5.10). However, the number of red cells in G1 in the observed field was fewer compared to
wild type (Fig. 5.10B), so that as a proportion it was similar to the mutant embryos from the
CRISPR B2 incross (Fig. 5.8C).
In summary, mutating cyclin B2 causes many cells to be in the S/G2 and likely M phase
of the cell cycle. However, in contrast to mutating cyclin B1, there is no sign of cells dying.
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Figure 5.10 Cells in the embryos from the CRISPR B2;WT crossed to CRSIPR B2;tu21 show no
signs of abnormal cell cycle progression.
(A-A'') Shown are populations of cells in the yolk of the wild-type and (B-B') mutant sibling at 24
hours. Dual FUCCI cell cycle reporter mCherry-Cdt1 (red) defines cells in G1(G0) stage and the
Cerulean-Geminin (blue) defines cells in S/G2/early M stages. Scale bar is 100 µm.
When cyclin B2 is mutated in the background of the sprtu21 mutant, in addition to more blue cells
in the S/G2/early M phase of the cell cycle now many are binucleate cells and I see signs of cell
death. Finally, because the CRISPR B2;WT and CRISPR B2;tu21 mutants are likely the result of
two independent mutations in cyclin B2 when I make the transheterozygote, I find that these
embryos do not have as severe a mutant phenotype, and cells are more likely to have a normal
cell cycle progress. These data suggest that mutations in cyclin B2 cause changes in zebrafish
cell cycle progression where cells now spend more time in S/G2/early M than in G1, and that
these alterations become more severe when combined with the null mutation in cyclin B1.

Analysis of the dividing cells in the CRISPR/Cas9 cyclin B2 edited fish
To further investigate changes in the cell cycle in the presumptive cyclin B2 mutants, I
looked at the cells in the G2 and M phase. As described in Chapter II, neural cells, which
normally divide at the midline, do not divide there in the sprtu21 mutant and neural cells in the
sprro1 mutants seem not to divide at all once the midline forms (Fig. 2.5A-A′′). I hypothesized
that the observed divisions in the sprtu21 mutant are possible because, even though Cyclin B1 is
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not produced, Cyclin B2 is still available to interact with Cdk1. However, there are no cell
division in the sprro1 mutant because it produces an altered Cyclin B1 that blocks access of
Cyclin B2 to Cdk1. Considering the Dual FUCCI cell cycle reporter data shown above, I
hypothesized that the CRISPR B2;tu21 double mutants, which exhibit a more severe phenotype
than the sprtu21 and that resembles sprro1 mutant, should also not divide at the midline or even not
divide at all.
To analyze if neural cells divide one time at the midline, I looked at anti-pH3 staining of
whole embryos of the sprtu21 wild-type and mutant siblings, sprro1 wild-type and mutant siblings,
and also wild-type and mutants from the CRISPCR B2;tu21 incross at 24 hours (Fig. 5.11). The

Figure 5.11 Mitotic cells do not align at the midline in the sprtu21, sprro1, and CRISPR B2;tu21
mutant embryos at 24 hours.
Mitotic cells stained with anti-pH3 (egr2b) align at the dorsal midline (red arrow) in the wildtype embryos (A, B, C), but are scattered in the mutant embryos (A′, B′, C′). Note fewer mitotic
cells in the sprro1 (B′) and CRISPR B2;tu21(C′) mutants compared to the sprtu21(A′) mutants.
Whole embryo, dorsal view.
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wild-type embryos from all three crosses resembled one another and all had a line of cells
dividing at the midline (Fig. 5.11A, B, C, red arrows). sprtu21 mutants had scattered cell along the
axis and no dividing cells at the midline (Fig. 5.11A′). sprro1 mutants had fewer scattered pH3positive cells (Fig. 5.11B′), and CRISPR B2;tu21 mutants had even less, with maybe a few cells
dividing at the midline (Fig. 5.11 C′). This result indicated that some mutant embryos from the
CRISPR;tu21 cross were more similar to the sprro1 mutant than to the sprtu21 mutant, suggesting
that our hypothesis might be correct and lack of both, Cyclin B1 and Cyclin B2 at the same time
caused cells to cease to divide.
Next, I wanted to analyze whether the dividing cells, that I saw with the Dual FUCCI
transgene and with the anti-pH3 staining, have any defects during mitosis. As described earlier in
Chapter II, specter mutants show signs of chromosomal instability. These chromosomal
abnormalities, such as lagging chromosomes and incorrect spatial orientation of the spindle,
during mitosis are worse in the tu21/ro1 transheterozygote and in the sprro1 mutant compared to
the sprtu21 mutant (Fig. 2.8). Since we saw that overall, the number of mitotic cells in the
CRISPR B2;tu21 embryos is comparable to the number of mitotic cells in the sprro1 mutant, I
hypothesized that the mitotic abnormalities should also be alike. Looking at anti-pH3 staining of
the sprtu21 and sprro1 wild-type and mutant embryos, I saw that the wild-type siblings have normal
looking cells in anaphase and prophase in the tail at 19 hours (Fig. 5.12 A-A′, C-C′). However,
sprtu21 mutants had many cells in anaphase with lagging chromosomes, and cells in that had
highly condensed chromosomes, phenotypes that I usually do not see in the wild-type siblings
(Fig. 5.12B). The sprro1 mutants did not have any normal looking cells in mitosis. Most of their
pH3-positive cells seemed to be arrested in an abnormal looking anaphase (Fig. 5.12D-D′) at 19
hours. The CRISPR B2;tu21 wild-type embryos also had many normal looking cells in mitosis,
like the other wild-type categories (Fig. 5.12 E-E′), but the pH3-positive cells in the mutantlooking embryos had severe abnormalities where highly condensed chromosomes were spread
apart (Fig. 5.12F), and missing chromosomes during anaphase (Fig. 5.12F′). Such chromosomal
instability observed in the CRISPR B2;tu21 mutant embryos at 19h (20-somites) is a
characteristic of mutant cells in the sprro1 mutant (Fig. 2.8), but not something I have observed in
the sprtu21 mutant this early.
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Figure 5.12 CRISPR B2;tu21 mutant embryos show signs of severe chromosomal
abnormality at 19-hours.
(A-B') Anti-pH3 (egr2b) staining shows mitotic cells in the sprtu21 embryos. Note, sprtu21
mutants (B-B') have abnormal anaphase and highly condensed chromosomes in prophase. (CD') Anti-pH3 staining shows mitotic cells in the sprro1 embryos. (E-F') Anti-pH3 staining shows
mitotic cells in the CRISPR B2;tu21 embryos. Note, mutant embryo (F-F') has pyknotic cells,
spread around condensed chromosomes (F) and abnormal metaphase (F'). Green arrow – cell in
prophase; blue arrow – cell in metaphase; orange arrow – cell in anaphase.

If mutants derived from the CRISPR B2;tu21 show such a distinct mitotic phenotype,
what of mutant embryos derived from the CRISPR B2;tu21 and CRSIPR B2;WT cross? Based
on gu expression, I hypothesized, that there should be no abnormal looking cell divisions in
these embryos because the cells in the S, G2 and early M phase did not differ from the normal
looking siblings. However, seeing fewer G1 cells raised the question whether there were fewer
G1 cells because most of the cells were in mitosis. After looking at the anti-pH3 staining in these
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transheterozygote embryos at 24 hours (Fig. 5.13D, D′), I found that the mitotic cells looked
normal (Fig. 5.13C, C′). However, it is unclear whether there are more dividing cells in the
mutant than in their wild-type sibling without more investigation.

Figure 5.13 Embryos from the CRISPR B2;WT crossed to CRISPR B2;tu21 show no signs of
abnormal mitosis at 24 hours.
(A-B') Anti-pH3 staining shows mitotic cells in the sprtu21 embryos. Note, sprtu21 mutants have
abnormal metaphase with lagging chromosomes (B) and pyknotic nuclei (B'). Transheterozygous
cyclin B2 embryos from the have normal anaphase (D) and metaphase (D').
In summary, I found that the CRISPR B2;WT and CRISPR B2;tu21 mutants have
abnormal cell cycle progression, and that embryos mutant for both cyclin B1 and cyclin B2 do
seem to resemble the sprro1 mutant nuclear phenotype during mitosis. These data show that it is
possible that Cyclin B2 is just as important for the cell cycle progression as Cyclin B1.
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Morphological changes in the specter and CRISPR B2;tu21 mutants
After observing changes in cell cycle progression in the CRISPR B2;tu21 mutants, I
compared their morphological phenotype to the specter mutants. In Chapter II, I described how
due to lack of functional cyclin B1, an abnormal cell cycle progression affects neural tissue
development and causes segmentation defects and misexpression of myoD in the mesoderm. We
concluded that a more severe morphological phenotype in the sprtu21/ro1 transheterozygote is
caused by the ro1 allele expressing a mutated cyclin B1. Therefore, changes in cell cycle
progression affected highly proliferative tissue development. After observing a very similar
abnormal phenotype in the mitotic cells of the CRISPR B2;tu21 mutant, I hypothesized a similar
phenomenon might be occurring in their nervous and muscle tissue. To describe changes in the
morphological phenotype of these mutants, I used 24-hour embryos from the sprtu21/+ and sprro1/+
heterozygote incrosses, the sprtu21/+ and sprro1/+ transheterozygote cross, and the CRISPR
B2;tu21 incross. All embryos were sorted by their morphological phenotype prior to fixing and
doing in situ hybridization with neural (notch1b, deltaA) and mesodermal markers (myoD).
As I saw previously, specter mutants had delayed notch1b expression which reached
almost the wild-type levels by mid-segmentation (Appendix B). At 24 hours, notch1b was
expressed in the stem cell population of the central nervous system, and the retina in wild-type
embryos (Fig. 5.14A). However, by 24 hours there were fewer notch1b positive cells in the tu21
mutant (Fig. 5.14B) and the tu21/ro1 transheterozygote (Fig. 5.14C), and even fewer cells in the
ro1 mutant (Fig. 5.14D). Most of the mutant looking embryos from the CRISPR;tu21 incross had
a weaker notch1b expression (34/37 embryos) compared to their wild-type siblings (40/40
embryos) (Fig. 14E). However, 3 (out of 37) mutant embryos had almost no expression in the
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central nervous system and no expression in the retina (Fig. 14F). These embryos with a weaker
expression also had a more severe morphological phenotype.

Figure 5.14 Lack of functional Cyclin B causes changes in the expression nervous and muscle
tissue mRNA markers in the specter and CRISPR B2;tu21 mutants at 24 hours.
(A-F) notch1b, (G-H) deltaA, (M-R) islet1, (S-X) myoD mRNA expression in the wild-type,
sprtu21, sprtu21/ro1, sprro1 and CRISPR B2;tu21 mutant embryos. (A-R) Lateral view, (S-X) dorsal
view. Insert boxes – dorsal view. Legend: tc – telencephalon, ep – epiphysis, bmn –
branchomotoneurons, pcr – pancreas, pmn – primary motoneurons, rb – Rohon-Beard sensory
neurons.
Next, I looked at the population of proneural cells in the process of leaving the cell cycle
and beginning to differentiate using deltaA mRNA expression (Fig. 14G-L). At 24 hours, the
wild-type embryos had a robust expression in cells throughout the central nervous system (Fig.
5.14G). The tu21 mutants had fewer deltaA positive cells (Fig. 5.14H), which was consistent
with our earlier observation during the mid-segmentation stage (Appendix B) and the tu21/ro1
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transheterozygote also had even fewer deltaA positive cells throughout the nervous system (Fig.
5.14I). The ro1 mutant had a very similar deltaA expression in the central nervous system
although expression in the brain was depleted (Fig. 5.14J). Compared to the wild-type and tu21
mutant embryos (Fig. 5.14G, I), deltaA expression also showed how narrow the central nervous
system was in the ro1 mutants (Fig. 5.14J). Because this deltaA expression in the brain resembles
that during mid-segmentation stage these data suggest there is very little development of
proneural cells beyond this time (Appendix B). Out of 24 CRISPR B2;tu21 mutant embryos, 20
had more robust deltaA expression in the central nervous system (Fig. 5.14K), like the tu21
mutant (Fig. 5.14H), which suggested that these embryos are only tu21 homozygotes. 4 mutant
embryos had a more severe morphological phenotype and weaker deltaA expression (Fig.
5.14L), compared to other mutant siblings (Fig. 5.14K). These embryos had a strong expression
in the forebrain and midbrain but few deltaA positive cells in the hindbrain however, in the
spinal cord there were almost no proneural cells.
Next, I looked at the differentiated neurons using islet mRNA expression (Fig. 5.14M-R).
At 24 hours, wild type embryos had robust islet1 expression in primary motor neurons and
Rohan-Bear sensory cells (Fig. 5.14M). The tu21 mutant embryos had weaker islet1 expression
overall and spinal cord neurons looked bigger and did not align in a ventral row of motor
neurons and a dorsal row of sensory neurons (Fig. 5.14N). A similar pattern was observed in the
tu21/ro1 transheterozygote and in the ro1 mutant (Fig. 5.14O-P). However, in the ro1 mutant,
cells were mostly scattered around the end of? the tail (Fig. 5.14P). Out of 42 mutant embryos
from the CRISPR B2;tu21 embryos, 38 had an islet1 expression like the tu21 mutant, suggesting
that these are only homozygous for the tu21 homozygous embryos (Fig. 5.14 Q). 4 mutant
embryos had a more severe morphological phenotype with a very few spinal cord neurons in the
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tail (Fig. 5.14R). I also noticed in some of the CRISPR B2;tu21 mutant embryos having a more
severe phenotype that in the spinal cord most cells were concentrated in the tail tip.
Lastly, I analyzed the muscle expression of myoD. Previously, we showed that the tu21
mutant had delayed expression of myoD in the somites at the early-segmentation stage and once
somite expression appeared, it was extremely disorganized diffused myoD expression in the
segments. However, the tu21/ro1 transheterozygote also had a delayed expression (Appendix B)
which recovered by 15-somites (data not shown). Considering that we saw a similar abnormal
morphological appearance in the muscle, it was unclear why the myoD expression patterns were
different. At 24 hours, all mutant embryos had myoD expression in the somites, but their borders
were disorganized, and the expression was diffused compared to wild-type (Fig. 5.14S-X).
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SUMMARY
Together these data suggest that changes in cell cycle progression affect the entire
population of the neural stem cells and their progeny. The tu21 mutant has a population of cells
that continues to enter new rounds of cell cycle; therefore, we see more proliferating neural stem
cells and more proneural and differentiated cells. The ro1 mutant and the CRISPR B2;tu21
mutants with a more severe mutant phenotype lack more of these category of cells, suggesting
that both cease divisions and probably undergo cell death, considering the levels of chromosomal
instability caused by abnormal cell cycle, described above (Fig. 5.12).
Finally, these data suggest that abnormal cell cycle progression does not prevent somite
muscle from forming but interferes with the timely manner of segmentation and differentiation in
cyclin B mutants.
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CHAPTER 6

DISCUSSION
Cell division is a necessary part of the life cycle of all organisms. During development of
a vertebrate embryo it is important both for subdivision of the large egg and growth of the
embryo. In animals, cell division is controlled by the cell cycle and defects in proper regulation
of the cell cycle can lead to overgrowth of cells, such as occurs in cancer. A normal progression
through the cell cycle is dependent on a biochemical progression of regulatory factors, which are
encoded by cell cycle genes. These genes are highly conserved throughout the animal kingdom.
In vertebrates many of these genes have been duplicated and it is not fully understood the exact
role of each. In most vertebrates, there are two Cyclin B’s: Cyclin B1 is thought to play an
essential role in cell cycle progression, specifically for entry into mitosis, whereas Cyclin B2 is
thought to be less important and only needed post-meiotic and post-mitotic entry. However,
Cyclin B2 has similar domains to Cyclin B1 and continues to be expressed in the fertilized egg,
thus its role is not clear during embryonic development.
In this study, I show that in the absence of functional zygotic Cyclin B1, cells in the
zebrafish embryo choose different paths: they can either arrest at the G2 to M phase of the cell
cycle, they can continue cycling with a longer M phase, or they exhibit signs of chromosomal
instability and undergo apoptosis (Fig. 2.9). The sprro1 mutant created using CRISPR/Cas9 failed
to complement the null mutation, confirming that the specter mutant phenotype is caused by a
mutation in cyclin B1. The only difference was that the ro1 allele was not a null mutation, but a
recessive gain-of-function splice-site mutation. Its alternative variant, if translated, would remain
in the nucleus, while being bound to Cdk1, and not undergo degradation. This allele caused more
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severe chromosomal defects, such as misaligned spindles, lagging chromosomes and overall
mitotic catastrophe, which leads to cell death. In addition, cells in the outer epithelium of the
embryo, the enveloping layer cells, cease to divide by the end of gastrulation, unlike the cells in
the tu21 null mutant, that continue to divide. I hypothesized that these cells arrest in the cell
cycle not because they do not have functional Cyclin B1, but because an alternative Cyclin B1
prevents another factor, such as Cyclin B2, to bind to Cdk1 and rescue the cells by promoting
new cell divisions (Fig. 2.9) (Petrachkova et al., 2019). Cyclin B2 has a Cdk1-binding domain
and together with Cdk1 can promote cells into mitosis in the absence of Cyclin B1 (Bellanger et
al., 2007), suggesting a redundant role of two cyclins. In an endeavor to test this hypothesis and
uncover the role of cyclin B2 in the cell cycle, I attempted to knock-out cyclin B2 using the
CRISPR/Cas9 gene editing tool. This resulted in two putative cyclin B2 mutations, one in the
wild-type background, and the second one in the sprtu21 mutant background.

Lessons learned from CRISPR mutation in cyclin B2
First, I discuss my putative mutation in the wild-type background. Like cyclin B1,
cyclin B2 is maternally expressed (Fig. 5.1), therefore I did not expect to see any phenotypic
changes until the onset of gastrulation in the injected embryos. After injecting CRISPR/Cas9
protein into wild-type fish (CRISPR B2;WT), I did not see any abnormal morphological
phenotypes, except for the slowed down growth of these embryos. Once the injected embryos
grew to adulthood, 5% of the G1 generation had an abnormal morphological phenotype, the
earliest of which was defects in blastoderm migration at the end of gastrulation (observation).
Embryos sorted by this phenotype later exhibited a small head, a very short trunk, and no
distinguishable muscle. Such embryos also exhibited a general loss of optical transparency
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causing their body to appear dark (Fig.5.3). While specter mutants (tu21 and ro1 alleles) also
have darkening of the body (Petrachkova et al., 2019) because the majority of cells eventually
undergo apoptosis due to aberrant mitoses, I saw no pyknotic cells in the CRISPR B2;WT
putative mutant. Therefore, this loss of optical transparency does not seem to be a result of
apoptosis. A similar effect is observed in the zebrafish cdc20 mutant, called zombie
(unpublished, Kane lab). Cells in this cell cycle mutant, round up in mitosis and arrest in the
metaphase/anaphase transition, but do not undergo apoptosis (Kane et al., 1996). Because the
cells in the zombie mutant refract light differently, the embryo becomes opaque. Perhaps cells in
the putative cyclin B2 mutant have a similar aberrant morphology.
In support of this idea, while current research (Daldello et al., 2019; Kotani et al., 2001b;
Li et al., 2018; van der Voet et al., 2009) has only examined the role of Cyclin B2 in oocytes of
different model organisms, it is thought to be important for proper spindle formation (Table 1.2).
No study has examined the role of Cyclin B2 in somatic cells, except in tissue culture where it is
thought to play a role in Golgi apparatus disassembly during mitosis (Draviam et al., 2001;
Jackman et al., 1995) (Yadav et al., 2009). If lack of Cyclin B2 affects Golgi apparatus
disassembly or spindle formation this might change the architecture of the cell. This might
explain the lack of optical transparency in the prospective cyclin B2 mutant. In the future we
hope to examine this by looking at the Golgi apparatus dynamics and spindle organization during
mitosis.
In situ hybridization revealed that a portion of the phenotypically wild-type embryos and
embryos with the putative mutant phenotype from the CRISPR;WT incross had weaker cyclin B2
expression (Fig. 5.3). This indicates that cyclin B2 mRNA expression is affected and although I
was unable to sequence the gene, it supports the idea that I successfully mutated cyclin B2. One
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possible explanation for these reduced transcripts is that one of the parents carries a nonsense
mutation while another parent has a different mutation making mRNA that is not degraded.
Weak expression excluded the possibility of having created a homozygous null mutant.
Finally, when I examined Dual FUCCI expression (Fig. 5.8) it revealed that there were
many cells in the “blue” phase of cell cycle (late S/G2/early M). This cellular phenotype was
unexpected because if Cyclin B1 is the major cyclin driving cells into mitosis, then it is unclear
why lack of Cyclin B2 would cause cells to perhaps stall in the “blue” phase similar to specter
mutants. However, cyclin B2 knockdown in HeLa cells increases the number of cells in G2
because of delayed entry into M suggesting that like Cyclin B1, Cyclin B2 has some role at the
G2/M checkpoint or entry into mitosis (Soni et al., 2008).

Phenotype of the putative cyclin B1;cyclin B2 mutant cells
To test the role of both Cyclin B1 and Cyclin B2 in cell cycle progression, I injected
CRISPR B2/cas9 mRNA into sprtu21 identified carriers. I hypothesized that by knocking out
cyclin B2 in the sprtu21 background, I would create a double mutant that would arrest in the G2/M
phase and would resemble the ro1 mutant phenotype. If the mutant clone size was 50% in the
germline, I would expect an independent assortment as: 9/16 wild-type, 3/16 mutant for one gene
(sprtu21), 3/16 mutant for the second gene (cyclin B2) and 1/16 double mutant phenotype
(CRISPR B2;tu21). However, because the CRISPR/cas9 mixture is injected in the 2-16-cell
embryo, the mutant clone size in the germline is unknown and can only be estimated by looking
at the mutant phenotype’s segregation in the G1. Before the stable mutant line is established (G3
generation), I began analyzing the G1 generation carrying the tu21 allele and putative CRISPR
B2 allele.
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After injecting CRISPR/cas9 mRNA into embryos from the sprtu21 heterozygous incross
(CRISPR;tu21), I did not see any abnormal morphological phenotype, except in the 25% of the
clutch exhibiting the sprtu21 mutant phenotype. The rest of the embryos had signs of slowed
down growth, similar to the CRISPR;WT embryos. On the average, 34% of the G1 generation
had the specter-like mutant phenotype, but some of the embryos had a more severe
morphological phenotype, such as a smaller and darker head, and a shorter trunk (Fig. 5.4). If the
G1 generation was a result of a monohybrid cross, I would expect 25% of the clutch to have the
mutant phenotype, however because a second gene must have been affected, it is possible that
9% of the clutch are the embryos with a mutated cyclin B2 or both, cyclin B1 and cyclin B2.
In situ hybridization revealed that some phenotypically mutant looking embryos
expressed cyclin B1 mRNA, which suggested that their mutant phenotype was not caused by the
cyclin B1 null allele. In situ hybridization for cyclin B2, revealed that on the average, a third of
the G1 generation had weaker cyclin B2 expression, suggesting that the cyclin B2 allele was
affected, but it was not a null mutation. This result was very similar to the cyclin B2 expression
in CRISPR;WT embryos, suggesting that both parents carry different mutations in cyclin B2, and
that the phenotypically mutant embryos in the G1 are not a result of a homozygous null mutation
in cyclin B2.
When I examined Dual FUCCI expression (Fig. 5.9), it revealed that there were many
cells in the “blue” phase of cell cycle (late S/G2/early M), many pyknotic cells, and surprisingly,
many binucleated cells in late S/G2 phase of cell cycle. The first two characteristics are common
for the tu21 mutant. However, the binucleated cells (Fig. 5.7), are never observed in the tu21
mutant. This observation suggested that this mutant phenotype could be the double mutant for
cyclin B1 and cyclin B2.
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Finally, when I examined mitotic cells using anti-pH3 antibody staining, it revealed that
putative CRISPR;tu21 mutant embryos had very few mitotic cells and aberrant mitotic
chromosomes similar to the ro1 mutant (Fig 5.11B′, C′; Fig. 5.12D, D′, F, F′). This observation
supports former research describing that chromosomal instability is increased when both cyclin
B1 and cyclin B2 are knocked out in cell culture (Gong et al., 2010). Bellanger and Gramont
(2007) showed that lack of both Cyclin Bs in human colorectal cancer cells fail to alight during
the metaphase plate, the chromosomes remain condensed resembling late prophase.
Chromosome condensation was striking in the pH3-positive cells in the CRISPR;tu21 mutant,
and I saw abnormal metaphase plates with highly condensed chromosomes being misaligned at
19 hours (Fig. 5.12F′), suggesting that these cells fail to promote normal mitosis progression. A
failed attempt at mitosis results in culture cells to exit mitosis early or proceeding into division
that results in abnormal cytokinesis before DNA is segregated (Bellanger and Gramont, 2007).
Similar phenotypes occur when cells are treated with the Cdk1 inhibitor RO-3306 (Vassilev et
al., 2006). One hypothesis is that the binucleated cells observed in the CRISPR;tu21 putative
mutants remain in this state arrested, a second hypothesis is that the cells eventually separate,
and the third hypothesis is that the cells leave the cell cycle and remain tetraploid in interphase,
as it happens in cell culture (Bellanger and Gramont, 2007).

Mutations in the CRISPR;WT and CRISPR;tu21 both affect the same gene
Using a complementation test, I confirmed that both, CRISPR;WT and CRISPR;tu21 fail
to complement, meaning that the two mutations affect the same gene. It is possible that,
disregarding the genetic background of the injected fish, there are multiple mutations. Genomic
DNA analysis using PCR and cDNA analysis showed that there are smaller cyclin B2 products
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and that some primer annealing sites are no longer recognized. This data is limited, and requires
a more thorough analysis using Sanger sequencing, which has been unavailable due to the
COVID-19 global pandemic. Our prediction was that by using the four sgRNAs at once, we
would target both alleles at once, by creating multiple mutations, which would increase the
chance of getting the null phenotype in the G0 as others have done (Wu et al., 2018). I did not
see any obvious morphological abnormalities in the G0 progeny, except for a slowed down
growth. Our in situ data suggests that we created different mutations that affected cyclin B2, and
the low numbers of the G1 embryos with abnormal phenotype might indicate incomplete
targeting (Wu et al., 2018). There might be several factors contributing to not creating null
mutations in all of the injected embryos. First, the concentration of the sgRNA and the cas9 or
Cas9 protein was low, however increased concentrations have shown to be toxic and lethal for
the injected embryos. Second, the combination of the four sgRNAs that was injected, was a
combination of the two sgRNAs sequences predicted using a Synthego CRISPR Design Tool and
two sgRNAs predicted by Wu et al. (2018), which might be not as efficient in targeting multiple
coding sites, as it could be if using the four guides generated by Wu et al. (2018). Third, because
the cyclin B2 coding sequence remains in frame in every exon, and it is possible that alternative
splicing might occur, like in the ro1 allele (Petrachkova et al., 2019) or non-homologous repair
generated hypomorphic alleles (Challa et al., 2016).

Cyclin Bs affect morphogenesis in zebrafish embryos
Using in situ hybridization, I previously showed that the tu21 allele causes changes in the
central nervous system (Petrachkova, 2015). Expression of notch1b was delayed and weaker and
there were fewer cells expressing deltaA (Fig. 5.14). The cellular and morphological changes in
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the sprtu21 mutant happen during mid-segmentation, which coincide with the onset of fewer Delta
positive cells (Appendix B). We hypothesize that notch1b cells do not exit mitosis, therefore
giving rise to fewer postmitotic deltaA cells. We also hypothesize the notch1b cells do not cell
cycle to maintain the stem cells pool and undergo apoptosis, therefore we see fewer notch1b
cells.
islet1expression showed that the sprtu21 mutant had fewer but bigger spinal interneurons,
sensory and motoneurons. Normally, the Rohon-Beard sensory neurons are specified at the
neural plate stage and are programmed to die no earlier than 3-4 days post fertilization. We
thought that fewer primary neurons could be explained by, first, delayed, and prolonged cell
cycle, which would prevent Notch cells from exiting mitosis. And second, the cells in the central
nervous system were dying (Petrachkova, 2015). Bigger neurons could be explained by cells
ceasing cell divisions, as seen in harpy mutants (Riley et al., 2010). The harpy mutant phenotype
is caused by a nonsense mutation in early mitotic inhibitor1 (emi1) (Zhang et al., 2008). Lack of
emi1 causes APC/C to block entry into mitosis, yet the cells undergo repeated rounds of
endoreplication and have bigger cells. The recessive gain-of-function ro1 allele had a more
severe phenotype, with very few deltaA cells and very few differentiated neurons that expresses
islet1. This observation was in agreement with our first prediction: the earlier cells arrest in the
G2/M phase, the fewer notch1b cells will exit mitosis and give rise to differentiated neurons. The
first cells cease cell divisions as early as end of gastrulation in the ro1 mutant. The CRISPR;tu21
embryos, on the contrary, have very few cells expressing notch1b, suggesting that these cells
cannot maintain the self-renewal state (Hatakeyama et al., 2014; Weinmaster et al., 1991). It is
possible that cells that differentiate early survive and cells that differentiate late arrest during cell
division and undergo apoptosis.
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Changes in cell cycle progression in the sprtu21 and the sprtu21/ro1 mutants affect somite
formation differently, however role of the cell cycle in somite formation is not clear. The somite
formation is regulated by the “segmentation clock” which creates expression of oscillator genes
in the cells in the presomitic mesoderm in zebrafish (Holley, 2007). In specter mutants, I saw
delayed and diffused expression of segmental myoD (Appendix B), and disorganized muscle
suggesting that it is possible that Cyclin B1 is important for the segmentation clock function as
well as proper somite formation, but the regulation of this process remains unclear. Another cell
cycle mutant harpy ceases cell divisions, and also has defects in somites’ formation, however the
nature of these defects is different, as the mesenchymal cells are hyperepithelialized and myoD
expression remains segmental (Zhang et al., 2008).
In summary, I show that Cyclin B1 is important during cell cycle progression in zebrafish
somatic cells, but in the absence of a zygotic product, there might be an alternative mechanism of
promoting cells through mitosis. In this work, I propose that Cyclin B2 can rescue cell cycle
progression in some population of cells in the Cyclin B1-deficient mutant embryo, but it is not
sufficient to sustain normal cell cycle divisions in all cells. By attempting to knockout cyclin B2,
I show that I created multiple mutations that affect cell cycle progression that resembles lack of
cyclin B1 and overall embryo morphogenesis, suggesting that Cyclin B1 alone is not enough for
successful mitosis in zebrafish.
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Appendix A
A list of used primers

No
1

5
6
7
8
9

Name
ccnb2 F1pGEM-T
Easy
ccnb2 R2pGEM-T
Easy
F1 pT2
GFP
R2 pT2
GFP
B2F1
B2F2
B2F4
B2F5
B2F6

10
11
12
13
14
15
16
17
18
19

F9563
GFP-F7
R-CFP
B2R1
B2R2
B2R4
B2R5
B2R8
R9567
R9565

20
21

R9571
T7

22

SP6

2

3
4

Location
ccnb2/gfp

Primer sequence
5’ GGGAGGTGTGGGAGGTTTTTTGGTCAGCTGTCGTGCACC 3’

ccnb2/gfp

5’ GCCCTTGCTCACCATGGTGGCGCCAGTGGGTTTTACACTTTGC 3’

gfp/ccnb2

5’ GTAAAACCCACTGGCGCCACCATGGTGAGCAAG 3’

gfp/ccnb2

5’ TTGGGGTGCACGACAGCTGACCAAAAAACCTCCCACACCTC 3’

ccnb2 5’UTR
ccnb2 exon 2
ccnb2 5’ UTR
ccnb2 exon 1
ccnb2 exon
1/intron 1
ccnb2 5’UTR
gfp
ccnb2
ccnb2 exon 4
ccnB2 intron 4
ccnb2 intron 4
ccnb2 exon 8
ccnb2 exon 3
Ccnb2 intron 4
ccnb2
exon4/intron4
ccnb2 exon 6
T7
promoter/pGEMT Easy
SP6 promoter
/pGEM-T Easy

5’
5’
5’
5’
5’

GTACTGTATACGCACGGCTTG 3’
AATCCCATTTACGTCGGTGC 3’
ATTTGAATCACCAGCAGGCC 3’
AGTTGAGTTGGACGAGAAAC 3’
TCATCATGGAAATGCACG 3’

5’
5’
5’
5’
5’
5’
5’
5’
5’
5’

CGCCAAACAAAGCTAAACGG 3’
AACGAGAAGCGCGATCACATG 3’
TCCTCGATGTTGTGGCGG 3’
GCCATTCTTGATCGCTTCC 3’
GATGGATACAGTTGATGAGCAC 3’
GAAGTGCTCATCAACTGTATCCATC 3’
CAGATCCTTCACCAGTGAGG 3’
GAAAGAGGCTGTTGGAAAAG 3’
CCCCTACAGTCACAGTAATG 3’
CCTGATTCTTACCTGGAGG 3’

5’ CAAGCACTAGTTGAGAGAGG 3’
5’ TAATACGACTCACTATAGGG 3’
5’ ATTTAGGTGACACTATAG 3’
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Appendix B
specter mutants exhibit signs of delayed morphological development
When we analyzed the differences in cyclin B1 mRNA expression and cell cycle
progression in the two specter mutants, we concluded that at least one allele (ro1) is enough to
cause a more severe mutant phenotype. To further characterize how the ro1 allele affects
embryonic development, I compared the expression of different mRNAs in embryos from sprtu21
incross and embryos from the sprtu21 and sprro1 transheterozygote cross.
For this analysis, I have chosen markers that are largely expressed in presumptive
nervous tissue or in progenitors of the muscle. The reason I chose these makers is that cells in the
nervous tissue rapidly divide (Kimmel and Warga, 1986, Kimmel et al., 1994), and this tissue is
the primary site of apoptosis in specter mutants. Why I chose to analyze muscle, is because
specter mutants have delayed somite formation and once segmentation, the muscle occurs looks
disorganized and of irregular shape.
I first examined notch1b and deltaA expression. The generation of differentiated neural
cells from neural progenitors is regulated by Notch-Delta signaling (Concha & Adams, 1998,
Bierkamp and Campos-Ortega, 1993). notch1b is expressed in proliferating undifferentiated

Figure 1. notch1b mRNA expression in the wild type, sprtu21 and sprtu21/ro1 mutant embryos
during segmentation. (A-A′) wild-type embryo, (B-B′) sprtu21 mutant embryo, at the 6-somites and
15-somites, respectively. (C′) sprtu21/ro1 mutant embryo at 15-somites. Dorsal view.
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neural stem cells (Bierkamp and Campos-Ortega, 1993) whereas deltaA is expressed in neural
progenitors shortly before they differentiate and cease to divide (Appel and Eisen, 1998). I found
that at 6-somites, notch1b expression in the central nervous system was weaker in the sprtu21
mutant (Fig. 1B) and the sprtu21/ro1 transheterozygote (data not shown), compared to the wildtype embryo (Fig. 1A). However, by 15-somites, notch1b expression in the mutant embryos (Fig.
2.9 B′, C) was as robust as in the wild-type siblings (Fig. 1A′).
Next, I analyzed deltaA expression to see the effect on the downstream neural progenitors

Figure 2. deltaA mRNA expression in the wild type, sprtu21 and sprtu21/ro1 mutant
embryos during segmentation. (A-A′) wild-type embryo, (B-B′) sprtu21 mutant embryo, (CC′) sprtu21/ro1 mutant embryo at 10-somites and 15-somites, respectively. Dorsal view.
(Fig. 2). I observed that at 10- and 15-somites, deltaA is expressed in the spinal cord neurons
(Haddon et. al. 1998). of both the wild-type embryo (Fig. 2A) and the mutants (Fig. 2B, C), but
was weaker in both mutants, suggesting fewer deltaA positive cells (Fig. 2B, C, B′, C′).
Neural cells support their population by maintaining a pool of stem cells (notch1b) and
differentiating progenitors (deltaA). Both specter mutants have delayed expression of notch1b
during early segmentation and fewer deltaA positive cell. Since cell cycle progression in the
specter mutants is compromised, it is possible that neural stem cells take longer time to cycle
because eventually by mid-segmentation, notch1b expression increases to normal levels.
However, perhaps, because notch1b cells cannot exit the Notch pathway in a timely manner the
proneuronal population is depleted, thus there are fewer deltaA positive cells.
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Based on the Delta-Notch signaling model for zebrafish spinal cord development, lack of
deltaA expression causes neural precursor cells to differentiate prematurely (Appel et al., 1999).
Since I saw a robust notch1b expression, but fewer deltaA positive cells during midsegmentation, I asked whether this affected the differentiated neurons. islet1 is expressed is
many differentiating tissues, including: primary motor neurons, branchiomotor neurons, RohonBeard sensory neurons, and the hatching gland (Korzh et al., 1993). At 6-somites, there was no
difference in the islet1 expressed in hatching gland in both wild type (Fig. 3A) and specter
mutants (Fig. 3B, C). At 15-somites, I saw fewer differentiated neurons of the sprtu21 mutant
embryos (Fig. 3B′). These data argue against neural stem cells differentiating prematurely in the
specter mutant, otherwise there would be more islet1 positive cells. Quite the contrary, fewer
neurons argue for the precursors affected by abnormal and slower cell cycle. Lack of expression
in the primary neurons could be also explained by the primary motor neurons progenitors dying.

Figure 3. islet1 mRNA expression in the wild type, sprtu21 and sprtu21/ro1 mutant embryos
during segmentation. (A) wild-type embryo, (B) sprtu21 mutant embryo, (C) sprtu21/ro1 mutant
embryo at 6-somites, ventral view. (A′) wild-type embryo, (B′) sprtu21 mutant embryo, (C′)
sprtu21/ro1 mutant embryo at 15-somites, lateral view. Legend: hg – hatching gland; ot - otic
vesicle; tc – telencephalon; bmn – branchiomotoneurons; pcr – pancreas; pmn – primary motor
neurons; rb – Rohon-Beard sensory neurons.
Somites in both specter mutants are not defined and have an irregular shape. To analyze
what changes are happening during somite formation I examined myoD expression. myoD is
expressed in a bi-lateral medial row of adaxial cells and in the posterior mesoderm of each
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somite boundary (Weinberg et al., 1996). Normally, myoD expression appears in the somites
once 6-somites form, although expression in the adaxial cells comes up earlier. At 8-somite, the
wild-type embryos had normal expression in all eight somites, while in both specter mutants
expression was only apparent in the adaxial cells (Fig. 4A-A′′). Notably, this expression was
much weaker in the transheterozygote (Fig. 4A′′) compared to its wild-type sibling (Fig. 12A).
At 15-somites, myoD expression in the somites of wild-type embryos was robust whereas in the
sprtu21 mutant this robust somite expression was disorganized. However, in the transheterozygote
expression remained weak and still lacking in all but the adaxial cells, which also segment as a
somite forms (Fig. 4B′′). Hence, having no Cyclin B1 function delays differentiation of the
muscle, but when an interfering copy of Cyclin B1 is produced very little muscle differentiates.

Figure 12. myoD mRNA expression in the wild type, sprtu21 and sprtu21/ro1 mutant
embryos during segmentation. (A-A′) wild-type embryo, (B-B′) sprtu21 mutant embryo, (C-C′)
sprtu21/ro1 mutant embryo at 6-somites and 15-somites, respectively. Dorsal view. Legend: ad –
adaxial cells, sb – segment boundaries.
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Appendix C
Approval letter from IACUC
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